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In the human genome, DNA variants give rise to a variety of complex phenotypes. Ranging from single
base mutations to copy number variations (CNVs), many of these variants are neutral in selection and
disease etiology, making difficult the detection of true common or rare frequency disease-causing
mutations. However, allele frequency comparisons in cases, controls, and families may reveal disease
associations. Single nucleotide polymorphism (SNP) arrays and exome sequencing are popular assays
for genome-wide variant identification. To limit bias between samples, uniform testing is crucial, including
standardized platform versions and sample processing. Bases occupy single points while copy variants
occupy segments. Bases are bi-allelic while copies are multi-allelic. One genome also encodes many
different cell types. In this study, we investigate how CNV impacts different cell types, including heart,
brain and blood cells, all of which serve as models of complex disease. Here, we describe ParseCNV, a
systematic algorithm specifically developed as a part of this project to perform more accurate disease
associations using SNP arrays or exome sequencing-generated CNV calls with quality tracking of
variants, contributing to each significant overlap signal. Red flags of variant quality, genomic region, and
overlap profile are assessed in a continuous score and shown to correlate over 90% with independent
verification methods. We compared these data with our large internal cohort of 68,000 subjects, with
carefully mapped CNVs, which gave a robust rare variant frequency in unaffected populations. In these
investigations, we uncovered a number of loci in which CNVs are significantly enriched in non-coding RNA
(ncRNA), Online Mendelian Inheritance in Man (OMIM), and genome-wide association study (GWAS)
regions, impacting complex disease. By evaluating thoroughly the variant frequencies in pediatric
individuals, we subsequently compared these frequencies in geriatric individuals to gain insight of these
variants' impact on lifespan. Longevity-associated CNVs enriched in pediatric patients were found to
aggregate in alternative splicing genes. Congenital heart disease is the most common birth defect and
cause of infant mortality. When comparing congenital heart disease families, with cases and controls
genotyped both on SNP arrays and exome sequencing, we uncovered significant and confident loci that
provide insight into the molecular basis of disease. Neurodevelopmental disease affects the quality of life
and cognitive potential of many children. In the neurodevelopmental and psychiatric diseases, CACNA,
GRM, CNTN, and SLIT gene families show multiple significant signals impacting a large number of
developmental and psychiatric disease traits, with the potential of informing therapeutic decision-making.
Through new tool development and analysis of large disease cohorts genotyped on a variety of assays, I
have uncovered an important biological role and disease impact of CNV in complex disease.
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ABSTRACT
BIOLOGICAL ROLE AND DISEASE IMPACT OF COPY NUMBER VARIATION
IN COMPLEX DISEASE

Joseph Glessner
Hakon Hakonarson
In the human genome, DNA variants give rise to a variety of complex
phenotypes. Ranging from single base mutations to copy number variations (CNVs),
many of these variants are neutral in selection and disease etiology, making difficult the
detection of true common or rare frequency disease-causing mutations. However, allele
frequency comparisons in cases, controls, and families may reveal disease associations.
Single nucleotide polymorphism (SNP) arrays and exome sequencing are popular assays
for genome-wide variant identification. To limit bias between samples, uniform testing is
crucial, including standardized platform versions and sample processing. Bases occupy
single points while copy variants occupy segments. Bases are bi-allelic while copies are
multi-allelic. One genome also encodes many different cell types. In this study, we
investigate how CNV impacts different cell types, including heart, brain and blood cells,
all of which serve as models of complex disease. Here, we describe ParseCNV, a
systematic algorithm specifically developed as a part of this project to perform more
accurate disease associations using SNP arrays or exome sequencing-generated CNV
calls with quality tracking of variants, contributing to each significant overlap signal. Red
flags of variant quality, genomic region, and overlap profile are assessed in a continuous
score and shown to correlate over 90% with independent verification methods. We
compared these data with our large internal cohort of 68,000 subjects, with carefully
iv

mapped CNVs, which gave a robust rare variant frequency in unaffected populations. In
these investigations, we uncovered a number of loci in which CNVs are significantly
enriched in non-coding RNA (ncRNA), Online Mendelian Inheritance in Man (OMIM),
and genome-wide association study (GWAS) regions, impacting complex disease. By
evaluating thoroughly the variant frequencies in pediatric individuals, we subsequently
compared these frequencies in geriatric individuals to gain insight of these variants’
impact on lifespan. Longevity-associated CNVs enriched in pediatric patients were found
to aggregate in alternative splicing genes. Congenital heart disease is the most common
birth defect and cause of infant mortality. When comparing congenital heart disease
families, with cases and controls genotyped both on SNP arrays and exome sequencing,
we uncovered significant and confident loci that provide insight into the molecular basis
of disease. Neurodevelopmental disease affects the quality of life and cognitive potential
of many children. In the neurodevelopmental and psychiatric diseases, CACNA, GRM,
CNTN, and SLIT gene families show multiple significant signals impacting a large
number of developmental and psychiatric disease traits, with the potential of informing
therapeutic decision-making. Through new tool development and analysis of large
disease cohorts genotyped on a variety of assays, I have uncovered an important
biological role and disease impact of CNV in complex disease.
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Chapter 1

1.1 Introduction and Significance
Francis Crick and James Watson used the clues of Chargaff’s base ratio rules and
Franklin’s X-ray crystallography to deduce the biochemical interactions that create the
DNA double-helix, the fundamental information source for human health and disease
biology. In an iterative process, the Human Genome Project has created the first draft
sequence of the human genome and a number of major revisions (builds) every few
years. The HapMap project assessed common (>5%) minor allele frequency variants in
populations across the globe using SNP arrays. The ongoing 1000 genomes project aims
to assess rare (<1%) minor allele frequency variants in populations across the globe using
SNP arrays, in addition to exome and genome sequencing.

1.1.1 Copy Number Variation
Copy number variants (CNVs) are deviations from the expected one maternal and
one paternal copy of DNA in a given genomic segment. Similar to considering four
possible nucleotide bases at each DNA point (A, T, C, and G), we consider five possible
copy states at each DNA point (0, 1, 2, 3, and 4). We expect that at most genomic loci,
individuals have copy state two, termed diploid. Similar to linkage disequilibrium blocks
where base genotypes are found in discrete patterns termed haplotypes, CNVs typically
show larger segments with the same copy state at each point, although it is not clear to
what extent these segments co-localize. While linkage disequilibrium is mediated by
recombination hotspots, CNV segments are mediated by unequal crossing over due to
1

highly similar base sequences such as segmental duplications or repeats. Non-allelic
homologous recombination is the primary mechanism for CNV formation. While base
Figure 1.1. Schematic representations of copy number
variation (CNV) stages evaluated in the human genome

changes may affect the resulting
amino acid at a given point,
CNV affects the gene dosage
and expression level in most
cases of the entire amino acid
chain product. The deleted copy
number (CN) one or duplicated
CN three or four may be
maternal or paternal with the

Example structural variation deviations from reference.

corresponding bases in the

segment causing different impact, especially in imprinted regions. The duplication may
be tandem or dispersed. A run of homozygosity (ROH) is similar to a deletion with
respect to a singular base genotype sequence for a given segment, but having two
identical copies. Mosaicism is defined as a percentage of cells being diploid and a
percentage of cells having a CNV leading to a complex mixing pattern and possible celltype or organ-type specific pathology. Inversion is a segment where the maternal copy is
inverted with respect to the paternal copy. Insertion is a novel sequence inserted into a
segment. Since ROH, mosaicism, inversion, and insertion do not fit the strict definition of
CNV, they are termed more broadly as structural variations (Figure 1.1).
Rare and common CNVs

2

Typically, we look for rare recurrent CNVs present in <1% of the population, but in more
than one patient to identify if the phenotype is consistent. The vast majority of samples
possessing normal diploid signals forms a reference baseline and supports the assumption
made by clustering that the majority of samples in the population are diploid. However, if
there is a relatively high standard deviation of normal samples, a sample observed in
isolation may appear falsely to have a CNV. A common CNV has more of the population
with the CNV signal, forming a representative profile for each CN state, but can be
unclear due to some copy alleles being out of Hardy-Weinberg equilibrium due to
embryonic lethality. Therefore, a three CN clustering SNP may be (0,1,2), (1,2,3), or
(2,3,4) based on which mode is considered the diploid mode. Consequently, it is good to
have baseline known CN state samples for particular genomic loci.

1.1.2 Copy Number Variation Assays
Historically, CNVs were first identified by karyotyping. Today, there are four
major genome-wide assays used to assess CNV, ordered in terms of sophistication and
price: array comparative genomic hybridization (aCGH), SNP microarray (array), whole
exome sequencing (WES), and whole genome sequencing (WGS). aCGH provides
intensity data (normalized at 0 for diploid) only so modes of relative less intensity are
indicative of deletion. Modes of relative more intensity are indicative of duplication.
Higher degrees of mosaicism may also be detectable, although mostly simplified into the
discrete deletion or duplication states. SNP microarray provides both intensity and
genotype data (normalized at 0, 0.5 and 1 for AA, AB, and BB, respectively) for
haplotype tagging points across the genome. The paired genotype data is important
confirmatory information, in which deletions have only homozygous genotypes in the
3

less intensity segment, and multiple heterozygote allelic genotype banding in the more
intensity segment. Furthermore, ROH may be detected when many homozygous
genotypes are paired with expected normal diploid intensity. Genotype frequencies show
banding indicative of mosaicism. WES uses targeted exon capture genome wide to assess
only protein coding gene content, which is of primary importance for base and copy
variants, alike. However, due to the discontinuous coverage and larger gaps between
exons of neighboring genes, flanking diploid data may not be available to observe a clear
mode shift for state transition Hidden Markov Model (HMM) detection and boundary
resolution of CNVs. Only exon-level intensity is used to inform CNV detection following
principal components analysis (PCA) outlier removal and z-score normalization of wavy
read depth data from exome capture. Therefore, the WES data utilization remains
constrained to deletion and duplication detection, similar to aCGH with less uniform
genomic coverage. WGS has the ultimate data potential to resolve the whole spectrum of
structural variation, leveraging novel complementary features of pairs and split to resolve
inversion and insertion, which are
Figure 1.2. Assay resolutions for CNV platforms

elusive to the other major
technologies. In addition to low
intensity and only homozygous
genotypes at dbSNP positions, pairs
distance high and split observed
supports deletion calling. In

Different genomic platforms are shown delineating
different coverage and density.

addition to high intensity and

triallelic genotypes at any position, low pairs distance and split reads rescuing orphan
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read pairs support duplication calling. While the whole genome is theoretically
sequenced, some regions are poorly sequenced or mapped to the genome creating
residual variability and imperfect continuous coverage (Figure 1.2).
The broad scope of this dissertation includes CNV detection in assays (SNP array
and whole exome sequencing) and association with diseases, including congenital heart
disease, neurodevelopmental disease and a few other major disease categories together
with longevity. Comparisons are also being made between different study designs, where
both family-based de novo and transmitted CNVs are being evaluated together with
standard case-control design.

Sample sources
Blood is the DNA source of choice for ease of collection and quantity of quality
DNA for genotyping. Saliva is easier for collection in infants but does not reliably yield
the proper DNA for non-wavy intensity signals in genotyping. Cell-lines yield great
quantities of DNA but can cause CNV artifacts from Epstein-Barr Virus transformation
and immortalization. Tumor samples have many complex CNVs and heterogeneity from
clonal expansion of cell subpopulations acquiring new CNVs. Over 95% of the 68,000
samples presented here are blood-derived.
CNV Verification
For verification, PCR probes are sufficient to confirm CNV presence, as hybridization to
specific regions in the CNV sample yields differing amplification curves compared to a
normal diploid sample. Experimental validation is additionally performed to verify
specific CNV sizes and frequencies to ensure the CNV calls are accurate.
5

Key Biological Questions
We have one genomic reference sequence, which is present with high fidelity throughout
the human body, yet we have different programs in operation stabilizing distinct cell
types. How does one genome encode 200 cell types? There are many CNVs detected by
certain assays but less is known about which CNVs contribute to complex disease. The
assays provide discontinuous and variable-quality data. How do we decipher
discontinuous genome/gene data? We wish to optimize the number of true positives
without missing any true signal, yet being too aggressive will lead to false calls. How do
we balance maximizing true signals and minimizing false signals? We will explore these
motivating questions throughout the dissertation.

1.2 Landscape in Genetic Disease
Monogenic Disease

By reviewing families in pedigrees, simple recessive and dominant modes of
inheritance are apparent, where the mutations of a single gene penetrate into a disease
phenotype. Phenylketonuria, cystic fibrosis, sickle-cell anemia, and oculocutaneous
albinism are examples of human autosomal recessive diseases. Huntington's disease,
myotonic dystrophy, familial hypercholesterolemia, neurofibromatosis, and polycystic
kidney disease are examples of human autosomal dominant diseases. Incomplete
penetrance, genomic imprinting, uniparental disomy, and a variety of other factors
account for imperfect inheritance models. Most monogenic diseases are caused by
mutations that are SNVs.
Complex Disease

6

Most genetic disorders are complex and multi-factorial, or polygenic, meaning
they are likely associated with the effects of multiple genes in combination with lifestyles
and environmental factors. Multi-factorial disorders include heart disease, diabetes,
asthma and arthritis to name a few. Although complex disorders often cluster in families,
they do not have a clear-cut pattern of inheritance, making it difficult to determine the
risk of inheriting these disorders. Complex disorders are also difficult to study and treat
because the specific factors that cause these disorders have not yet been identified.
Based on pedigree information, polygenic diseases do tend to run in families, but
the inheritance pattern does not fit simple Mendelian disease patterns; however, this does
not mean that the genes cannot eventually be located and studied. There is also a strong
environmental component to many of these polygenic diseases (e.g., high blood
pressure).

1.3 Study Design for Genetics Disease Discovery
Case-Control

To identify complex disease loci, it is crucial to uniformly genotype large patient
cohorts of those affected and unaffected by the disease of interest. Doing so allows for a
more generalized scope of the case and control populations, as well as flexible patient
recruitment. Population stratification must be corrected, using the principal components
analysis as a covariate in association. With an arbitrarily large control cohort, we gather a
more robust control minor allele frequency definition and increase the power for
association p-value compared to family-based studies. In addition, unaffected parents
7

used as controls may indeed have subtle phenotypes related to the disease; thus, an
unaffected population control may be more suitable.

Family Trios and Transmission Disequilibrium Test
Families are immune to population stratification biases. For cases where a parent is
heterozygous for an allele, the major or minor allele may be biased in its transmission
rate across many families, specifically with unaffected parents and an affected child.
Families require verification through a reasonably low inheritance error rate.

De novo
De novo is a Latin expression meaning new. De novo mutation is a genetic
mutation that neither parent possessed nor transmitted. de novo CNVs are the clean
explanation of unaffected parents, but an affected child, namely a novel variant not
present in the parents is present in the child. True de novo CNVs are exceedingly rare,
especially when considering the desired recurrent de novo at a particular locus associated
recurrently with a disease phenotype.
Statistics
Fisher’s Exact Test involves defining a two by two contingency table of: counts
case CNV (a), case not CNV (b), control CNV (c), and control not CNV (d). Instead of
all CNV, we may count deletions separately from duplications of each copy number state
separately. The probability is given by the hypergeometric distribution:

8

The transmission disequilibrium test is defined as: the quantity transmitted minus
untransmitted squared divided by the quantity transmitted plus untransmitted. The
distribution follows a chi squared with 1 degree of freedom.
Χ2 = (transmitted – untransmitted)2 / (transmitted + untransmitted)

1.4 Congenital Heart Disease
Heart defect subtypes, clinical picture
Figure 1.3. Heart Defect Locations

Congenital heart disease
(CHD) is a leading cause of infant
mortality and accounts for one
third of all birth defects. While
population and familial studies
have improved our understanding
and diagnosis of CHD, only about

Locations of heart malformations that are usually identified
in infancy, and estimated prevalence based on the
CONCOR database. Numbers indicate the birth prevalence
per million live births. AS indicates aortic stenosis; ASD,
atrial septal defect; AVSD, atrioventricular septal defect;
CoA, coarctation of the aorta; Ebstein, Ebstein anomaly;
HLH, hypoplastic left heart; MA, mitral atresia; PDA,
patent ductus arteriosus, PS, pulmonary stenosis; PTA,
persistent truncus arteriosus; TA, tricuspid atresia; TGA,
transposition of the great arteries; SV, single ventricle;
TOF, tetralogy of Fallot; and VSD, ventricular septal
defect.
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20% of the genetic architecture of
CHD defects has been resolved.
Present at birth, CHD is a
defect of the heart and great
vessels structure. Numerous types

of heart defects occur, either by obstructing blood flow in the heart or vessels, or by
causing blood to flow through the heart in an abnormal pattern, mixing oxygenated with
deoxygenated blood (Figure 1.3).
The most common heart defect is ventricular septal defect (VSD) at a prevalence
of 0.36% of live births based on the CONCOR database, a national registry and DNAbank of patients with CHD in the Netherlands. The ventricular septum serves as a
separating wall between left and right ventricles. The ventricular septum contains many
cardiomyocytes.
Atrial septal defect (ASD) occurs in 0.09% of live births, and is a defect of the
interatrial septum, allowing blood to flow incorrectly between left oxygenated and right
deoxygenated blood atria. Oxygen levels in arterial blood are often lower than normal,
depending on the size of the defect.
Patent ductus arteriosus (PDA) occurs in 0.08% of live births. In PDA, the ductus
arteriosus remains open incorrectly after birth causing abnormal blood transmission to the
aorta and pulmonary artery.
Pulmonary stenosis (PS) occurs in 0.07% of live births, and is a defect that
obstructs the flow of blood from the right ventricle to the pulmonary artery.
Tetralogy of Fallot (TOF), coarctation of the aorta (CoA), and aortic stenosis (AS)
each occur in 0.04% of live births. TOF involves four anatomical abnormalities of the
heart: pulmonary infundibular stenosis (right ventricular outflow narrowing), overriding
aorta (aortic valve with biventricular connection), ventricular septal defect (hole between
bottom chambers), and right ventricular hypertrophy (hyper-muscular right ventricle).
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CoA involves narrowing of the aorta, where ductus arteriosus inserts. AS involves
narrowing of the aortic valve connecting the left ventricle with the aorta.
Atrioventricular septal defect (AVSD), transposition of the great arteries (TGA),
and hypoplastic left heart (HLH) each occur at 0.03% of live births. AVSD is an
atrioventricular septum deficiency. TGA is an abnormal arrangement of superior/inferior
venae cavae, pulmonary artery, pulmonary veins, and aorta. HLH is an
underdevelopment of the left ventricle.
Persistent truncus arteriosus (PTA), single ventricle (SV), tricuspid atresia (TA),
and Ebstein anomaly (EA) each occur at 0.01% of live births. PTA involves the truncus
arteriosus not dividing into the pulmonary trunk and the aorta, as expected. SV means the
left ventricle feeds both left and right atrium. TA involves an absent tricuspid valve; thus,
the right atrioventricular connection, ASD and VSD, is required to maintain blood flow
into the pulmonary arteries. EA involves the septal leaflet of the tricuspid valve being
Figure 1.4. Genomic Regions of Congenital Heart Disease
Associations

displaced towards the apex of the
right ventricle of the heart.

Known Causes of CHD

Large chromosomal abnormalities,
such as trisomies 21, 13, and 18,
cause 5-8% of cases of CHD.
Microdeletion of 22q11 (DiGeorge
Blue: Developmental Syndromes With Prominent CHD
Phenotypes
Red: Copy Number Variations (CNVs) Associated With
Recurrent Cases of Non-syndromic CHD(31, 50, 78, 132,
165, 186, 187, 203)
Black: Genes That Cause Isolated CHD
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syndrome), 1q21, 8p23, and other
loci identified by array

comparative genomic hybridization (aCGH), are cataloged in the database CDHWiki.

Mutations of a heart muscle protein, α-myosin heavy chain (MYH6), are
associated with atrial septal defects. Several proteins that interact with MYH6 are also
associated with cardiac defects. The transcription factor GATA4 forms a complex with
TBX5, which interacts with MYH6. Another factor, the homeobox (developmental) gene,
NKX2-5, also interacts with MYH6. Mutations of these proteins are associated with both
atrial and ventricular septal defect. In addition, NKX2-5 is associated with defects in the
electrical conduction of the heart; TBX5 is related to the Holt-Oram syndrome, which
includes electrical conduction defects and abnormalities of the upper limb. Another Tbox gene, TBX1, is involved in velo-cardio-facial syndrome, or DiGeorge syndrome, the
most common deletion syndrome, which has extensive symptoms, including defects of
Figure 1.5. Genes That Cause Isolated CHD ProteinProtein Interaction DAPPLE Network

the cardiac outflow tract and
tetralogy of Fallot. The Notch
signaling pathway, a regulatory
mechanism for cell growth and
differentiation, plays broad roles in
several aspects of cardiac
development. Mutations of a cell
regulatory mechanism, the
Ras/MAPK pathway, are

Permutation p-value of connectivity is shown by shade of
color.
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responsible for a variety of

syndromes, including Noonan syndrome, LEOPARD syndrome, Costello syndrome, and
cardiofaciocutaneous syndrome. A significant proportion of this thesis work focuses on
CNV analysis in children with CHD and their family members.

Numerous genomic loci are implicated in CHD phenotypes (Figure 1.4). A network of
interacting genes, based on protein-protein interactions, is also emerging (Figure 1.5).

1.5 Neurodevelopmental Disease
The following diseases are briefly reviewed and CNV analysis subsequently performed
jointly across all disease phenotypes.
Autism
Autism presents as impaired social interaction, distinct verbal/non-verbal
communication, and restricted/repetitive behavior typically in children by three years of
age. Autism affects neural development and information processing in the brain by
altering how nerve cells and their synapses connect and organize. Autism spectrum
disorders (ASD) include Asperger syndrome and pervasive developmental disorder, not
otherwise specified (PDD-NOS). Autism has a strong genetic basis based on very high
heritability in families, although the genetics of autism are complex and it is unclear
whether ASD is explained more by rare mutations, or by rare combinations of common
genetic variants. All of these phenotypes are examined in detail in this thesis project.
ADHD
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental psychiatric
disorder characterized by issues with attention, hyperactivity, or impulsive activity that
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are inappropriate for a person's age, presenting typically by ages six to twelve. ADHD is
diagnosed approximately three times more frequently in boys than in girls.
ADHD management usually involves some combination of counseling, lifestyle
changes, and medications. Medications are only recommended as a first-line treatment in
children who have severe symptoms, and may be considered for those with moderate
symptoms who either refuse or fail to improve with counseling. Long-term effects of
medications are not clear and they are not recommended for preschool-aged children.
Schizophrenia
Schizophrenia is a mental disorder often characterized by abnormal social
behavior and failure to recognize reality. Common symptoms include false beliefs,
auditory hallucinations, confused or unclear thinking, inactivity, and reduced social
engagement and emotional expression. Symptoms begin typically in young adulthood
(13-18) and about 0.3–0.7% of people are affected during their lifetime.
The mainstay of treatment is antipsychotic medication, which primarily
suppresses dopamine receptor activity. Counseling, job training, and social rehabilitation
are also important in treatment. In more serious cases, where there is risk to self or others,
involuntary hospitalization may be necessary, although hospital stays are now shorter and
less frequent than they once were.
Bipolar Disorder
Bipolar disorder is a mental illness characterized by episodes of elevated moods,
known as mania, alternating with episodes of depression. During manic episodes, an
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individual feels abnormally happy, energetic, or irritable, but often makes poor decisions
due to unrealistic ideas, or poor regard of consequences. Manic and depressive episodes
can impair the individual's ability to function in ordinary life. The most common age at
which symptoms begin is 25.
About 3% of people have bipolar disorder worldwide, a proportion consistent for
both men and women and across racial and ethnic groups. Treatment commonly includes
mood stabilizing medications and psychotherapy.
Depression
Major depressive disorder (MDD) is a mental disorder characterized by a
pervasive and persistent low mood that is accompanied by low self-esteem and by a loss
of interest or pleasure in normally enjoyable activities. The most common time of onset is
between the ages of 20 and 30 years, with a later peak between 30 and 40 years.
Typically, people are treated with antidepressant medication and, in many cases,
also receive counseling. Psychological treatments are based on theories of personality,
interpersonal communication, and learning. Most biological theories focus on the
monoamine chemicals serotonin, norepinephrine and dopamine, which are naturally
present in the brain and assist communication between nerve cells.

Known CNV Gene Associations in Neurodevelopmental Disease

CACNA
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Voltage-dependent calcium channels mediate the entry of calcium ions into excitable
cells, and are also involved in a variety of calcium-dependent processes, including muscle
contraction, hormone or neurotransmitter release, and gene expression. Calcium channels are
multi-subunit complexes composed of alpha-1, beta, alpha-2/delta, and gamma subunits. The
channel activity is directed by the pore-forming alpha-1 subunit, whereas, the others act as
auxiliary subunits regulating this activity. The distinctive properties of the calcium channel
types are related primarily to the expression of a variety of alpha-1 isoforms, alpha-1A, B, C,
D, E, and S.

GRM
G-protein coupled receptor for glutamate. Ligand binding causes a conformational
change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and
modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositolcalcium second messenger system. GRM may participate in the central action of glutamate in
the CNS, such as long-term potentiation in the hippocampus and long-term depression in the
cerebellum.

CNTN
The protein encoded by this gene is a member of the immunoglobulin
superfamily. It is a glycosylphosphatidylinositol (GPI)-anchored neuronal membrane
protein that functions as a cell adhesion molecule. It may play a role in the formation of
axon connections in the developing nervous system. Contactins mediate cell surface
interactions during nervous system development. CNTN is involved in the formation of
paranodal axo-glial junctions in myelinated peripheral nerves and in the signaling
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between axons and myelinating glial cells via its association with CNTNAP1. CNTN
participates in oligodendrocytes generation by acting as a ligand of NOTCH1. Interaction
with Tenascin-R induces a repulsion of neurons and an inhibition of neurite outgrowth.
SLIT
The protein encoded by this gene is secreted, likely interacting with roundabout
homolog receptors to effect cell migration. SLIT may act as molecular guidance cue in
cellular migration, and function may be mediated by interaction with roundabout
homolog receptors.
Given this perspective on the field of CNV detection and association that I have
already contributed to in a significant way, we proceed into the specific aims and scope
of this dissertation project aimed at improving CNV discovery, analysis and
interpretation.

1.6 Specific Aims
Revealing functionally important variants in the human genome for different cell types,
in complex disease such as heart, is a major challenge. Congenital heart defects are a
leading cause of infant mortality and contribute to one third of all birth defects(52).
Population and family studies look to advance the early diagnosis and treatment of heart
defects by understanding the genetic architecture, a quarter of which has been resolved
(52). Efforts in DNA data assessment are shifting from SNP array and aCGH to whole
exome and genome sequencing (36, 146). However, the use of these methods presents a
significant limitation in confident association of variant bases (SNPs) and copies (CNVs

17

The overall goal of this project is to revolutionize the association of genetic variation to
complex disease, representatively addressed through in-depth examination of
neurodevelopmental disorders ad congenital heart defects, by fundamentally improving
the integrated array and exome analysis for copy variation. This work is now possible by
having access to large disease populations on exomes with high resolution on genes. Our
lab has unique access to a large family cohort of heart defect patients studied on array and
exome platforms. My previous CNV work from SNP array data importantly uncovered
rare recurrent CNVs impacting ubiquiting and neuronal cell adhesion molecule genes
impacting brain cell function in children with autism (65), CNV enrichment in synaptic
transmission genes in schizophrenia (67), and disruption in metabotropic glutamate
receptor genes in ADHD(49).

To advance the field, it is necessary to improve confidence related to association of
exome and array variants with heart defects, thus opening up better detection and
treatment options. I am proposing to test the hypothesis that de novo CNVs contribute to
the etiology of complex diseases, such as CHD with the following specific aims:

Aim 1: To determine impact of de novo CNVs in complex disease, I will compare de
novo CNV frequency between CHD families and healthy control families (termed
burden).
I hypothesize that uncovering de novo CNV in critical genes and pruning false genes will
yield a more complete and accurate genomic architecture of heart defect tested by
validation.
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We have uncovered and reported significantly increased burden of de novo CNVs in
congenital heart disease compared to controls with an odds ratio of approximately 4. To
optimize CNV results, we prioritize putative de novo CNVs by the trio recall option in
PennCNV, use at least 2 algorithms to call de novo events (PennCNV, QuantiSNP, and
Nexus), evaluate parental origin (if enough informative markers), ensure there are greater
than 5 SNPs per locus and we have low/absent untransmitted CNV rate. We also make
sure there is low/absent control rate in public databases (DGV, SSC healthy trios, CHOP
control, Framingham), that BAF/LRR inspection passes quality control measures (full
trio in case false negative parent), and that the CNV is confirmed by ddPCR validation.
Non-allelic homologous recombination (NAHR) is the primary biological mechanism to
create CNVs (1 mother and 1 father copy deviation) which intriguingly affect expression
dosage (86, 196) and imprinted (45) heart loci. CNV is noisier than SNP data and
occupies genomic non-standard ranges rather than points, posing novel challenges
addressed here by capturing significant CNV profiles which may be atypical. Here, I will
implement bi-directional (detrimental, neutral, protective) gene/pathway based
association to improve sensitivity over existing collapsing methods. I will create a formal
CNV association confidence score based on a variety of rare genomic, variant, and
overlap features to improve specificity over existing heuristics, validated by qPCR.

Aim 2: To identify and define CNV genes, I will look for true recurrent de novo
CNVs.
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I hypothesize that relatively dense and uniform genome coverage will provide good CNV
detection and boundary definition yielding significant heart biology further evidenced by
gene expression.
We observed novel recurrent de novo CNVs in four families on 15q11.2 encompassing
CYFIP1, NIPA1, and NIPA2.Study experiments include diagnosed heart defect, parents
and healthy control blood samples collected in the clinic, DNA extracted, and Array and
Exome genotyping performed in the lab. Using improved association methods from Aim
1, I can now confidently evaluate array data of heart defect families and controls boosting
discovery of 1 gene with existing methods to 10 genes. These genes will aggregate in
biological categories of transcriptional regulation, signal transduction, cardiac structure,
and histone-modifying. I will use the latest sequencing informed SNP array Illumina
Omni2.5 on 400 trios, 900 cases, and 1000 controls for de novo, TDT, and case-control
analysis. Potential de novo CNVs will be prioritized using trio recall prior probability,
parental origin, untransmitted (TDT), and control (case-control) data. Given low
heritability of heart defect, de novo variants may play a large role. I will further prioritize
the heart biology search informed by our parallel research finding of 4,162 genes
expressed in the top 25% of developing heart by RNA-seq analysis.

Aim 3: To assess biological gene function of single de novo CNVs, I will perform
integrative gene network analysis of multiple datasets.
I hypothesize that a gene focused CNV study will better resolve functional boundaries of
complementing CNVs shown to exist by array and novel submicroscopic CNVs.
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De novo CNV genes form a significant protein-protein interaction network hub
elaborated by de novo base variant genes. After the heart genome association map is
elucidated by Aim 2, I can now enhance the picture by fine resolution on genes. Exome
sequencing exhibits very discontinuous data and most platforms have wavy read depth
due to DNA capture and sequencing mapping biases normalized by PCA. Exon based vs.
base level intensity, genotype, pairs, and split will be used for filtering higher confidence
variants. Exome sequencing specific confidence features will be devised for CNV
association.
Much emphasis is placed on CNV detection but relatively little is placed on
association. PennCNV arose as the dominant CNV calling algorithm for SNP arrays, but
no accompanying association tool existed. In chapter 2 I describe a new tool I developed
to confidently evaluate CNVs for association with biological traits. In the following
chapters I address the biological impact of CNVs in CHD and neurodevelopmental
disorders as outlined in Specific Aims 1-3.
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Chapter 2
2.0 ParseCNV Integrative Copy Number Variation Association
Software with Quality Tracking

Summary
A number of copy number variation (CNV) calling algorithms exist, however
comprehensive software tools for CNV association studies are lacking. Here, we
developed ParseCNV, unique software which takes CNV calls and creates probe-based
statistics for CNV occurrence in both case-control design and in family-based studies
addressing both de novo and inheritance events which are then summarized based on
CNV regions (CNVRs). CNVRs are defined in a dynamic manner to allow for a complex
CNV overlap while maintaining precise association region. Using this approach, we
avoid failure to converge and non-monotonic curve fitting weaknesses of programs such
as CNVtools and CNVassoc and while Plink is easy to use, it only provides combined
CNV state probe-based statistics, not state specific CNVRs. Existing CNV association
methods do not provide any quality tracking information to filter confident associations, a
key issue which is fully addressed by ParseCNV. In addition, uncertainty in CNV calls
underlying CNV associations is evaluated to verify significant results including CNV
overlap profiles, genomic context, number of probes supporting the CNV, and single
probe intensities. When optimal quality control parameters are followed using ParseCNV,
90% of CNVs validate by polymerase chain reaction (PCR), an often problematic stage
due to inadequate significant association review. ParseCNV is freely available at
http://parsecnv.sourceforge.net.
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2.1 Introduction and Significance
CNV association is being increasingly adopted in genetic investigations of disease
susceptibility loci (64, 116). Large de novo CNVs were once considered to be the cause
of syndromes, but more complete CNV maps now show that CNVs pervade the genome
and small CNVs can also be disease causing (35). Thus, CNV frequency difference
between cases and controls at specific loci is necessary to determine if a given CNV
plays a role in disease or impacts the expression of a clinical trait. Conceptually, the most
important variables involved in CNV analysis include disease under study, sample
cohort, array data, CNV calling algorithm and data interpretation using an algorithm
implementing CNV statistics. CNV calling and methods of demonstrating association
have been hampered by many challenges which has discouraged researchers from
investigating CNVs. ParseCNV is designed to simplify data processing and improve
transparency to render CNV studies more accessible to researchers.
Many CNV calling algorithms have been developed but relatively few CNV
association methods exist. As a result, streamlined implementation of association
methods is lacking. CNV calling algorithms evaluate allelic intensity and genotype states
in the case of SNPs, whereas CGH signal is based on intensity alone. Typically, both
SNP and CGH arrays assess raw data for CNVs at the genome wide level with discrete
genetic determinants. The latter include CN=0, 1, 2, 3, 4 copy number states captured by
both SNP and CGH arrays, together with AA, AB, BB genotype states for SNP arrays.
Since the intensity of array probes have a Gaussian distribution, clustering algorithms are
used to determine the expected value for a given state based on a population from which
variation of a given sample can be quantified as a LogR-Ratio/Log2-Ratio, together with
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B allele frequency for SNP arrays (156). PennCNV (211) is a popular option for SNP
array analysis, implementing a hidden Markov model algorithm. A number of other CNV
calling options are available, including QuantiSNP (34), CNVCALL (24), CNVDetector
(27), CGHCall (206), and CNV-Seq (222), all of which are publicly available tools and
highly enabling to researchers.
While there are several available CNV association methods in the public domain,
including CNVtools (likelihood ratio trend test)(9), Birdsuite (regression sum number
copies each allele) (112), Plink (permutation-based test) (167), and CNVassoc (latent
class model) (197), all of them have significant limitations as they lack simple standard
input and integrative reporting functions, which limits their discovery power,
investigation potential, and validation success (Supplementary Note). While CNVtools
and CNVassoc do both CNV calling and association, they make the actual CNV calls
hidden to the user and are batch dependent. Here we demonstrate the robustness of
ParseCNV in producing high quality CNVR calls by improving transparency and
accuracy of CNV association studies.

2.2 Materials and Methods
2.2.1 Upfront Quality Control
Since multiple confounding factors can bias the detection of CNV calls, it is essential to
apply filters, using sample based quality metrics affecting CNV detection accuracy.
Several steps are taken upfront to remove samples with outlier values for the CNV
metrics which can be briefly conceptualized as: low call rate, intensity noise, intensity
waviness, population stratification, high number of CNVs, and relatedness. In this regard,
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there are several important sample quality metrics measures, specifically: 1) sample call
rate/clustering quality; 2) standard deviation of allelic intensity (SD LRR); 3) G/C base
content waviness factor (GCWF); 4) count CNV; 5) majority ethnicity cluster using
principle components analysis from Eigenstrat smartpca (163), multi-dimensional scaling
(MDS) (125) or population stratification correction by covariate, and; 6) no duplicates.
For Illumina 550k data and related Illumina chip platforms, the key data quality metric
thresholds we have observed are: call rate > 98%, SD LRR < 0.3, |GCWF| < 0.05, and
count CNV< 100. For Affymetrix 6.0 data, these measures include: call rate > 96%, SD
LRR < 0.35, |GCWF| < 0.02, and count CNV < 80. In addition, observations of quality
metric modes from individual labs and sample sources are advisable to determine
appropriate QC thresholds. The distribution of these metric measures are constantly
reviewed to include only those that fall within three standard deviations from the mean or
a linear mode of the quality metric outside exponential modes for any given genotyping
platform. Sample call rate/clustering quality and standard deviation of allelic intensity are
crucial minimal sample exclusion metric measures that have been established as a field
consensus (158). By providing the PennCNV log files (i.e., summary lines), together with
GenomeStudio/GenotypingConsole/Plink missing call rates as input, ParseCNV
generates images of the distributions of these quality metrics values to make informed
decisions of the necessary data thresholds needed (balancing the tradeoff between sample
number attrition and study bias). Also, different CNV calling programs provide different
quality control fields so less standardization of input is possible. Among several highquality programs that are available, we find PennCNV to provide the most complete
quality metrics.
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2.2.2 Input Files
After generation of CNV calls, independent of algorithm, CNV association is
performed by the newly developed ParseCNV algorithm. ParseCNV utilizes four
standard inputs: case CNV calls
Figure 2.1. CNV Analysis Workflow.

(PennCNV format is the default but
any CNV calling method may be
used), control CNV calls
(PennCNV format), fam file (Plink
format), and probe map file (Plink
format) (Figure 2.1).
Optional input of raw signal
files used as input to the CNV
calling algorithm allows raw
genotype (B-allele frequency
(BAF) if available) and intensity

Pre-processing, file formats, and post-processing. This
general framework shows the stepwise procedure to
prepare input data to utilize and evaluate ParseCNV output.
“...” represents additional columns not shown.

(LogR-Ratio (LRR) or Log2-Ratio)
(156) signals of associated regions
to be parsed with an image that is

automatically generated for review. Sample batches can be defined to track their expected
vs. observed contribution to significant associations.
2.2.3 Probe-Based CNV Statistics
The general outline of data processing involves mapping the individual level CNV calls
into population level probe-based CNV statistics followed by filtering significantly
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associated population CNV Regions (CNVRs). CNV calls are mapped onto probe based
statistics defined by the probe map file and tested for significance based on Fisher’s exact
test. The Fisher’s exact test statistic consists of a two by two contingency table (with
cases deleted vs. cases not deleted and controls deleted vs. controls not deleted) and is
evaluated separately for
Figure 2.2. Possible Statistical Contingency Table
Definitions to Capture CNV Frequency Difference in Cases
vs. Controls.

duplications. This is a conceptual
medium between associating all
CN states separately and all CNVs
together (Figure 2.2).
Singular state and combined
state statistics are also calculated
for reference. Probes without
nominal significance (p<0.05) are
discarded from further association
testing. Case-enriched significant

The middle statistical definition of deletions signifying loss
of function mutations and duplications signifying gain of
function mutations is used predominantly. This is in
contrast to a view that all CNVs are all similarly
detrimental put forth by the top statistical definition and the
view that all CNV states lead to a unique outcome put forth
by the bottom statistical definition.

probes are then separated from
control-enriched significant probes.
If a family based study is

being done, the transmission disequilibrium test (TDT) is calculated and used to drive
CNVR definition. Quantitative trait association is also supported by running ParseCNV
with the includePed option, Plink association, and InsertPlinkPvalues (part of
ParseCNV).
2.2.4 Merging Probe Based Statistics into CNVRs
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Flexibility in probe aggregation incorporated into CNVRs allows for boundary
truncation variability problems inherent in many CNV calling algorithms and dynamic
case/control overlap to be made, while refining the association region. The above
mentioned probe-based statistic output is then merged into CNVRs based on probe
proximity (less than 1MB) and comparable significance (+/- one log p-value) of
neighboring probes. One Mb allows for extension of CNVRs over sparse probe coverage
regions. This can be tuned by command line option in keeping with the average probe
spacing of the dataset or can be made region-specific based on the distance of 5-10
proximal probes.
Figure 2.3. Complex CNV Overlap and CNVR Definition
Examples.

CNV boundary
determination remains a challenge
to differentiate true boundary
variations vs. variability in the
probe’s ability to differentiate CNV
states. The difficulty is typically

Rectangles represent individual sample CNV call
boundaries as provided by a CNV calling algorithm. Each
assayed point represented by the probe framework listed in
the map file input determines the possible boundary
assignments. The CNVR definition assigned by ParseCNV
is shown as a dashed box. Small variance in individual
CNV call boundaries allows extension of CNVR definition.
CNV peninsula is shown as the most common false
positive based on variable extension of CNV boundary
(typically the region common to cases and controls has
many probes while the case only extension has few
probes).

attributed to noisy probes within
true CNVs. Thus, certain
fluctuation in CNV frequency of
cases vs. controls is captured by the
respective p-values. Some case

calls may stop and others start within the CNVR making p-value based merging of probe
based statistics highly flexible. Therefore, the next probe with available data may be
noisy and any probe available substantiating the similar p-value within 1 Mb can be used
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to extend the CNVR. Noisy probes cannot be filtered out before CNV calling due to lack
of metrics with specificity for noise and not for true CNV with both behaving similarly in
classic probe-based call rate metrics.
Many CNV detection and association tools have difficulties handling CNVR breakpoints
and some algorithms make the assumption of considering CNVR breakpoints as static,
which is an oversimplification often leading to false negative results. For example, a
static CNVR may extend outside the boundary in some cases with only partial overlap in
controls, while having pathogenic impact. Merging neighboring probes based on
proximity and p-value supports dynamic CNVR definition and is flexible for the CNV
boundary variations of complex CNVs (Figure 2.3). The most significant sub-region is
included when multiple significant proximal extensions of the respective CNVR exist, to
reduce redundancy.

2.2.5 Review of Association Signals by Quality Tracking
Based on various parameters that have been referenced in the CNV literature and
review of many putative CNV associations by informatics and PCR validation, we have
amassed red flags for evaluation of significant CNVRs for confidence. These contributing
CNV call features are automatically annotated, viewable in the UCSC browser and are
specifically tailored towards reducing false positive calls from the following criteria:
1) Many segmental duplications (i.e., nearly identical DNA segments), representing
genomic segments that are difficult to uniquely hybridize probes to, which could underlie
false positive CNV detection (185).
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2) Overlapping multiple Database of Genomic Variants (DGV) (225) entries,
representing CNV signals observed in “healthy” individuals, suggesting that a potential
association result in the study at hand may be false.
3) Residing at centromere and telomere proximal regions as they often have sparse probe
coverage and only have a single flanking diploid reference to base CNV calls.
4) Harboring high or low GC content regions that bias probe hybridization kinetics even
after GC model correction is done by CNV calling algorithms, producing false CNV
calling and biasing the result.
5) CNVs captured with low average number of probes, contributing to association with
low confidence. If an association depends on a preponderance of small CNVs, the
likelihood of false positive is high.
6) Locus frequently found in multiple studies such as T cell receptor, immunoglobulin,
human leukocyte antigen, and olfactory receptor genes. T cell receptors undergo somatic
rearrangement due to somatic recombination causing inter-individual differences in the
clonality of T-cell populations (119) and thus are not true CNVs, necessitating exclusion.
7) CNV regions with high population frequency (for rare CNV focused studies) indicate
that probe clustering is likely biased due to a high percentage of samples with CNV used
in clustering definition thus biasing CNV detection.
8) CNV peninsula of common CNV (sparse probe coverage and nearby high frequency
CNV) indicates that within the range of contributing CNV boundaries there is a nonsignificant (p>0.05) p-value which is notably different from the CNVR association
typically due to random extension of common CNVs to neighboring sparse or noisy
probes (Figure 2.3).
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9) The same inflated sample driving multiple CNV associations signals. Certain samples
have many noisy CNV calls arising in rare regions despite upfront sample quality
filtering.
All these features are built into ParseCNV and are annotated automatically for optimal
CNVR association confidence.
10) Sparse coverage with large gap in probe coverage exists within the CNV calls
indicating uncertainty in the continuity of a single CNV event, typically due to dense
clusters of copy number (intensity only) probes with large intervening gaps.
11) Low BAF AB Frequency (0.1,0.4) or (0.6,0.9) are important for duplications, AB
banding of BAF at 0.33 and 0.66 for CN=3 or 0.25 and 0.75 for CN=4 are very important
observations given the relatively modest gain in intensity observed in duplications.
12) Low average confidence based on the HMM confidence score of calls contributing to
a CNVR association in PennCNV is a superior indication of CNV call confidence
compared to numsnps and length in studies comparing de novo vs. inherited CNV calls,
giving an indication of the strength of the CNV signal or aggregate difference in
probability between the called CN and the next highest probability CN. Other CNV
calling algorithms give different range confidence scores or lower values might mean
more confidence (i.e. call p value) so threshold may need modification. It is
recommended to be in .rawcnv file as column 8 i.e. “conf=20.659” but not required.
13) Low average CNV length is a classical confidence scoring parameter of interest. If
the CNV is too small, it is submicroscopic and even if many probes are tightly clustered,
bias of local DNA regions and probe overlap make confidence low.
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2.2.6 Multiple Testing Correction
To inform the assessment process of statistical significance of CNVR association
and reject the null hypothesis of no association of CNVs to the disease under study,
various CNV metrics are calculated including: 1) the number of probes with a nominal
frequency of CNV occurrence (only probes with some CNV detected are informative) 2)
the number of probes with enrichment in cases vs. controls and vice versa (evidence of
more case enriched loci than control enriched loci above certain significance thresholds)
3) probes with less than 1% population frequency of CNV (optionally for rare CNV
studies); and 4) the number of CNVRs (multiple probes are needed to detect a single
CNV and these do not count as separate events for multiple testing correction). These
calculated values provide a realistic number of statistical tests to correct for. In practice,
using the Illumina and Affymetrix high density SNP arrays, we find p=5x10-4
uncorrected p-values meet conservative multiple testing significance based on these
criteria.
2.2.7 CNV Validation by Quantitative Polymerase Chain Reaction (QPCR)
To validate the PennCNV algorithm I performed experimental validation. For the
experimental CNV validation I used qPCR, including sample input of 60 ul at 6.25 ng/ul
(to run a random set of discovery lloci and 4 house-keeping genes in triplicate at 4ul each
run). Twenty base forward and reverse primers are developed for each locus. Universal
Probe Library (UPL; Roche, Indianapolis, IN) probes are selected using the ProbeFinder
v2.41 software (Roche, Indianapolis, IN). Quantitative PCR is performed on an ABI 7500
Real Time PCR Instrument or on an ABI Prism™ 7900HT Sequence Detection System
(Applied Biosystems, Foster City, CA). Each sample is analyzed in quadruplicate either
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in 25 ul reaction mixture (250 nM probe, 900 nM each primer, Fast Start TaqMan Probe
Master from Roche, and 10 ng genomic DNA) or in 10 ul reaction mixture (100 nM
probe, 200 nM each primer, 1x Platinum Quantitative PCR SuperMix-Uracil-DNAGlycosylase (UDG) with ROX from Invitrogen, and 25 ng genomic DNA). The values
are evaluated using Sequence Detection Software v2.2.1 (Applied Biosystems, CA). Data
analysis is further performed using either the ΔΔCT method or qBase. Reference genes,
chosen from COBL, GUSB, and SNCA, are included based on the minimal coefficient of
variation and then data was normalized by setting a normal control to a value of 1.
The data output is 0.5 for deletions, 1 for diploid, 1.5 for duplications with standard error
values from replicate runs.

TaqMan® Copy Number Assay experiments are also run on Applied Biosystems
7900HT Fast Real-Time PCR System to validate the presence of CNVs. Applied
Biosystems CopyCaller™ Software performs relative quantitation analysis of genomic
DNA targets using the real-time PCR data from TaqMan® Copy Number Assay
experiments. Two replicates are run with confidence score >0.99 for CNV calls. Positive
and negative controls are used to confirm probe accuracy.

2.3 Results and Discussion
I have generated a deletion and duplication CNVR report showing significant
association, including 127 fields in a final output file with 54 highly informative fields
included in the default output format and 11 fields in a brief report (Table 2.1) to aid
accessibility for ParseCNV users.
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Table 2.1. Significant CNVR Output Fields Description
Column
CNVR
CountSNPs
SNP
DelTwoTailed
DupTwoTailed
ORDel
ORDup
Cases Del
Cases Diploid
Control Del
Control Diploid
Cases Dup
Cases Diploid
Control Dup
Control Diploid
IDsCasesDel
IDsCasesDup
StatesCasesDel
StatesCasesDup
TotalStatesCases(1)
TotalStatesCases(2)
TotalStatesCases(5)
TotalStatesCases(6)
IDsDelControl
IDsDupControl
StatesDelControl
StatesDupControl
TotalStates(1)
TotalStates(2)

Description
CNV Region of greatest significance and overlap coordinates
The number of probes available in the CNVR for this dataset In this case,
contributing individual CNV calls may be larger
Tag SNP for ease and clarity of reporting and replication
Two Tailed Fisher's Exact P-value based on the contingency table Cases
Del/Cases Diploid/Controls Del/Controls Diploid as listed separately
Two Tailed Fisher's Exact P-value based on the contingency table Cases
Dup/Cases Diploid/Controls Dup/Controls Diploid as listed separately
The Odds Ratio for deletion.
The Odds Ratio for duplication.
The number of cases with a deletion detected in this region by PennCNV
The number of cases without a deletion or duplication detected in this
region by PennCNV
The number of controls with a deletion detected in this region by PennCNV
The number of controls without a deletion or duplication detected in this
region by PennCNV
The number of cases with a duplication detected in this region by
PennCNV
The number of cases without a deletion or duplication detected in this
region by PennCNV
The number of controls with a duplication detected in this region by
PennCNV
The number of controls without a deletion or duplication detected in this
region by PennCNV
The sample IDs of cases corresponding to the Cases Del column for clinical
data lookup. To convert to list in Excel: Data-TextToColumns-DelimitedSpace then Copy-PasteSpecial-Transpose
The sample IDs of cases corresponding to the Cases Dup column for
clinical data lookup. To convert to list in Excel: Data-TextToColumnsDelimited-Space then Copy-PasteSpecial-Transpose
CN states listed corresponding to IDsCasesDel (1(CN=0)/2(CN=1))
CN states listed corresponding to IDsCasesDup (5(CN=3)/6(CN=4))
The number of cases in Cases Del with a homozygous deletion or both
copies lost
The number of cases in Cases Del with a hemizygous deletion or one copy
lost
The number of cases in Cases Dup with a hemizygous duplication or one
copy gained
The number of cases in Cases Dup with a homozygous duplication or two
copies gained
The sample IDs of controls corresponding to the Control Del column for
clinical data lookup.
The sample IDs of controls corresponding to the Control Dup column for
clinical data lookup.
CN states listed corresponding to IDsDelControl (1(CN=0)/2(CN=1))
CN states listed corresponding to IDsDupControl (5(CN=3)/6(CN=4))
The number of Controls in Controls Del with a homozygous deletion or
both copies lost
The number of Controls in Controls Del with a hemizygous deletion or one
copy lost
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TotalStates(5)
TotalStates(6)
ALLTwoTailed
ORALL
ZeroTwoTailed
ORZero
OneTwoTailed
OROne
ThreeTwoTailed
ORThree
FourTwoTailed
ORFour
Gene
Distance
Description
Pathway
AverageNumsnpsCaseDel
AverageLengthCaseDel
CNVRangeCaseDel
AverageNumsnpsControlDel
AverageLengthControlDel
CNVRangeControlDel
CNVType
Cytoband
redFlagCount
redFlagReasons

The number of Controls in Controls Dup with a hemizygous duplication or
one copy gained
The number of Controls in Controls Dup with a homozygous duplication or
two copies gained
All CNV states considered together p
All CNV states considered together OR
Only CN=0 CNV state considered together p
Only CN=0 CNV state considered together OR
Only CN=1 CNV state considered together p
Only CN=1 CNV state considered together OR
Only CN=3 CNV state considered together p
Only CN=3 CNV state considered together OR
Only CN=4 CNV state considered together p
Only CN=4 CNV state considered together OR
The closest proximal gene based on UCSC Genes which includes both
RefSeq Genes and Hypothetical Gene transcripts
The distance from the CNVR to the closest proximal gene annotated. If the
value is 0, the CNVR resides directly on the gene.
The gene description delimited by "/" for multiple gene transcripts or
multiple genes listed
Annotated pathway membership of Gene with reference compiled from
Gene Ontology database, BioCarta database and the KEGG database
(definition files in GeneRef folder)
The average numsnp of CNV calls contributing to Case Del CNVR. Allows
for much more informative CNV size (confidence) filtering post-hoc.
The average length of CNV calls contributing to Case Del CNVR. Allows
for much more informative CNV size (confidence) filtering post-hoc.
Alternative larger CNV Range Case Del definition compared to minimal
common overlap definition of CNVR
The average numsnp of CNV calls contributing to Control Del CNVR.
Allows for much more informative CNV size (confidence) filtering posthoc.
The average length of CNV calls contributing to Control Del CNVR.
Allows for much more informative CNV size (confidence) filtering posthoc.
Alternative larger CNV Range Control Del definition compared to minimal
common overlap definition of CNVR
Deletion or duplication CNVR Significant in combined report
Cytoband genomic landmark designations
Count red flag from association review of 9 (see text, briefly: SegDups,
DGV, Centro/Telo, GC, ProbeCount, PopFreq, Peninsula, Inflated)
The failing metrics for association review and their values

Besides p-value and odds ratios for each CNVR for all combined CNV state
definitions (Figure 2.2), contributing sample IDs, their CN states, closest gene, gene
description, pathway, and the average number of probes underlying contributing CNV
calls are provided for confidence scoring and biological interpretation. Such tracking
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information to enable quality assessment beyond initial sample based quality filtering is
not available in other CNV association software tools.
In addition to the main association results file, contributing calls to each
association are included for trackability. Contributing calls allow for specific breakpoint
assessment of individual samples and clear correlation of relevant raw input (i.e. intensity
and genotype state). An UCSC custom track is created for graphical review of individual
CNV boundaries to assess CNV overlap profiles (Figure 2.3). BAF and LRR value files
for each CNVR are created with all samples having CNV contributing to association for
review of the specific association region across many samples (Supplementary Figure
2.1). Viewing probe intensity data across multiple cases for an associated region allows
for generalization of robust signal qualities of a CNVR in a relatively quick manner. An
image is automatically generated showing intensity and genotype raw values evaluated
by the CNV calling algorithm delimiting each CNVR and each sample (Supplementary
Figure 2.2). Ped files are created separately for deletion and duplication to allow for
additional statistical output in Plink, including quantitative trait association. We define
deletion ped: cn=0 → 1 1, cn=1 → 1 2, other → 2 2, and duplication ped: cn=4 → 1 1,
cn=3 → 1 2, other → 2 2, designed from lowest to highest frequency in keeping with
Hardy-Weinberg Equilibrium. An accessory function InsertPlinkPvalues allows for Plink
generated output files to be imported into ParseCNV for Plink p-value driven CNVR
definition. Full SNP based statistics are generated in ParseCNV to allow for specific
locus queries regardless of significance.
Correction of the CNV association statistics for population stratification can be
achieved based on the PCA or MDS result. The deletion and duplication CNV peds

36

generated by ParseCNV are run in Plink with PCA/MDS as a covariate for a logistic
statistical test. The additive model of population stratification corrected p-values is then
imported into ParseCNV using InsertPlinkPvalues.
Uncertainty in CNV calls underlying CNV associations is thoroughly evaluated
by multiple lines of evidence to verify significant results including CNV call overlap
profiles, genomic context, number of probes supporting the CNV call, and single probe
intensities. CNV association results review follows four steps (Figure 2.1).
First, CNV association review is facilitated by automatic red flag annotations
which can be evaluated more carefully by UCSC track review for spurious association.
Many segmental duplications, centromere, telomere, CNV peninsula of common CNV,
extreme GC content regions, low average number of SNPs for CNV calls contributing to
association, locus frequently found in diverse studies, greater than 1% population
frequency, and same sample driving multiple CNV associations are all red flags for
evaluation (See Methods). The number of red flags is scored automatically with their
failing metric values provided. We use UCSC reference files which can be updated or
adapted to different genome builds, as instructed.
Second, intensity signal is reviewed for specific association regions across many
samples, based on an automatically generated image of BAF and LRR probe values.
Deletions are only accepted if they show clear drop in intensity (majority are below 0)
and lack of heterozygous genotypes (BAF 0, 1). Duplications are similarly accepted only
if they show AAB or ABB banding (BAF 0.33, 0.66) and increase in intensity (majority
are above 0) although the latter is not always clear cut for duplications which is the
reason duplications are often under called.
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Third, probe based intensity is reviewed for whole chromosome data of a sample
with each associated CNVR and population probe clusters, as done in Illumina
GenomeStudio and Affymetrix Genotyping Console. This review establishes clear
diploid (CN=2) signal in flanking regions to limit noise likely to increase bias of false
positive CNV calls. Intensity waves flanking a region with genotype support of CNV can
be spotted that represent copy neutral loss of hetereozygosity (LOH)/ or run of
homozygosity (ROH), which are often overcalled as a deletion by coinciding intensity
waves.
Fourth, qPCR wet lab review for confirmation of true positives and true negatives
is critically important. These steps are done in order of increasing effort per locus but the
number of loci will be filtered down by each step thus providing incremental stringency
and re-review to establish confidence. Using ParseCNV with the robust quality tracking
and confidence scoring through red flags, our validation success rate has been 90% in
studies of autism (65), schizophrenia (67), depression (68), obesity (66),
immunodeficiency (152) and attention deficit hyperactivity disorder (ADHD)(49). Here,
we present the results of 409 attempted and 367 successful validation assays from 7
disease studies with a range of different genomic loci and CN states (Table 2.2, Figure
2.5).
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Table 2.2. Quantitative PCR Validation of CNVR Associations
Validations
Attempted
Autism
37
Schizophrenia
52
Obesity
104
ADHD
135
AutSczAdhd
10
OldYoung
23
Progressive
Supranuclear
48
Palsy
Project

Cases Controls Loci
2,195
1,735
2,559
3,506
9
9,392

2,519
3,485
4,075
13,327
1
7,393

25
8
35
12
1
23

1,855

6,701

24

Count
PCR Validation Success
CN0 CN1 CN2 CN3 CN4
Del
Failed Failed
Rate
13
0
8
13
13
3
0
4
0.89
47
14
21
14
3
0
0
10
0.81
36
0
31
45
27
0
10
5
0.95
57
0
35
56
37
7
7
11
0.92
10
0
9
1
0
0
0
0
1
12
0
9
3
11
0
1
3
0.87
38

0

32

9

7

0

4

9

0.81

Reviewing the failed loci has led to establishment of the various red flag features
presented. Over time, the validation
Figure 2.4. Increased Frequency of Specific CNV State
in Cases

success rate has improved as more
rare and subtle red flags were
identified and refined. Validation of
CNVs with an independent method
has remained a standard expectation
due to false positives. With high
validation success rate due to quality
tracking and confidence scoring of

chr14:104241048-104348254 4:0 (case:control) deletions 2:11
duplications 6:11 combined ParseCNV provides case enriched
deletion significance for this region p=0.03 (duplication
control enriched p=0.09). Since Plink only uses combined
count definition the p=1 and the region is missed.
chr11:133663955-133715739 1:3 deletions 5:0 duplications
6:3 combined ParseCNV provides case enriched duplication
significance for this region p=0.01 (deletion control enriched
p=0.65). Since Plink only uses combined count definition the
p=0.12 and the region is missed.

known confounders leading to failed
validations based on experience, we
are confident that the majority of
significant loci with good confidence

scores can be interpreted for biological relevance to disease without prolonged suspicion
of a false positive CNV call until PCR validation is done.
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To provide a simplified

Figure 2.5. Quantitative PCR Validation of CNVR
Associations.

demonstration of the file input
format and output, we simulated
data for 4 cases and 4 controls with
CNV calls derived from 10 probes
which after running ParseCNV
results in a 1 probe CNVR deletion

Each sample with attempted validation for a specific CNV
at a specific locus is shown. The validation data output is
0.5 for deletions, 1 for diploid, 1.5 for duplications with
standard error values from triplicate runs.

and a 3 probe CNVR duplication
with nominal significance due to

the reported ranges being observed in 4 cases and 0 controls along with other files for
Figure 2.6. Sampling of Different Settings of Distance (1
MB) and significance (+/- 1 power of ten p-value).

association and CNV signal review
(Figure 2.1).
As an example of a real
dataset using a case/control publicly
available dataset, 785 autism cases
and 1110 controls were assessed
with 561,308 probes. PennCNV

Based on 785 cases vs. 1110 controls 561,308 probes
dataset. By this sampling procedure, we show these
defaults are justifiable based on balancing CNVR extension
to allow boundary variability while maintaining unique loci
except in rare instances. The x axis shows the CNVR typed
and distance setting. The color shows the p-value variance
setting. The y axis shows the count CNVRs resulting from
these settings.

called cases CN=0 1,855, CN=1
19,484, CN=3 11,393, CN=4 1,060
and controls CN=0 959, CN=1
10,051, CN=3 6,236, CN=4 579.

ParseCNV detected Del/Dup Probes p<0.05 Case Enrich: 696/1,309 and Del/Dup Probes
p<0.05 Control Enrich: 468/1,313. Deletion CNVRs: 103 Duplication CNVRs: 59 were
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found (after joining based on 1MB probe neighbors and +/- power of ten p-value) before
selecting the most significant CNVR in tightly clustering regions with varying
significance. ParseCNV then condensed these probe based statistics into 57 deletion and
33 duplication CNVRs with nominal significance. These loci were reviewed with red flag
annotations, UCSC, raw intensity, and qPCR as described above resulting in 7 deletion
and 12 duplication CNVRs (65). We used this dataset to sample different settings of
proximity (1 Mb) and significance (+/- 1 power of ten p-value) (Figure 2.6).
By this sampling procedure, we show these defaults are justifiable based on
balancing CNVR extension to allow boundary variability while maintaining unique loci
except in rare instances. The rawcnv, fam, and map files can be freely downloaded from
parsecnv.sourceforge.net to replicate the analysis.
To further emphasize the unique output features of ParseCNV, we ran Plink on
the same dataset. Plink detected the same number of cases and controls at each probe and
calculated statistical significance with similar values, albeit not the same since ParseCNV
uses Fisher exact test and Plink uses permutation (Supplementary Figure 2.3). However,
CNVRs were not called by Plink so part of ParseCNV was used to reduce redundancy in
the Plink result. 4 deletion CNVRs and 4 duplication CNVRs were missed (not
significant, p>0.09) by Plink due to the assessment of all CNV states together, while the
opposite state was enriched in controls (Figure 2.4).
All CNVRs called via Plink statistics were also significant in ParseCNV results.
Plink found 92 combined CNV state groups of probes which were called as CNVRs by a
ParseCNV component script. With combined CNV state statistics in ParseCNV, 79
CNVRs resulted. Highly significant p-values using Fisher’s exact test were less
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significant when asessed with permutation while marginally significant with control
frequency using permutation were more constrained with Fisher’s exact test (i.e. 5:1
case:control). Overall the counts of CNV per probe match exactly and the p-values
correlate highly between ParseCNV and Plink providing independent validation of
correctness (Supplementary Figure 2.3). However, the lack of CNVR calling and quality
tracking in Plink makes for a strong contrast of Plink with ParseCNV.
When families are available, inheritance rates of CNVs can improve confidence
of CNV calls. Importantly, de novo events should show consistent parent of origin across
genotypes of a given CNV. For example, if mother is AA, father is BB, and child is A,
the parent of origin is mother for the remaining copy. Trio and joint family based CNV
calling procedures in PennCNV can further improve the de novo rate (212). Such metrics
can be developed by retrospective evaluation of raw data contributing to false positive
associations and failing PCR validation. Waviness of the intensity data can be
ameliorated using the GC wave correction model options (48). Individual CNV call
quality metrics include confidence score, number of probes contributing to CNV call and
physical CNV size. CNV call filtering may create false association by encountering a
locus with control boundary truncation just under the threshold while case calls were just
above. If multiple SNP array or exome capture versions are being used with different
probe sets, filtering for the intersection set before CNV calling is recommended. If
overlap is minimal between different platforms, a discovery phase with the largest subset
can be done with replication in other subsets using all probes available on the chip.
ParseCNV has the flexibility of handling multiple different input files and is optimized to
handle CNV heterogeneity.
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In conclusion, the above referenced probe resolution statistics and dynamic
CNVR definition applied in ParseCNV will become increasingly important as the number
of CNVs identified in each individual and the resolution of variable CNV boundaries
expands in dense probe arrays and sequencing. With this increased resolution comes
additional multiple testing burden although multiple probes are needed to call a given
CNV and many probes may not detect any CNVs (conservative standard is p<5x10-4(65),
See Methods). Assessment of CNVs across the genome has continued to improve (58, 61,
94, 105, 140, 175). Recent reports of the extent of discordance between different arrays
and CNV calling algorithms have been published (158). This can be readily seen in the
Database of Genomic Variants entries with widely disparate CNV frequencies across
different healthy populations. This is why large cohorts of cases and controls typed at a
single facility are important with full tracking of quality metrics for each CNVR provided
by ParseCNV rather than simply probe based significance values. Success frequency of
qPCR CNV validation has continued to improve by association signal review enabled by
ParseCNV.
Note: Supplementary Data are available at NAR online: Supplementary figures 2.1-3,
Supplementary methods, and Supplementary reference(221).

2.4 Model for Continuous Red Flag Score
CNV calling has inherent uncertainty due to imperfect data modes at normal intensity (0)
and normal genotype (0,0.5,1) and deviations thereof. The stronger the deviation, the
stronger the PennCNV HMM confidence score, one of the red flags. Red flags were
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defined over time of reviewing failed qPCR verification underlying intensity and
genotype.
Progressing from a heuristic confidence score involving the count red flags exceeding
predefined thresholds into a formal statistic continuous confidence score will improve
specificity. Here, I have created a continuous RedFlag score to increase specificity
robustly correlating to validation and true association. I then provide a Pass/Fail
annotation based on RedFlags.
Red Flags are in main categories of genomic annotations, overlap profile, and average
quality of overlapping calls (Table 2.3). Genomic annotations include SegDups,
DgvEntries, TeloCentro, and AvgGC. Recurrent overlap profile annotations include
PopFreq, PenMaxP, FreqInflated, Sparse, and ABFreq.Average quality of overlapping
calls annotations include AvgConf, AvgProbes, and AvgLength.
To accomplish a continuous red flag confidence score, first I designed ParseCNV with
the –includeAllRedFlags command

Figure 2.7. Continuous Confidence Score

line option, plot R histogram of each
read flag. This design uses
MakeRedFlagPlots. pl,
CNVR_ALL_ReviewedCNVRs_bri
ef.txt, and plot R curve.
Lines(density(a$a)) is used to
integrate observed value at
Histogram of all red flags, curve fitting, and normalization, weights
based on generalized linear model, correlation/ROC curve to
independent verification

significant CNVR in proper
direction of red flag (+/-) depending
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on if low or high values are detrimental. This algorithm uses dens2 <density(a$SegDups, from=0, to=a$SegDups[i]) with(dens2, sum(y * diff(x)[1])), and
correlate/weight with validation success using Generalized Linear Model weights
assigned and correlation of 0.8 with validation success achieved with reasonable cutoff
for GLMWeightedConfidence of 0.2. ROC curve looks solid and the AUC score is 0.983
using ROCR package. Simple average (same weights) of the integration likelihoods was
not very well correlated with validation success.
Table 2.3. ParseCNV Red Flags Definition
RedFlag

Default Report
Threshold

Explanation

SegDups (count,
max, avg)

>10, >0.98 max Fraction
Matching

Many segmental duplications (i.e., nearly identical DNA segments), representing genomic segments that are
difficult to uniquely hybridize probes to, which could underlie false positive CNV detection. Segmental
Duplications inform CNV breakpoints if flanking (include) and noisy regions if overlapping (exclude).

DgvEntries

>10

Overlapping multiple Database of Genomic Variants (DGV) entries, representing CNV signals
observed in “healthy” individuals, suggesting that a potential association result in the study at hand may
be false.

TeloCentro

any overlap

Residing at centromere and telomere proximal regions as they often have sparse probe coverage and
only have a single flanking diploid reference to base CNV calls.

AvgGC

31>GC>60

Harboring high or low GC content regions that bias probe hybridization kinetics even after GC model
correction is done by CNV calling algorithms, producing false CNV calling and biasing the result.

AvgProbes

<10

CNVs captured with low average number of probes, contributing to association with low confidence. If
an association depends on a preponderance of small CNVs, the likelihood of false positive is high.

Recurrent

any overlap

Locus frequently found in multiple studies such as TCR, Ig, HLA, and OR genes. TCRs undergo
somatic rearrangement due to VDJ recombination causing inter-individual differences in the clonality
of T-cell populations and thus are not true CNVs, necessitating exclusion.

PopFreq

>0.01

CNV regions with high population frequency (for rare CNV focused studies) indicate that probe
clustering is likely biased due to a high percentage of samples with CNV used in clustering definition
thus biasing CNV detection.

PenMaxP_Freq_Hi
ghFreq

PenMaxP >0.5, Freq >0.5,
HighFreq >0.05

CNV peninsula of common CNV (sparse probe coverage and nearby high frequency CNV) indicates
that within the range of contributing CNV boundaries there is a non-significant (p>0.5) p-value which is
notably different from the CNVR association typically due to random extension of common CNVs to
neighboring sparse or noisy probes. PenMaxP is the worst p-value in the span of CNV calls contributing
to the significant CNVR. Freq is the frequency of this PenMaxP worst p-value. HighFreq is the
frequency any non-nominally significant p-value (P>0.05).

FreqInflated

>0.5 sids at this locus have
>(maxInflatedSampleCoun
t-2) occurrences in all
significant results

The same inflated sample driving multiple CNV association signals. Certain samples have many noisy
CNV calls arising in rare regions despite upfront sample quality filtering.

Sparse

>50kb

A large gap in probe coverage exists within the CNV calls indicating uncertainty in the continuity of a
single CNV event, typically due to dense clusters of copy number (intensity only) probes with large
intervening gaps.

ABFreq

<1% values (0.1,0.4) or
(0.6,0.9)

For duplications, AB banding of BAF at 0.33 and 0.66 for CN=3 or 0.25 and 0.75 for CN=4 are very
important observations given the relatively modest gain in intensity observed in duplications.
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AvgConf

<10

The HMM confidence score in PennCNV is a superior indication of CNV call confidence compared to
numsnps and length in studies comparing de novo vs. inherited CNV calls, giving an indication of the
strength of the CNV signal or aggregate difference in probability between the called CN and the next
highest probability CN. Other CNV calling algorithms give different range confidence scores or lower
values might mean more confidence (i.e. call p value) so threshold may need modification. It is
recommended to be in .rawcnv file as column 8 i.e. “conf=20.659” but not required.

AvgLength

<10kb

A classical confidence scoring parameter is the length of the CNV. If the CNV is too small, it is
submicroscopic and even if many probes are tightly clustered, bias of local DNA regions and probe
overlap make confidence difficult

2.5 Comparison of CNV Association Tools
Multiple CNV tools have been developed and their features are compared in Table 2.4.
Table 2.4. Comparison of CNV Association Tools Features Currently Available
CONAN

BirdSuite

Plink

Input Platform

Affymetrix

Affymetrix

ALL

CNV Call Data

PennCNV

Array data

PED1)

QuantiSNP

CNVineta
Illumina
Affymetrix
APT1)

BirdSuite2) QuantiSNP1)

Genotyping
Console
Text file1)
MS Exel1)

OS
Frequent CNV
Region3)

ALL
CNVR

CNVTools

R-Gada

CNVRuler

HD-CNV

ALL

ALL

ALL

ALL

ALL

ALL

CGHcall

Text file1)

BeadStudio1)
Genotyping
Console1)

CSV

Nexus
PennCNV
Genomic
Workbench
TCGA
NimbleScan
APT
Genotyping
Console
Genome Studio
Text file
ALL
CNVR
RO
Fragment
Yes
R

ALL
CGHregions

ALL
N/A

ALL
N/A

No
R

No
R

No
R

Nexus
PennCNV
Genomic
Workbench
TCGA
NimbleScan
APT
Genotyping
Console
Genome Studio
Text file
ALL
CNVR
RO
Fragment
Yes
R

Logistic
regression

Maximum
likelihood

Logistic
regression

Fisher’s exact
test

Linear
regression

EM

Likelihood
Ratio Test

Chi-Square

Plink
Text file1)

Linux
N/A

ALL
N/A

ALL
Fragment

Yes
No
Yes4)
No
Oracle
Matlab
No
R
(Optional)
R
Annotation File Annotation File
Linear
Logistic
Regression
Statistical Methods
CA Trend regression
regression
Test
Fisher’s
exact test
(SNP ref)
Stratified
Test
Multi-locus
Test
Likelihood
Ratio Test
Logistic
regression
Linear
regression
GUI
Required

Support
Platform

Data
conversion

Text file1)

Logistic
regression
Linear
regression

Support
Data
Platform
conversion
Single
Statistical User Interface
Method
User
Interface

ALL
CNVR
Yes
Java Swing
JGraphT

ParseCNV

Interval
Fisher’s exact
Graph
test
Bron
Chi-Square
Kerbosch
CA
Trend
Test
Clique
Stratified Test
Finder
Algorithm Multi-locus
Test
Gephi
Likelihood
Ratio Test
Logistic
regression
Linear
regression
Confidence
Score

Data
Graphical
Graphical
User Interface
P-value
conversion
Report
Report
Region
Single Statistical Large data
Region
Confidence
definition
Method
handling
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ParseCNV was the first CNV association software when the idea was first conceived and
the groundwork was laid out. As shown in Table 2.4, there are currently nine other
published softwares that exist with a variety of features. ParseCNV has the most features
currently and I continue to improve functionality based on worldwide user feedback.
ParseCNV has enabled CNV associations to be applied to all major disease categories
and allows for evaluation of different versions of the SNP arrays and examination of
CNV profiles in different ethnicities at the population level. The novel association utility
of ParseCNV is more thoroughly delineated in the chapters presented below.
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Chapter 3
3.0 Genome Wide Rare Copy Number Variation Landscape and
Disease Implications in 68,000 Humans

Summary
Copy number variants (CNVs) are commonly observed in healthy individuals and have
gene dosage-sensitive effects on specific phenotypes. Several CNV maps have been
reported that illustrate the wide-spread impact of CNVs on the human genome,
implicating compelling biological functions for certain CNV regions; however, they are
generated from relatively small sample sizes and therefore lack depth of rare CNV
coverage. Here we evaluate 68,000 individuals typed with 520 thousand probes in
common and report 4,969 deletion, 2,633 duplication, and 263 homozygous deletion
CNVRs observed in multiple unrelated individuals. Of those, 17% are novel CNVRs,
64% overlap genes, and 18% overlap significant genome-wide association (GWA) single
nucleotide polymorphisms (SNPs) loci. We performed CNV association clustering across
broad disease categories of cancer, autoimmune, cardio/metabolic disease, neurological
disease populations in comparison with healthy controls, uncovering strong associations
with OMIM genes, GWAS genes and non-coding RNAs and we subsequently assessed
their contributions in different ethnic groups. We show that total CNV burden per
individual averaged ~600kb and was ethnicity-dependent. We conclude that the rare
CNVs identified represent a robust frequency definition for large scale rare variant
association studies, which are enriched for disease associations at OMIM, GWAS and
non-coding RNA loci with differential ethnicity-dependent impact.
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Prior to the introduction of CGH- and SNP-microarrays and affordable sequencing,
detection of CNVs was limited to observation based on karyotyping and fluorescence in
situ hybridization (FISH). These technologies were limited to the discovery of large
CNVs that are typically rare and thought to be disease causing based on their startling
impact on the genome (11). As the SNP array technology developed for assaying the
diploid human genome in mid-2000, the wide spread and common nature of CNVs
became more readily apparent and multiple regions of the genome were shown to have
such high frequency of CNVs that they are referred to as copy number polymorphisms
(CNPs) (54). As a result, a wave of studies has assessed the frequency of CNVs across
the human genome using different arrays, algorithms, and presentations (35, 39, 88, 94,
98, 129, 139, 172, 182, 183, 185, 205).
The functional consequence of CNVs was first described in model systems (19). In
addition to conventional Mendelian inheritance of parental CNVs, a small subset of
CNVs occurs as de novo events. Both inherited and de novo structural changes can
impact gene expression, phenotypic variation, adaptation and influence or be causal to
disease (95). Moreover, association of a rare CNV with a disease trait can flag a more
common genotype variation by uncovering a new disease pathway potentially impacted
by other types of variants (213).
Evolution and genome condensation occurs through various mechanisms, including
chromosome splicing of highly similar sequences known as homologous recombination
(HR) (32). In somatic cells, HR is needed to repair extreme DNA damage such as double
strand breaks (DSB). If spliced incorrectly, CNVs and genomic instability can result. An
intermediate state is formed between two DNA strands which proceeds by crossover (two
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way sharing, meiosis and DSB) or gene conversion (one way sharing and DSB) both of
which can impact gene dosing and predispose to disease. The human genome has
numerous regions of segmental duplication that provides similar sequences for HR to
occur. Segmental duplications can masquerade as allelic sequences during meiosis that
can lead to erroneous splicing with non-allelic homologous recombination (NAHR).
Likewise, gene conversion can insert non-expressed sequences into homologous
expressed genes resulting in reduction in gene function. Large datasets are required to
examine the impact of these mechanisms on disease phenotypes and genome evolution.
To elucidate the impact of CNVs at the genome level and their potential relevance to
disease states, we analyzed Illumina genome-wide SNP array data sharing 520,017 SNPs,
Figure 3.1. Individual Sample CNV Burden based on
Total CNV Length Genome Wide.

including both genotype B allele
frequency (BAF) and intensity log R
ratio (LRR), from 68,028 unrelated
high quality DNA samples. The
CNVs were distributed in a
heterogeneous manner throughout the
genome and no large stretches of the
genome were exempt from CNVs.
The proportion of any given
chromosome susceptible to CNV
varied from 46.7% to 96.1%

A) High Frequency CNVRs distribution; B) Low
Frequency CNVRs distribution. The total combined
length of CNVs impacting individual subject is shown.
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(Supplementary Fig. 5), due in part to
SNP resolution.

3.1 Detection of Rare Recurrent CNVs
CNVs were characterized by assembling a large population CNV map of the human
genome through the study of 68,028 genotyped individuals from four populations with
ancestry in Europe (52,321), Africa (12,548), Asia (2,299), and Latin America (860).
CNV calls per individual sample averaged 18.6 with a median of 16, with CNV state per
individual as follows: a) CN=0 with average of 1.48 and median of 1; b) CN=1 with
average of 11.8 and median of 10; c) CN=3 with average of 5.71 and median of 5; and d)
CN=4 with average of 2.20 and median of 1. The total size of the CNVs called per
individual sample averaged 68,425.3 Kb with median of 20,750 Kb. The number of SNPs
in a contiguous region in support of the CNVs call averaged 15.19 SNPs with median of
7 SNPs. The average individual CNV burden amounted to ~600 kb with rare CNV
component of ~200 kb (Figure 3.1 and Suppl. Fig. 3.1).
We detected a total of 5,238 deletion copy number variation regions (CNVRs) and 2,707
duplication CNVRs based on the above stringent CNV criteria. A CNVR was defined by
a contiguous region of SNPs within sample frequency (0. 03% corresponding to 20
samples) with spacing between SNPs not exceeding one MB. This allows for CNVR
boundary extension to be defined with flexibility to uncertainty in CNV call boundary
truncation at the sample level manifesting in a population scale and extension of a CNVR
over SNPs with aberrant frequency (Suppl. Fig. 2). It should be noted that our CNVR
definition is distinct from CNVRange, which would include minimum and maximum
boundaries of overlapping CNVs, an alternative CNVR definition specifying a different
CNV frequency range. While many CNVRs were rare, we detected 4,969 deletion, 2,633
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duplication, and 263 homozygous deletion CNVRs in multiple unrelated individuals
Figure 3.2. Genome-wide CNV Frequency of Deletions,
Duplications, and Homozygous Deletions.

(Figure 3.2, Suppl. Figs. 3.3-4, and
Suppl. Tables 3.5-7).
The average deletion CNV frequency
of these CNVRs was 0.22% with a
median of 0.05%. The average
duplication CNV frequency of these
CNVRs was 0.21% with a median of

Frequency plot of the CNV occurrence in the human
genome with alternating color scheme to delineate each
chromosome.

0.06%. This indicates that the vast
majority of the CNVs called were rare

in keeping with the genotyping platforms used (the shared SNP content resides outside of
common CNV regions). We estimated CNV call sensitivity based on our detection rate
of known CNVs in reference Hapmap individuals and CNVs reported in the Database of
Genomic Variants. Similarly, we found CNV specificity to be high given positive
independent experimental validation in 91% of 2,127 samples, testing different CNV size
ranges across the entire genome, using qPCR (Sup. Fig. 7). We validated both the
presence and absence of CNVs in various loci across randomly chosen samples.
Furthermore, the inheritance rate of CNVs was 94% and concordance between biological
replicates was 100%.
The Database of Genomic Variants (DGV) is a centralized resource for CNV
observations(133). There are over 200,000 entries of CNVs reported through various
studies that have been run on different platforms, by different laboratories at different
times and ascertained with different CNV calling algorithms (UCSC Table DGVMerged
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Downloaded 3-31-14). Our study identified a common set of SNPs across different
Figure 3.3. PCA Population Genetics and Geographical
Ancestry.

Illumina chip versions and used a
unified SNP content of 520,017 SNPs
to uncover 795 deletion and 265
duplication CNVRs harboring
74,516(54,655 and 19,601
respectively) individual CNVs that
were not reported in the DGV. We
additionally uncovered 178
homozygous deletion CNVRs
impacting 260 individuals that did not
have annotation in DGV.

D

CNVs can make genome sequence
assembly difficult (103). By
referencing the frequency of CNVs
flanking a given sequence run, the
true sequence of the genome can
more accurately predicted with
improvement in continuity. Of 1,387
such CNV regions identified
A) Overall PCA of CVS (Heart Disease), NEU
(Neurological), AID (Autoimmune), CCR (Cancer), and
HLT (Healthy). B) Density based PCA differentiating
areas of high overlap. C) Separate Hapmap and disease
category overlaid PCAs. D) PCA Population Genetics
and Geographical Ancestry of Table 2 CNV Loci
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exceeding 50 kb in size, it is
noteworthy that many of the largest
regions of the genome with sequence

uncertainty reside at the centromeres (n=70) and telomeres (n=86), especially the
centromeres of chromosomes 1 and 9 and the p arms of the acrocentric chromosomes, 13,
14, 15, and 22 (Sup. Fig. 3.5). These regions are not covered by arrays due to highly
repetitive DNA sequences that are chromosome non-specific. The average CNV
occurrence on SNPs flanking DNA stretches exceeding 50kb in the Illumina array
coverage was 58% for deletion and 78% for duplication. This frequency is much lower
for regions of high SNP density (<18bp) which had an average CNV observation of 19%
for deletion and 18% for duplication. Thus, sequence gaps in the reference human
genome assembly are at least in part due to CNVs and segmental duplications and large
gaps in SNP coverage and lack of continuity of spacing, in general, decrease confidence
in CNV calls made by SNP platforms. Moreover, to differentiate the pattern of rare
recurrent CNVs geographically at the population level, we applied principal components
analysis (PCA) and evaluated identity by descent (IBD)(Figure 3.3). For main CNVR
finding (Table 3.2), we investigated PCAs in the absence and presence of different
disease states to determine the impact of ancestry on disease-associating CNVs.

3.2 Deletion and Duplication Frequency and Genome
Clustering
We observed homozygous deletions in 894 CNVRs across the genome, with 376 (42.1%)
homozygous deletion CNVRs residing on segmental duplications (Suppl. Fig. 4). While
70.6% of homozygous deletion regions were only observed in a single individual, 10%
were observed in 10 or more individuals encompassing 60 Mb of sequence, suggesting
that approximately 2% of the human genome may be “disposable.” However, phenotypic
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information on these individuals is of particular interest with respect to a potential role of
a given disease gene and direction of intervention at a gene or biological pathway level.
To determine if CNVs cluster at specific genome hotspots, we investigated the sequence
content at the sites of CNV. Among 5,378 CNVRs uncovered, 1,725 (32.9%) deletion
CNVRs and 1,150 (42.5%) duplication CVNRs reside on segmental duplications. The
majority of CNVRs harbored both deletions and duplications: 5,091 (97.2%) of the
deletion CNVRs also have duplications and 2,623 (96.9%) of duplication CNVRs also
have deletions at these loci. Segmental duplication rearrangements are generated by nonallelic homologous recombination; however, not all annotated segmental duplications are
fixed in humans, but rather are CNVs. Thus, CNVRs harbor both deletions and
duplications, whereas pairs of segmental duplications with high sequence similarity,
including dispersed repetitive elements (Alu elements), retrotransposons, and sequence
homology within 100bp segments, are all features of the human genome that contribute to
extensive CNV aggregation over generations (43).

The recombination hotspots of the genome predispose to CNVs and were found to be
enriched for CNVs (Sup. Figure 3.8) as previously published (39). To further emphasize
this point, we have overlaid our CNVRs with publicly available recombination hotspot
maps in order to make a collective conclusion that recombination hotspots correlate with
CNV boundaries (Sup.Figure 3.9).

To explore the potential of lethal homozygozity loci as determined by absence of
expected homozygotes, we evaluated high frequency single copy deletions at specific loci
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with significantly low homozygous deletion rate in search for loci out of Hardy Weinberg
equilibrium that are likely to be homozygote lethal. We observed ATP binding,
intracellular organelle lumen, transmembrane transport, and metal ion binding genes to
meet these criteria (Sup. Table 3.17), suggesting that these genes are of fundamental
biological importance for survival.

We did PCA on the raw GWAS data to address population stratification and to verify
reported ethnicity. By using the correlates as a covariate for the logistical regression test
statistic, the correlates are removed from any confounding.
Figure 3.4. Frequency, Length and Gene Impact Features of
CNVRs detected in this study.

Regarding novelty of the CNV
content uncovered, 17% of the
CNVs we observed are novel, thus
83% concur with previous reports,
of which about 15% would be
classified as large CNVs (i.e.,
above 100kb). Of the 17% novel
CNVs, all CNVs represented with
10 or more SNPs were

Increased frequency CNVRs tend to be biased away from
genes and be restrained to smaller genomic regions.
Duplications appear to be less constrained.

experimentally validated without
failure. Over 95% of the large

CNVs (>100kb) are captured by more than 10 SNPs. These CNVs replicate between
ethnicities in our study and frequency observed here compares to published studies such
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as Conrad et al., typically used as gold standard. The ParseCNV algorithm used for the
analysis (70), has been extensively validated for CNV confidence measures, providing
another level of QC standard for CNV call validation.

It is noteworthy that in general, deletions tend to be biased away from genes, whereas
ancestral duplications appear to cluster on certain gene families throughout the course of
evolution (Figure 3.4). While it can be difficult to define the exact CNV breakpoints, it is
usually clear if a CNV disrupts genes/exons or not. Common CNVs are less likely to
disrupt genes and are therefore less likely to impact on disease than are rare CNVs.
Common variants typically flank disease associated regions, consistent with the intricate
and fragile balance of such variation.

3.3 Functional impact of CNV loci and relations to specific genomic elements
To evaluate the relationship between CNV location and disease impact, we investigated
functional elements of the genome to see if CNVs were observed in critical regions
including RefSeq genes, OMIM genes, Ultra-conserved elements, conserved non-coding
elements, non-coding RNAs, gene exons, and OMIM morbid (Table 3.1), all of which
have the ability to influence phenotype expression.

We used DAVID(46) to evaluate genes impacted by CNVRs for functional annotation
clustering by searching through Gene Ontology, INTERPRO and several other functional
databases. We observed functional enrichment of deletion CNVR impacting several gene
classes, including secreted proteins, growth factor mediators, molecules involved with

57

regulation of protein kinase cascade, regulation of protein amino acid
phosphorylation,and tumor necrosis factor-like molecules. In contrast,
we observed significant functional enrichment of duplication CNVR in molecules

Table 3.1. Impact of CNVR Loci on Functional Elements at the Genome-Wide Level

Ultraconserved
OMIM
non-coding
conserved non-coding
genes
RNAs
elements elements

RefSeq
genes

Loci Deletions

1.11

1.13

0.92

0.67

2.47

1.18

2.24

1.41

0.44

1.60

1.10

1.13

0.87

0.60

2.68

1.17

2.19

1.42

0.27

1.40

0.97

0.98

0.96

0.95

4.00

1.04

7.00

1.33

1.67

3.87

1.29

1.07

1.59

0.63

1.70

0.36

1.51

2.14

0.31

1.73

1.41

0.91

1.70

0.46

1.48

0.09

1.56

2.24

0.22

6.12

0.96

1.32

0.88

1.17

5.00

1.14

8.00

2.00

2.15

10.82

Loci
Duplications
Loci CN=0
Deletions
Genes Deletions
Genes
Duplications
Genes CN=0
Deletions

Gene
Exons

DGV Freq High NHGRI
OMIM
CNV Map Conserved GWAS
morbid
Study
>1%
Catalog

CNVRs

involved with negative regulation of signal transduction, negative regulation of cell
communication, phosphoprotein, DNA binding, as well as in several sequence variants
affecting diversity of adult human height, or largely opposing effects to those of the
deletion CNVRs. For homozygous deletion CNVRs, we observed significant enrichment
for gene classes involving intermediate filament protein and cytoskeletal keratin
molecules. The CNV enriched regions of most interest included Coil 1A, Coil 1B, Coil
2, Head, Linker 1, Linker 12, Rod, Tail, all of which are fundamentally biologically
relevant with respect to disease influence (Sup. Figure 3.6).

GWAS has been a powerful tool in uncovering disease loci and unfolding new biology in
hundreds of complex medical disorders; thus, we leveraged the GWAS genotyping data
from over 68k individuals to detect copy number variation. CNVs likely complement the
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genetic burden of many genes identified by genotype association. Among 5,378 CNVR
loci uncovered, 1,409 resided in GWAS regions associating with one or more complex
OMIM disease traits (Sup. Table 3.9). Moreover, 28% of deletions, 34% of duplications
and 39% of homozygous deletions overlapped significant GWAS signals at P<5x10-8.
For comparison, we generated random SNP seeded CNVR windows of equal number and
size to the observed CNVRs to model the null distribution resulting in 17% deletions,
24% duplications, 10% homozygous deletions overlapping reported GWAS signals at
p<5x10-8, resulting in p=3.96x10-38 for deletions, p=5.94x10-15 for duplications and
p=1.31x10-47 for homozygous deletions (p=4.56x10-78 combined) in favor of CNV
enrichment for GWAS loci. Co-localization of CNVs with GWAS genomic regions is
significantly above expectations, suggesting complementary genetic mechanisms
perturbing disease genes through both common and rare variants that co-exist at GWAS
loci.

There are several genomic regions in the human genome that are unstable and hard to
characterize. The reasons for this vary but in general, these regions are highly duplicated,
polymorphically inverted, contain assembly sequence gaps, or may be flanked by
segmental duplications of variable copy number. All of these features are being
increasingly observed in CNV regions of the human genome and their biological
implications are likely to unfold in the near future. Genotype calls in regions of CNVs
characterized by homozygous deletions result in random genotyping since there is no
DNA template to bind. Mendelian discrepancies in families are more often observed in
deletions and Hardy–Weinberg disequilibrium regions, whereas no call SNP genotypes
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are more often observed in duplications at the population level. The latter can also flag
CNVs based on a region of genotypes (172).

Due to the design of the Illumina SNP-array platform, common CNVs are poorly
captured as SNPs are omitted from the array that resides in such regions. The platform’s
SNP tagging approach is based on linkage disequilibrium (LD), which is a measure of
correlation between markers. When occurring in LD regions, SNP genotype studies have
the power to tag and associate CNVs with the trait under study. When the LD between
any two variations (r2) is close to 1, then either variation can be typed and the other
inferred by the tagging approach. We calculated LD between each of the 48 common
CNVRs we detected with frequency >5%. CNV tagging by SNP genotypes was poor
with only 5 r2 values exceeding 0.8. Loci showing r2 of 0.6-0.8 accounted for 5 CNVRs.
Loci showing r2 of 0.3-0.6 accounted for 11 CNVRs. Loci showing r2> 0.1 accounted for
32 CNVRs. Thus, only 10% of CNV events could be effectively tagged by SNP
genotypes in the surrounding region (Sup. Table 3.10). Since the CNV events dominantly
captured by the platform are relatively rare (<1% population frequency) for the majority
of loci while SNP genotypes are typically common (>1% population frequency) the
common GWAS SNPs have diminished ability to tag rare CNVs. Therefore, these CNVs
are rare events rather than copy number polymorphisms (CNPs) which could be more
amenable to SNP genotype tagging. This underscores the value of CNV detection in
addition to SNP genotype association to reveal novel insights into disease pathogenesis,
as these are independent variants.
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The recent Wellcome Trust Case Control Consortium (WTCCC) CNV study typed
19,000 individuals on targeted Agilent Comparative Genomic Hybridization (CGH)
uncovering 3,432 polymorphic common CNVs(39). However, a study of association of
CNVs with disease revealed the same exact loci as the previously done SNP genotype
GWAS (2), suggesting that analysis of common CNV may be somewhat redundant to
SNP genotyping. Logically, it follows that rare CNV association may reveal novel
disease association loci. Comparing the regions with >5% CNV occurrence in the current
study with those reported by WTCCC, 16/29 deletions agree while 2/5 duplications agree
for an overall concordance rate of 51% (Sup. Table 3.11). After reviewing the clustering
of probes underlying these regions we conclude that the discordant calls are most likely
due to incorrect or biased cluster definition due to high CNV frequency, leading to
ambiguity of the diploid cluster based on the intensity only CGH array used by WTCCC.
Thus, the apparent lack of overlap with the previous WTCCC study (39) results from the
fundamental difference between the platforms used, where our focus is on rare recurrent
CNVs which is tailored for the Illumina platform used, and that of the WTCCC is tailored
towards common CNPs, with the two having little in common and yielding
complementary findings.

3.4 CNV Clustering by Sex and Ethnicity
We assessed the impact from inferring the ancestral linkage disequilibrium blocks of
African Americans (AA) on rare CNV frequency. Unlike several previous reports from
smaller studies (141), we did not observe any differences in the overall frequency
spectrum of duplication and deletions from such a selection process; however, we
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observed clear differences in the distribution of CNV clustering, which was vastly
different between the ethnic groups (Sup. Table 3.15). Further, we note that over 95% of
the key CNV observations presented occur on a single ancestral haplotype so a very
minor proportion of the CNVs presented are de novo. Thus, the vast majority of our
observations represents single ancestral events and therefore sits on a single local
haplotype (with similar CNV breakpoints) with the remaining being de novo events on
multiple haplotypes with irregular breakpoints. The distribution of these types of events
in different ancestries was surprising as several previous studies claim that overall CNV
frequency is greater in African-Americans compared with Caucasians or Asians,
presumably due the relative evolutionary age of these ethnicities (141). To the extent we
have family material for subjects of African-American and Asian origin, our familybased analysis shows that the frequency of such events is comparable between the
different ethnic groups (Caucasian, African-American and Asian). However, evaluation
of population specific CNVs has unveiled several genes impacted by CNVs and
demonstrated ethnicity-specific enrichment in the frequency of specific CNV loci (Sup.
Table 3.15). While intriguing, overall, the frequency differences in the spectrum of
duplication and deletions are not informative about selection as the overall CNV
frequency observed was comparable between the African Americans, Caucasians and
Asians.

While inference of the ancestry linkage disequilibrium blocks in the African Americans
and assessment of rare CNVs on different backgrounds did not reveal significant
differences between the three major ancestry groups presented. Thus, we did not observe
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differences in our much larger dataset as the overall CNV frequency was not greater in
subjects of AA origin. Loci with significantly enriched and different frequencies in
respective ethnicities are included in Sup.Table 3.15.

It is well known that subtle effects of population stratification are particularly
problematic for rare variants. It is therefore encouraging that the rare recurrent variants
we observed impact all ethnic groups showing similar phenotypic effects based on the
datasets we have reported in the past (49, 65-68, 152), as well as on the data we are
reporting on here. We used base genotype (A/T/C/G) PCAs as a covariate to successfully
correct for population stratification for the entire dataset.

As we perform CNV association tests that are well standardized (70), the strength of this
cohort of 68k subjects is that even many rare events occur recurrently enough to meet
statistical standards of significance. In this regard, aggregation, bi-directional, and
collapsing statistical tests are being adopted from rare genotype variation association
studies of sequencing data and across the 3 major ethnic populations. Details on the
statistical methods used are in our recently published ParseCNV algorithm (70).

3.5 CNV Clustering by Disease Categories
In addition to disease-free “super control” subjects (n=4,352), broad disease categories of
autoimmune/inflammatory disease (n=11,489), cancer (n=9,105), congenital
heart/metabolic disease (n=2,581), and neurological disorders (n=14,756) were present
among the samples analyzed, providing CNV frequency at the population level with high
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statistical power for association of rare CNVs (Box 1). We first flagged CNVRs with
significant association to chip version (in addition to intersection set of probes used

Box 1. Key CNV Map Study Features

PennCNV

Genome-wide CNV
Frequencies

ParseCNV

Genome Feature Disease Category Version, Ethnicity,
Referencing
Association
Sample Set Bias

CNV calling involves interpreting the normally distributed values (in terms of genotype red/yellow/green
continuum (B allele frequency) and fluorescent intensity (Log R Ratio)) of neighboring probes using
hidden Markov model and Viterbi algorithm implemented in PennCNV to create discrete copy number
states for genomic segments. Genomic CNV burden of individuals can be determined directly by adding
the length of CNV calls or sorting large CNVs. The median of total length of CNVs is 600kb (Figure 1) but
there is a long tail to the distribution representing much of an individual’s genome burdened by CNV
without significant correlation to severe disease. Therefore, more careful comparison of locus specific CNV
boundaries and population frequencies stratified by type is needed genome wide. CNV boundaries can vary
slightly due to differential probe sensitivity so our CNVR determination allows small frequency
fluctuations. Overlap of genomic functional elements and CNVs is done by comparing the many genome
annotations provided by UCSC genome browser to determine which elements are enriched or depleted for
CNVS. Since the healthy population is just a part of the overall study, subjects were assigned to broad
disease categories and CNV association performed to find meta-features of disease with CNVs in specific
loci, to maximize the power of rare CNV association with large sample sets. Bias of discernibly different
subsets of data must be exhaustively considered. Although we used all Illumina beadchips, chip version,
ethnicity, and sample set bias are key factors for evaluation. The intersect of probes makes datasets from
different chip versions logically equivalent for CNV calling but SNP clustering modes and clustering
accuracy may vary due to different probe populations in beadpools and reagent chemistry. Ethnicity has
shown to have different frequencies of SNP genotypes and CNV states alike due to ancestral lineage of
CNV generation and inheritance. Sample set bias can be subtle from blood collection, DNA extraction,
storage, cell line immortalization, quantification, and fragmentation.
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across all chips to minimize bias) and by ethnicity, which yielded the following
categories of CNV bias: 304 deletion, 631 duplication, and 12 homozygous deletion
CNVRs showed significant chip version bias; 335 deletion, 925 duplication, and 32
homozygous deletion CNVRs showed significant ethnicity bias, both of which were
adjusted for in relation with disease clustering described below.

For statistical measures, CNVRs were scored based on chi square and Fisher’s exact test.
In addition to overall CNV analysis and analysis separated by deletions and duplications
across the entire cohort, we analyzed each disease category, such as autoimmune/
inflammatory disease, cancer, neurological disease etc. Loci reaching P values of 5x10-8
for deletion or duplication CNVs (and 9x10-4 in case of homozygous deletion) were
considered significant after multiple testing correction. Several chromosomal regions
aggregated many contiguously significant CNVRs that were subsequently merged (Table
3.2).
Table 3.2. Loci enriched with CNVs in Disease Categories
CNVR (hg18)

CNV
Type

chr17:73799302-73808867

Del

chr22:17257787-19792353

Del

chr22:18170308-21353745

Del

chr1:2380448-62205688

Del

chr17:1403257-7200392

Dup

65
120
(113450)
119
70
(10-427)
58

chr4:133156765-135766744

Del

chr16:83162917-88131087
chr16:1132214-1781034
chr14:103629376-103638225
chr4:39661333-39722082

Dup
Del
Del
Del

chr19:19762136-20585008
chr11:67505393-67573512

Count

Count In
Disease
Category
48
40
(37-54)

P

Category

RefSeq Genes

Count GWAS
Sig

1.86E-28

cancer

LOC283999#

0

6.41E-27

cardiovascul
ar

59

0

74

1.95E-21 neurological

61

8

43

1.08E-20

714

94

43

2.33E-17 neurological

12

65

46

3.76E-17 neurological

53
338
185
130

40
103
68
59

1.05E-16 neurological
2.64E-16
cancer
1.02E-15
cancer
3.56E-14 autoimmune

Del

292

121

3.63E-14 neurological

Del

65

34

8.86E-14

147
PABPC4L,PCDH1
0
52
26
ASPG
LOC344967
ZNF[253,486,506,
682,737,826,90,
93]
ALDH3B1,NDUFS
8,TCIRG1,UNC93
B1

65

cancer

cancer

1
16
1
0
0
1
0

Disease category enrichment in CNVRs P<9x10-14.Complete results P<5x10-8 provided in Supplementary
tables 12-14. Each disease category represents at least 10 distinct specific diseases. #CNVR does not
overlap a gene so closest proximal gene provided. Count genes overlapped provided when many. Regions
without parenthesis did not vary by more than 20 samples across the CNVR.

We observed several regions of significant association with disease state, including
chr1p36.2-p31.3, which was significantly enriched for deletions in cancer; chr17q21.1q25.3, which was significantly duplicated in cancer; and chr22q11.21, which was
significantly deleted in congenital heart/metabolic disease, replicating previous reports
(28, 136, 149). The significantly associated CNVRs were enriched for association in
cases for the respective disease category they represented. In addition, several novel CNV
loci demonstrated associations with the integrative disease category approach, all of
which were rare, and we show that 55% of significantly associated CNVRs to disease
category overlapped GWAS significant loci based on previous reports.

In addition to the above CNV enrichments observed at OMIM genes and GWAS loci, we
also noted significant CNV enrichment at genomic regions harboring noncoding RNAs
(combined CNV P= 5.97E-91) (Table 3.1). While the biological consequences of the
latter CNV enrichment are unclear, the data suggest that in keeping with the implications
of enrichment at disease genes linked to OMIM genes and GWAS loci, CNVs impacting
noncoding RNAs may confer disease-causing effects. In addition, more attention should
be paid to noncoding RNAs in disease association studies, as shown by a recent autism
study (102) where a modern RNA tiling approach uncovered and validated such a
relationship.
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Figure 3.5. Deletion CNVR Samples Observed vs.
Subgroups Represented with circle size as the number of
CNVRs.

Thus, evaluation of population
specific CNVs has unveiled several

A

genes impacted by CNVs and
demonstrated ethnicity-specific
enrichment in the frequency of CNV
loci (Sup.Table 3.15). As noted
B

above, we specifically addressed
CNVR distributions that were
enriched as a result of specific
Illumina BeadChip version, subject
ethnicity or sample source to

C

A) Illumina Chip Version B) Ethnicity C) Sample
Source. Circle size represents the number of CNVRs at
each point.

3.6 Replication of
Known CNVs and
Impact at the
Population Level
We observed known Mendelian CNV

disorders at an expected frequency in our sample set of 68,000 samples, including but not
limited to Prader-Willi syndrome (15q11-13); Smith Magenis (17p11.2); DiGeorge
(22q11.2); Williams (7q11.23); and X-linked ichthyosis (Xp22.31). As we did not have
known Mendelian disorders pre-identified in our study, which in fact constitutes healthy
controls and four major classes of complex diseases, the association of CNVs in these
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individuals with OMIM genes is novel and of high biological interest; however, one still
needs to determine if these are Mendelian phenocopies of complex disease or if CNVs in
Mendelian diseases are significant pathogenic factors in complex disease – which is a
subject of future studies. Moreover, unlike CNVs in the disease cohorts, there were
clearly no CNVs in the super controls that were enriched at genome-wide significance
level. We have healthy control enriched loci (Sup. Tables 3.12-14) as indicated in Table
3.2, but none of those are genome-wide significant.

It is important to note that the CNV associations we have captured are independent events
and we do not have a measure on if two or more rare recurrent CNVs are disease causing
– this requires complex biological studies beyond the scope of this manuscript. Indeed,
two known disease associated CNVs in one individual is extremely rare and we carefully
prioritized such cases for clinical evaluation.

As noted above, our study is focused on reporting rare recurrent CNVs and, as such, is
fundamentally different from that of Donnelly and colleagues (39), which is devoted to
common CNVs. The fact that rare recurrent CNVs co-occur with GWAS genes is
unexpected, however, the common GWAS SNPs cannot tag these rare CNVs
necessitating direct CNV detection herein.

For power reasons, we report on four major disease categories (autoimmune/
autoinflammatory; cancer, neurological; metabolic/cardiovascular), as well as healthy
controls, as individual diseases are underpowered for association with rare variants. This
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gives us a focus which is fundamentally different from any previously reported GWAS
study. For example, we demonstrate association to autoimmune/autoinflammatory
diseases as a class (IBD T1D, JIA, SLE, Celiac disease, asthma). Thus, the observation
that CNVs associate with the respective disease classes is novel and of important
biological relevance, as it extends beyond any previous GWAS/CNV report.

We have captured the global impact of rare recurrent CNVs in terms of frequency,
distribution and the role of such structural variants in health and disease across four major
disease categories as well as controls, including across different ethnicities following
thorough correction for population stratification measures. We note that our evaluation of
population specific CNVs has unveiled several genes impacted by CNVs and
demonstrated ethnicity-specific enrichment in the frequency of CNV loci (Sup. Table
3.15); however, no difference was observed in overall CNV frequency across the
different ethnic groups (EA, AA, Asian).

3.7 Discussion
Our results demonstrate that there is an abundance of CNVs across the genome that
impact and flank functional elements with potential for major disease implications
(Tables 3.1-2). While CNVs have been shown to importantly contribute to disease
association studies, it is critically important that databases with CNVs and associated
phenotypes be annotated along with platform and CNV call confidence scores. The
Database of Genomic Variants Structural Variation which is available in UCSC genome
browser is currently one of the most informative and useful resources of CNV
information for investigators (94). The current CNV map has uncovered numerous novel
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CNV regions, many of which are disease associated (Tables 3.1-2). GWAS has similarly
been highly successful in unfolding novel loci of strong disease and biological relevance
(2); however, lack of linkage disequilibrium with rare CNVs at over 90% of loci
underscores the needs for CNV detection to be performed separately, particularly for very
rare CNVs. SNPs with three or more states and considerable heterozygote frequency are
well suited to differentiate duplication based on genotype states.
Copy number variation (CNV) is a commonly observed phenomenon in healthy
individuals and also has gene dosage-sensitive effects on specific phenotypes. While
several CNV maps have been reported that illustrate the wide-spread impact of CNVs on
the human genome and implicating compelling biological functions for some CNVs, they
are all built on relatively small sample sizes and lack depth of rare CNV coverage (35,
39, 88, 94, 98, 129, 139, 172, 182, 183, 185, 205). This study was designed to
characterize rare CNV by assembling the largest population CNV map of the human
genome through the study of 68,028 genotyped individuals from four populations with
ancestry in Europe (52,321), Africa (12,548), Asia (2,299), and Latin America (860). We
processed genotype and intensity data for CNV detection using Illumina singlenucleotide polymorphism (SNP) genotyping arrays intersection set of 520,017 SNPs.
CNVs called per individual averaged 18.6 probes and the length of the CNVs called
averaged 68 Kb, with average individual CNV burden was 600 kb, including a rare CNV
component of 200 kb (Figure 3.1).

By mapping individual CNVs into population statistics, 5,378 copy number variable
regions (CNVRs) were identified, with deletions covering 2.35 gigabases (78% of the
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genome) and duplications covering 2.46 gigabases (82% of the genome), in keeping with
the pervasive nature of CNV (Sup. Tables 3.5-7). While most CNVRs were rare, 4,969
deletion, 2,633 duplication, and 263 homozygous deletion CNVRs were detected in
multiple unrelated individuals (Suppl. Tables 3.5-7). Reported GWAS loci were present
in 2,729 of the CNVRs identified demonstrating strong enrichment for CNVs at GWAS
loci (P=5.97E-91) and similarly 1,531 CNVRs overlapped OMIM disease associated
genes. A total of 964 deletion and 343 duplication novel CNVRs were uncovered that
were not reported in the DGV. Of the CNVRs detected, 64% overlapped genes. Of note,
genes functionally enriched for growth factor signaling and other signal transduction
processes and intermediate filaments, were most commonly enriched for CNVs. Genes
residing in segmental duplications and disease associated regions were also notably
enriched for CNVs.
All CNVRs were controlled for beadchip version, ethnicity, and sample source to exclude
any processing bias. Linkage disequilibrium between common SNP genotypes and rare
CNVs was poor. In addition to determining CNV distribution in healthy subjects, we also
examined CNV clustering across broad disease categories of cancer, autoimmune disease,
congenital heart/metabolic disease and neurological populations, with high statistical
power for comparison, demonstrating significant enrichment for specific chromosomal
regions impacted by CNVs to these disease categories (Table 3.2 and Suppl. Tables 3.1214). Similar enrichment in CNV association was also observed for noncoding RNAs
(Table 3.1), suggesting they may be more relevant to human disease that previously
thought.
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We additionally demonstrated population frequency differences of CNVs in loci across
the genome (Figure 3.3 and Suppl. Table 3.15), suggesting the process of evolution
through gene family extension is enabled by CNVs, and that CNVs impact gene networks
across all major disease categories (Table 3.2 and Suppl. Tables 3.12-14).
We thoroughly evaluated our dataset for inflation in the test statistic and adjusted for
CNV classes. This approach is fundamentally no different from standard statistical tests
for GWAS. Since there is no other cohort of this size that has GWAS performed by the
same laboratory, we are setting standards for the genetics field with our analysis. We
note that details of the statistical methodology used for the CNV reporting herein were
recently described inParseCNV (70), a novel algorithm developed by our laboratory
(Suppl. Material).

As noted, the average individual CNV burden is approximately 600kbp (Figure 3.1),
including distribution of all CNVs across the study cohort. The median CNV size of 7
SNPs with minimal call size in SNPs of 3. The mean SNP coverage is 5,280 bp between
neighboring SNPs. The median SNP coverage is 2,965 bp between neighboring SNPs.
Our recently published CNV algorithm, ParseCNV, was used for CNV association
capture, definition of CNVRs and statistical analysis, an algorithm that has been
extensively validated for CNV call accuracy, based on experimental validation. Thus, in
addition to random experimental validation of CNV loci from the 68,000 samples with
excellent success as presented (>90%), the algorithm used has been independently
validated providing high level of confidence (>90%) for the results presented here.
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While somatic alterations and mosaicisms exist in DNA samples derived from blood,
their contributions overall are minimal and do not impact the results presented here.
Moreover, we have no example of a common GWAS SNP capturing any of the rare
recurrent CNVs reported. The Illumina chips we used are designed to stay away from
common CNV regions so they are highly underrepresented in our report as a result of
chip design. We note that 48 common CNVs remained in our observed data despite the
array being strongly biased away from copy number polymorphisms with >1%
population frequency, which is a minor subset of what we are reporting here.

The raw CNV counts (Sup. Table 3.16) were used to create randomized set of genomic
regions of best matched length and number of SNPs to compare to CNVRs for genomic
features to score statistical significance. We searched for functional enrichment across
all CNVRs to find insight into biological functions tempered by CNV as a major
mechanism. As a result, we specifically reduced the phenotype variables to 4 major
disease classes, all of which show strong association to specific CNV loci. We note that
96% of the genome is CNVR-based refined to the portion of the genome we have
reasonable coverage so the analysis is truly genome-wide and hypothesis-independent.
The NHGRI GWAS catalog is the source of the GWAS signals that were intersected with
CNVRs compiled across diverse disease association studies. In the CNV clustering by
disease categories, we performed 7,602 statistical tests to correct for in association (4,969
deletions and 2,633 duplications). To be inclusive for ethnicity differences we included
both the super control cohort and the subjects in the four major disease categories.
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Our extensive CNV validation measures (including those intrinsically supporting the
ParseCNV algorithm which was used to make these CNVR calls) included separate
deletions from duplications with respect to CN state. Over 100 random deletion and 100
random duplication validations are presented across diverse genome regions, length, and
number of SNPs on our array with success rate in the above 90% (70). As we and others
have reported previously, deletions and duplications co-exist in multiple disease-causing
CNV regions, including well established disease loci such as16p11 and 15q11-13. We
note that the population frequency of the alternate event is often much lower but
recurrent.

One limitation is that if a sample is A, AA, or AAA we cannot differentiate these allelic
states based on B allele frequency. CNV sensitivity is supported with quantification with
reference to HapMap samples typed on our arrays compared to the current gold standard
set by Conrad et al. (35). Population frequency <1% (<680 subjects) defines a rare CNV
in our study. It is important to note that we need to accurately assess CNVs in a
“reference genome” sample in order to correctly make genotype A/T/C/G calls. Since
genome sequencing always does mapping to this “reference genome” sequence assuming
diploid status, we have implicated more of the genome than previously thought (133) is
impacted by rare CNV.

We have included the few common CNVs available by our array content to cross
reference our findings with the popular gold standard paper by Conrad et al. Otherwise,
the Illumina arrays stay away from common CNVs, which is in sharp contrast with the
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aCGH arrays used in the Conrad et al study. For all statistical measures, Fisher’s exact
test was used as a conservative test. As described earlier, a maximum variance of 20
samples between neighboring probes was allowed.

The present CNV study has high rare CNV coverage and encompasses the majority of the
genome based on the large sample size used (Figure 3.2 and Suppl. Tables 3.5-7). We
believe that our large population-based frequency characterization provides a unique
opportunity to characterize the distribution and impact of CNVs in the genome and the
fact that all samples were typed on comparable platform and with vast majority
genotyped at the same laboratory accounts for high data quality. Future resequencing
studies will ultimately improve our resolution and confidence of detecting smaller CNV
calls of 1kb or less, we are unable to address in this study. Indeed, combinations of
sequence assembly comparisons, paired-end sequence relationships, sequence trace
analysis, and higher-resolution tiling arrays will similarly aid in determining the precise
CNV breakpoints and genotype state for individual CNVs. While GWAS and genomewide CNV analyses have contributed in a major way to the understanding of the
distribution and biological impact of CNVs, whole-genome sequencing studies (146)will
ultimately provide the most continuous and confident information of individual CNVs
and their role in disease.

Taken together, the CNV results reported herein include results from over 68,000
subjects, an order of magnitude greater in the amount of data previously published. In
addition, we took the unprecedented step to couple this dense map of SNP data to clinical
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association findings. As a consequence, we show for the first time that rare CNVs, which
cannot be tagged by standard genotyping arrays, are associated with the following
genomic elements genome-wide: 1) GWAS genes; 2) OMIM genes; and, 3) non-coding
RNAs. These observations present a fundamental new concept on how GWAS genes
(linked to common variants), OMIM genes (linked to rare diseases) and non-coding
RNAs (most of which are thought to play no or unknown role in disease biology), impact
on common complex disease through rare highly penetrant CNV providing new insight
into the mechanistic role of rare recurrent CNVs in complex disease biology and etiology.

Moreover, the analyses presented here are highly robust, as demonstrated by the strong P
values generated and only made possible by the exceptional size of the cohort. As such
confidence in these findings is extremely high by adding further support of the key
findings validated by either family-based analyses (heritable CNVs), visual inspection of
B-allele frequency/LRRs of the genotyping data or by experimental validation if any
uncertainty, resulting in over 90% validation success rate of the CNVs reported. These
validation parameters are further supported in a recent manuscript reporting on a novel
CNV analysis approach and statistical applications that were used here (70). Moreover,
our novel CNV reporting, extensive mapping and reporting of homozygous CNVs
(human knockouts) in the context of novel association findings delineate multiple bona
fide discoveries that are well powered and of biological interest for others to follow.

Thus, we have mapped multiple novel homozygous CNVs and observed novel
associations to the four major disease categories we examined, and observed that CNVs
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co-localize to important genomic elements, including GWAS genes, OMIM genes and
non-coding RNAs, that surprisingly include the most significant genomic elements at the
genome wide level that track with disease-associating CNVs.

3.8 Methods
The study inclusion criteria included: 1) availability of high-quality genotype data from
subjects typed on a high-density SNP arrays; 2) sample having de-identified status and
residing in the bio-repository at the Center for Applied Genomics (CAG) of the
Children’s Hospital of Philadelphia (CHOP) where they were genotyped; 3) informed
consent authorizing de-identified use of GWAS data with limited phenotype information.
Different ancestry populations were analyzed and all 68,028 samples were typed at the
same genotyping center within a five year interval from August 2006 to July 2011. Over
95% of the DNA was extracted from fresh blood. Six incremental versions of the
Illumina 550k SNP set was used with a total of 520,017 SNPs in common to all the chip
versions. PennCNV was used for CNV calls and validated by QuantiSNP. Quality
metrics were calculated and their distributions assessed to ensure optimal quality and to
minimize bias. Only samples with call rate >98% and Log R Ratio (LRR) standard
deviation <0.35 were included in the analysis. Furthermore, autosome genotype
relatedness, excessive CNV calls as a measure of poor sample quality, and intensity wave
variations following GC content wave correction were assessed for sample exclusion.
CNV sensitivity was excellent based on CNVs in reference Hapmap individuals and
CNV specificity exceeded 91% based on validation in 2,127 samples, testing different
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size ranges across the entire genome, using qPCR. Here, we present the results of 409
attempted and 367 successful validation assays from 7 disease studies with a range of
different genomic loci and CN states (Sup. Fig. 7).

Case and control matching was insured by calculating a genomic inflation factor between
groups. Wave artifacts roughly correlating with GC content resulting from hybridization
bias of low full length DNA quantity are known to interfere with accurate inference of
copy number variations. Only samples where the GC corrected wave factor of LRR
<|0.02| were accepted. If the count of CNV calls made by PennCNV exceeds 100, it is
suggestive of poor DNA quality, and those samples were excluded. Thus, only samples
with CNV call count < 100 were included. Any duplicate samples (such as monozygotic
twins or repeats on the same patient) were identified and as a result one sample was
excluded.

CNV frequency was compared between various groups, including between cases and
controls. Comparisons were made for each SNP using Fisher’s exact test. To determine
CNV enrichment, we only considered loci that were nominally significant between the
comparative groups (p<0.05). For case-control comparisons, we looked for recurrent
CNVs that were observed across different independent cohorts or were not observed in
any of the control subjects, and were validated with an independent method. Three lines
of evidence establish statistical significance: independent replication p<0.05, permutation
of observations, and no loci observed with control enriched significance. We used
DAVID (Database for Annotation, Visualization, and Integrated Discovery) to assess the
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significance of functional annotation clustering of independently associated results into
InterPro categories.

Taken together, apart from unveiling multiple important disease associations, our
genome-wide CNV analysis in over 68,000 individulas has provided a robust population
frequency distribution for rare CNVs in general. Now we proceed onto the challenge of a
similar meta-view of disease in lifespan.
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Chapter 4
4.0 Copy Number Variations in Alternative Splicing Gene Networks
Impact Lifespan

Summary
Longevity has a strong genetic component evidenced by family-based studies.
Lipoprotein metabolism, FOXO proteins, and insulin/IGF-1 signaling pathways in model
systems have shown polygenic variations predisposing to shorter lifespan. To test the
hypothesis that rare variants could influence lifespan, we compared the rates of CNVs in
healthy children (0-18 years of age) with individuals 67 years or older. CNVs at a
significantly higher frequency in the pediatric cohort were considered risk variants
impacting lifespan, while those enriched in the geriatric cohort were considered longevity
protective variants. We performed a whole-genome CNV analysis on 7,313 children and
2,701 adults of European ancestry genotyped with 302,108 SNP probes. Positive findings
were evaluated in an independent cohort of 2,079 pediatric and 4,692 geriatric subjects.
We detected 8 deletions and 10 duplications that were enriched in the pediatric group
(P=3.33x10-8 - 1.6x10-2 unadjusted), while only one duplication was enriched in the
geriatric cohort (P=6.3x10-4). Population stratification correction resulted in 5 deletions
and 3 duplications remaining significant (P=5.16x10-5-4.26x10-2) in the replication
cohort. Three deletions and four duplications were significant combined (combined
P=3.7x10-4-3.9x10-2). All associated loci were experimentally validated using qPCR.
Evaluation of these genes for pathway enrichment demonstrated ~50% are involved in
alternative splicing (P=0.0077 Benjamini and Hochberg corrected). We conclude that
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genetic variations disrupting RNA splicing could have long-term biological effects
impacting lifespan.

4.1 Introduction and Significance
The idea of extended lifespan has fascinated generations of scholarly thought. Specific
diseases have been the focus of much biomedical research rather than overarching
longevity which in essence successfully avoids a variety of diseases. The average lifespan
of the human population has continued to increase at a slow rate due to medical and
technological advances that aim at preventing and treating both acute and chronic
diseases and attenuating morbidity and mortality of old age (208).Identification of
underlying causes of early fatality provides information that can facilitate preventive
measures. As hypothesis free approach is the gold standard to assay genomic variants for
disease states, it is equally important to take a hypothesis free approach to assay
longevity, one of the most informative measures of health vs. disease states. This
approach also addresses the complication in genetics of pleiotropy (one gene:many
diseases) where disease phenotype variability results in insufficient power of single
disease association studies.

Model systems have demonstrated that lifespan can be dramatically extended by
mutations in conserved pathways that regulate growth, energy metabolism, nutrition
sensing, and reproduction (101). A low activity level of organs in many cases extends
lifespan perhaps by reduction of somatic damage and increase of somatic maintenance
and repair (101). Strict diet maintaining just above malnutrition has been shown to extend
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longevity (30). The leap from model system to human is substantial given the lack of
genetic diversity and protective laboratory environment of model systems. It is more
probable that significant longevity was achieved by subtle changes in many genes over
the course of evolution, not by single mutations with large effects, which often increase
lifespan at a cost to reproduction or survival under stress (100).

Genome instability, macromolecular aggregates, decrease in innate immunity,
skin/cuticle morphology changes, decreased mitochondrial function, degenerative loss of
skeletal muscle mass and strength, and decreased fitness are highly conserved phenotypes
of ageing. Lifelong accumulation of various types of damage, along with random errors
in DNA maintenance, might underlie intrinsic ageing. Early findings of mutant C.
Elegans with extended lifespan (107) and linkage studies (166)showed that longevity
could be associated with genetic traits. A meta-analysis of 4 cohorts of individuals
surviving over 90 years of age found MINPP1(involved in cellular proliferation) as well
as LASS3 and PAPPA2 to be involved (150). Genes impacting lipoprotein metabolism (6,
7, 10), FOXO proteins (57, 215), and insulin/IGF-1 signaling (16, 110, 153) in humans
have also been associated with lifespan.

Copy number variations (CNVs) are rare losses and gains in DNA sequences that have
been importantly implicated in the pathogenesis of various neurodevelopmental and
psychiatric diseases (65, 67, 116). As opposed to SNP genotypes which have revealed
common variants conferring modest relative risk to the individual with the variant, CNVs
are often rare variants not observed or extremely rare in a normal control population and
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conferring high relative risk. SNP arrays have vastly improved the detection of CNVs
across the human genome over classical methods of karyotype review under a
microscope. While the realm of neuropsychiatric and other system disorders have been
explained in part by CNVs, it remains to be determined if there are certain gene classes or
networks of genes that are pathogenic or disease-causing in general, and if there are other
gene networks that may be protective in the same manner. One way of testing this is to
compare CNV states and frequencies between pediatric and geriatric subjects and
determine if certain CNVs are lost in the older age group (i.e. suggesting pathogenic
impact with shortened lifespan), and if other CNVs are enriched and considered
protective. Since the detection of CNVs has greatly improved and continues to improve
with simultaneous evaluation of genotype and intensity data with continuous coverage of
the genome and differentiating models of the diploid from the CNV state, we have
undertaken such comparisons in cohorts of pediatric cases (0-18) and adults above the
age of 67.

4.2 Results
Table 4.1. Discovery and Replication Case:Control Sample Sets

Cohort
Discovery
CHOP Pediatric
Discovery IHA
Geriatric
Replication
CHOP Pediatric
Replication
Geriatric

Samples
Count

Country of
Origin

7,313

United States

2,701

Iceland

2,079

United States

4,692

United States

Contributing project totals in discovery and replication phases. The totals represent the number of high
quality datasets derived from samples.
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The pediatric discovery group included 7,313 children recruited at the Children’s
Hospital of Philadelphia (Table 4.1). The geriatric discovery cohort included 2,701
individuals recruited by the
Figure 4.1. Principle Components Analysis of Pediatric and
Geriatric Cohorts.

Icelandic Heart Association in the
AGES Reykjavik study of 67 years
or older. Only samples meeting
strictly established data quality
thresholds for copy number
variation were included in the
analysis. Pediatric subjects were
genotyped on the Illumina Human

Discovery U.S. Pediatric vs. Icelandic Geriatric A) Principal
components (PC) 1 vs. 2 shows distinct clusters likely due to
sporadic differential profiles of a specific subset of SNPs
between arrays. Since CNV calling is based on multiple
neighboring SNPs and differential clustering SNPs are
randomly distributed, CNV discovery should not experience
significant bias. B) PC2 vs. 3 representing population
structure showing some overlap of pediatric and geriatric
cohorts C) SNP genotype allele frequency differences
genome wide showing close correlation.
Replication U.S. Pediatric vs. U.S. Geriatric D) Replication
of U.S. pediatric and U.S. geriatric PC1 vs. PC2 showing
high overlap unlike panel A U.S. pediatric and Icelandic
geriatric E) Geriatric replication cohort in isolation for
clarity F) Population structure of pediatric subjects with
significantly associated risk CNVs for short lifespan
showing broad normal distribution minimizing test statistic
inflation for rare variants opposed to tight clustering(37) G)
Pediatric replication cohort in isolation for clarity.

Hap550 while geriatric subjects
were genotyped on the Illumina
HumanCNV370-Duov1.0. To
ensure comparability of results,
only the intersection set of 302,108
SNPs common to both platforms
was evaluated. All arrays used the
Illumina Infinium II

beadchiptechnology with standardized reagents, oligos, and experimental protocol to
minimize variation between genotyping at different sites. Multiple neighboring SNPs
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(minimum 3) are required to make a CNV call so one biased SNP in a region will not bias
the CNV calling. CNVs were scored with both PennCNV (211) and QuantiSNP (34) for
copy number deviating from normal diploid state 2: states 0 and 1 for deletions and 3 and
4 for duplications. We compared frequency of deletions and duplications between
pediatric and geriatric subjects to assess significant enrichment of rare recurrent CNVs in
either group. Evaluating the SNP
Figure 4.2. Manhattan Plot of (A)Deletion and
(B)Duplication SNP based CNV Statistics

genotype data revealed tight clustering
of populations at the origin by principle
components analysis (PCA) indicative
of European ancestry. Unfortunately,
low overlap of populations was
observed when the pediatric and
geriatric cohorts were plotted together
(Figure 4.1A and 4.1B). Many CNV
and genotype associations made in
cohorts of European ancestry have
shown robust replication in Icelandic
cohorts (53, 76, 79, 189, 191, 202),
indicating that CNVs observed in the
more broadly-defined European and
American Caucasian gene pool are also

Black and gray alternating chromosome coloring to
differentiate.

important in the Icelandic population.
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The Icelandic cohort is unique in having risk factor assessments earlier in life and
detailed late-life phenotypes of quantitative traits (85). Our rationale for comparing these
cohorts was the availability of large pediatric and geriatric populations with extensive
phenotype characterization both genotyped on the Illumina microarray. While the PCA
analysis clearly shows this comparison to be impacted by population stratification and
that PCA cannot be applied as covariates due to this lack of overlap, we believe this
comparison can be hypothesis generating in showing if such associated variants can be
replicated in an independent
Figure 4.3. Independent Technology Validation of
Presence of CNV Events to Confirm CNVs Detected by
Illumina Array.

population with a very good PCA
overlap, but less phenotype depth.

To associate CNV loci potentially
contributing to shortened lifespan, we
applied a segment-based scoring
approach that scans the genome for
consecutive probes with more frequent
copy number changes in pediatric
compared to geriatric subjects. The
genomic span for these consecutive
Error bars denote the standard deviation of quadruplicate
runs.

probes forms common copy number

variation regions (CNVRs). We uncovered 101 loci with deletion and 76 with duplication
enrichment in the pediatric cohort. Conversely, we identified 90 loci with deletion and 74
with duplication enrichment in the geriatric cohort (Figure 4.2).
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After raw data QC and genomic context review, a high confidence discovery set of 55
deletions and 40 duplications that were significantly enriched in the pediatric cohort
resulted while 53 deletions and 43 duplications were enriched in the geriatric cohort.
These filtering criteria included exclusion of telomere, centromere, CNV boundary
uncertainty, extreme GC content, poor SNP coverage, and CNVR sample bias. CNVR
sample bias refers to the same sample contributing to the association signal of many
different significant CNVRs, despite up-front sample quality control, often due to
atypical intensity wave patterns.

We next sought to independently replicate these CNV findings in additional pediatric and
geriatric subjects. CNVs were called for 2,079 young age subjects from independent
pediatric cohorts all of which were recruited in the U.S.A and genotyped on the Illumina
Infinium HumanHap550. We compared the CNV frequency in young with an
independent cohort of 4,692 older subjects (over 50), all of which were recruited in the
U.S.A. and genotyped on the Illumina Infinium Human660W-Quad. We replicated in the
same direction 11 deletions and 10 duplications that were significantly enriched in the
pediatric cohort, while 1 duplication was enriched in the geriatric cohort. As shown in
Figure 4.1, in contrast to the Icelandic geriatric vs. U.S. pediatric PCA plot (panel 1A),
the replication U.S. geriatric vs. U.S. pediatric did show strong overlap (panel 1D)
indicating comparable population structure.
Furthermore, we were able to correct for any residual population structure using the first
three components of the PCA as covariates for logistic CNV association. This gives the
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unique opportunity to test replication of associated loci between non-overlapping PCA
populations which cannot be corrected by covariates with well overlapping PCA
populations controlled by covariates. We can also assess replication between Illumina
array versions for consistent CNV detection. We believe leveraging existing data with a
variety of variations may lead to associations more likely to remain significant by further
studies where these variations are often manifest in addition to data processing variations
which we were able to control by applying consistent processing across all data.

To assess the reliability of our CNV detection method, we experimentally validated all
the significant CNVRs using an independent wet lab method, quantitative real time
polymerase chain reaction (qPCR) (Figure 4.3) on a randomly selected samples with a
CNV at each associated locus and samples without a CNV to normalize the measurement.

This yielded a final confident set of 8 deletions and 10 duplications that were
significantly enriched in the pediatric cohort (Table 4.2) while 1 duplication was enriched
in the geriatric cohort (Table 4.3).
Table 4.2. CNVs Enriched in Pediatric Individuals
CNVR hg18
chr8:23379182570171
chr22:1840987818439763
chr16:35530053590430
chr1:226561413226623411
chr19:1724526717245267
chr1:62406566289806
chr11:4738887947443461
chr7:5342818053557744

CHOP
IHA
P
Replication Replication
Pediatric Geriatric Discovery Pediatric
Geriatric

P PCA
P
Corrected
Combined
Replication

Gene

Type

AK128880,BC045738

Dup

87

4

3.33E-08

30

24

0.001406

0.00037

42

0

3.89E-06

9

4

0.00487

0.003862 C22orf25,DKFZp761P1121 Del

60

1

1.37E-07

16

0

0.9961

0.008209

BTBD12,NLRC3

Dup

50

0

1.87E-07

7

0

0.9975

0.00924

KIAA1639,OBSCN

Dup

19

1

0.02286

12

3

5.16E-05

0.018451

HSPC142/BABAM1

Del

26

0

0.0005

8

3

0.002979

0.020119

ACOT7,BACH,GPR153

Del

66

4

9.00E-06

16

0

0.9965

0.038865 PSMC3,RAPSN,SLC39A13 Dup

29

0

0.00019

8

5

0.1969

0.064854

88

FLJ45974*

Del

chr17:7111248671153309

20

1

0.02352

9

1

0.002534

chr21:4369748844395416

14

0

0.01601

5

1

0.007178

25

1

0.00626

9

1

0.02017

37

3

0.00369

8

1

0.0426

0.10708

MGC87315

Dup

25

0

0.0005

7

0

0.9981

0.15837

KIAA0397,RUTBC1

Dup

38

3

0.00246

8

0

0.9979

0.26546

CACNA1H*

Del

14

0

0.01601

4

0

0.9986

0.46396

CDC37,PDE4A,TYK2

Dup

22

2

0.03849

10

0

0.9974

0.5864

NFIC

Del

11

0

0.04318

12

0

0.997

0.60362

11

0

0.04318

9

0

0.9977

chr4:9730601068187
chr7:7173462671921501
chr17:22135492231452
chr16:11322141138939
chr19:1032683210403610
chr19:33996943421862
chr1:62455236472963
chr17:7683692676916744

LOC643008,MYO15B,REC
Del
QL5
AGPAT3,C21orf125,C21orf
33,C21orf84,CSTB,HSF2BP,
0.096104
Del
LOC284837,PDXK,PWP2,R
RP1,RRP1B,TRAPPC10
FGFRL1,IDUA,LOC285498,
0.099286
Dup
RNF212,SLC26A1
0.076432

ACOT7,ESPN,HES2,PLEKH
Dup
G5,TNFRSF25
C17orf55,MGC15523,TME
0.60373
Dup
M105

*Gene not overlapped so closest proximal gene annotated. Gene delimiters were defined based on UCSC
genes table reference including exons and introns. Any direct overlap of any segment of the gene delimiters
is considered a hit such that complete overlap of the gene is not required. Combined p-values were
calculated using Fisher’s method.

To fully correct for population stratification, in addition to multi-dimensional scaling, we
performed principal component analysis (PCA) on the genotypes and used the resulting
first three components as covariates of logistic test CNV association in the replication
cohort. CNV events in our study are rare and arise randomly shown by evaluating the
Table 4.3. CNVs Enriched in Geriatric Individuals
CNVR hg18
chr5:26,246,32026,273,890

CHOP
IHA
P
Replication Replication
Pediatric Geriatric Discovery Pediatric Geriatric
1

7

0.00063

0

24

P PCA
P
Corrected
Combined
Replication
0.9963

0.17091

Gene

Type

CDH9*

Dup

spatial distribution of samples having a risk CNV on the PCA plot revealing a Gaussian
(at minimum uniform due to few data points) distribution which indicating minimal test
statistic inflation (even less than common variants) as opposed to a small, sharply defined
region (137) (Figure 4.1F). We verified that population stratification was fully controlled
for based on a genomic inflation factor of 1.0. Eight of eighteen pediatric enriched CNV
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loci remained significant (p<0.05) following PCA population stratification correction
(five deletions and three duplications; see Table 4.2). These results indicate that, while
population stratification did indeed influence nominal p-value of the associated rare CNV
variants in the discovery cohort, it could be corrected in the independent replication
cohort, leaving a number of associated loci that replicated.

Given the diverse etiology of diseases and more generally, lack of fitness in an
evolutionary context, the genes underlying the broad consideration of ageing are similarly
diverse. Single significant loci are certainly of interest to the common genomic CNVs
resulting in specific genes to study. However, strong confidence in the result set
generated can be achieved by observing the same biological system being perturbed by
multiple independently significant loci. Motivated by this, genes directly overlapped by
associated CNVs were prepared as a single list and non-RefSeq hypothetical gene IDs
were removed. This list was entered into DAVID functional annotation enrichment tool
in contrast with a background representing genome-wide regions covered by the array.
Taking into account the size of different genes and the gene family size of different
annotations, the enrichment of our CNV impacted list was assigned a p-value with
Benjamini and Hochberg correction for multiple testing. Functional annotations from
multiple databases were used including KEGG and GO (gene ontology). Functional
categories were reviewed for genes contributing from distinct genomic regions to reject
enrichment of closely clustered gene families.
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To identify potential functional biases specific to CNVs observed at significantly higher
frequency in young individuals, we evaluated clustering into specific functional
categories using DAVID (46, 92) (Database for Annotation, Visualization, and Integrated
Discovery). We found significant overrepresentation of alternative splicing genes
impacted by the CNVs. To limit contribution of regions with gene families of related
function, each CNV loci was limited to contributing one gene to a functional cluster,
done by referencing resulting gene clusters back to the input genes from each CNV
region. Among the alternative splicing genes are AGPAT3, BTBD12, NLRC3, RECQL5,
SCAPER, ACOT7, C19orf62, C21orf33, C22orf25, ESPN, HES2, LUZP2, NFIC,
OBSCN, PDE4A, PLEKHG5, PLXDC1, KCNT1, PDXK, RAPSN, RRP1B, RNF212,
SGSM2, SLC38A10, SLC39A13, and TNFRSF25 all of which were significantly enriched
in the young age group (P=0.0077 Benjamini and Hochberg corrected), suggesting that
genetic variations that disrupt RNA splicing may have long-term biological effects on
human lifespan.

4.3 Discussion
Limited nutrition, somatic maintenance and growth are pathways to longevity. Emphasis
on somatic maintenance is more important than early growth and reproduction. Posttranscriptional modification of mRNA is an important mechanism which results in a
variety of protein isoforms and occurs in at least 80% of human genes, and known to
harbor variations that have been associated with human disease (138). It is therefore of
interest that 50% of the genes impacted by CNV loci significantly enriched in young and
replicated in an independent cohort were responsible for alternative splicing, suggesting
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that genetic variants in these gene networks may be pathogenic and disease causing in a
more global way than previously thought.

Alternative splicing is an abundant violation of the original assumption of one gene one
protein theory. The exons of an mRNA can be edited producing a variety of combinations
which result in a variety of protein

Figure 4.4. Regions of CNV in Young Individuals
observed at low levels in Older Individuals.

isoforms. This mechanism allows for a
great diversity of protein products
based on the same DNA code and
branches out gene families, in a similar
mechanism that ancestral duplications
extend gene families in DNA. Proteins
responsible for alternative splicing bind
to specific RNA sequences to promote
or repress splicing.
ACOT7 locus shows significant excess of deletions and
duplications in young individuals. Blue lines indicate
SNP marker coverage to resolve CNV boundaries.
Histogram shows the number of subjects with deletion
and duplication CNVs in the Icelandic older population
(very low). The red and green boundaries show
individual CNVs observed in specific young samples
from CHOP. Genomic region references including GC
percent, RefSeq Genes, and Database of Genomic
Variants are provided for reference.

SNPs in the RNA editing genes
ADARB1 and ADARB2 were associated
with extreme old age in a United States

based study of centenarians with replication to four other ethnic backgrounds (181). DNA
maintenance is of fundamental importance throughout the lifespan and is under assault by
environmental conditions such as sunlight and chemical exposures. BTBD12 and
BABAM1 are part of a multi-protein complex containing enzymes involved in DNA
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maintenance and repair of serious damage such as collapsed replication forks and doublestrand breaks (DSBs)(198). Of note, BABAM1 is the most highly significant CNV
associated locus following full statistical correction of population stratification
(p=5.16x10-5).

ACOT7 is involved with biosynthesis of unsaturated fatty acids and decreased expression
is associated with mesial temporal lobe epilepsy. Young individuals showed significantly
Figure 4.5. Representative Interactions of the Lifespan
Longevity Associated Genes Identified.

higher frequency of both
deletions and duplications of
this locus compared to older
individuals (Figure 4.4).

Nuclear factor kappa B
(NFKB1) signaling pathway is
a fundamentally important
Gene-gene interactions of independently significant loci.
Additional genes implicated by interacting with genes in
significantly associated longevity loci. Alternative splicing
gene function annotation enrichment of significant loci
suggests diverse genetic perturbation with a common biological
role. Extension of this functional category to other genes
annotated by functional studies with interactions to associated
genes implicates potential for screening diverse etiology.

protein complex that controls
the transcription of DNA and
responds to external factors
such as stress, cytokines, free

radicals, ultraviolet radiation, oxidized LDL, and bacterial or viral antigens. PLEKHG5
activates the NFKB1 signaling pathway. TNFRSF25 encodes a receptor that has been
shown to stimulate NF-kappa B activity and regulate cell apoptosis. The TNF-receptor
signaling pathway is critically involved in the pathogenesis of inflammatory bowel
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disease and rheumatoid arthritis (12). Such a pivotal gene is an example of autoimmune
disease and strong immunity aiding survival in early age but early death as a
consequence. Increased recombination rate has been shown to occur in older age
mothers(111). RNF212 is essential for recombination & chiasma formation in C elegans.
A CNV in a gene controlling recombination could lead to genome instability and
excessive recombination with more chances for errors.

Given that typical cause of death among different individuals is highly heterogeneous
from a clinical perspective, the underlying genetic causes of premature death or
attenuated longevity are likely to have similarly variegated set of genes. Therefore, based
on the specific loci found significantly associated with lifespan, more integrative systems
biology is possible leveraging protein-protein interactions using Cytoscape (184) (Figure
4.5).
Profiling expressed sequence tags (ESTs), smaller numbers of cDNA sequences assayed
by microarrays and RNA-Seq has allowed for more complete profiling of alternative
splicing (15). Continuing study on different tissues of the body coupled to CNV findings
through high-throughput sequencing approaches in the future can help elucidate
underlying mechanisms of ageing.

This study represents the first genome-wide population based copy number variation
study of human longevity, applying a unique study design to identify the pathogenic
nature of CNVs at a global scale in human. The use of the relatively large cohorts
assembled here was essential, both to discover and to confirm the findings and
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demonstrates the potential of genome-wide association in complicated polygenic ageing.
This type of unbiased study has discovered many novel targets that may underlie short
lifespan. We have focused on robustly identifying CNVs observed in a large sample of
pediatric and comparing those observations to a large geriatric sample to see which
CNVs limit the lifespan from reaching old age. This is distinct from the question of
longevity to extremely late age but CNV occurrence in these genes reduces longevity and
its effects need to be counteracted to produce exceptional longevity. These genetic
variations present risk factors that can be screened in a clinical setting to prognosticate
the risk of future premature death where preventive measures could potentially be taken
to reduce risk.

4.4 Materials and Methods
Ethics Statement
This research was approved by the Institutional Review Board of the Children’s Hospital
of Philadelphia. All subjects were recruited and signed written informed consent if age 18
or older. Parents signed written consent on the behalf of minors/children age 0-17 and the
child signed a written assent if 7-17 years of age. The Data Protection Commission of
Iceland and the National Bioethics Committee of Iceland approved this research on adult
samples. The appropriate written informed consent was obtained for all adult sample
donors.

Study subjects
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A cohort of healthy children under the age of 19 recruited within the Health Care
Network of the Children’s Hospital of Philadelphia was compared with adult subjects
above the age of 67 (average age 76), recruited for the AGES-Reykjavik study (85). The
replication cohort was composed of young previously published in the context of autism
(65) and older individuals accessed from dbGaP, including the Personalized Medicine
Research Project (PMRP). The average age of the children was 8.6 years and average age
of the adults was 60 years, with equal numbers of males and females.

Illumina Infinium assay for CNV Discovery
We performed high-throughput, genome-wide SNP genotyping, using the InfiniumII
HumanHap550 BeadChip technology (Illumina San Diego CA), at the Center for Applied
Genomics at CHOP. The genotype data content together with the intensity data provided
by the genotyping array provides high confidence for CNV calls. Importantly, the
simultaneous analysis of intensity data and genotype data in the same experimental
setting establishes a highly accurate definition for normal diploid states and any deviation
thereof. To call CNVs, we used the PennCNV algorithm, which combines multiple
sources of information, including Log R Ratio (LRR) and B Allele Frequency (BAF) at
each SNP marker, along with SNP spacing, a trained hidden Markov model, and
population frequency of the B allele to generate CNV calls. The intersection set of
302,108 probes common to the Illumina 550K: 532,898 probes and Illumina 370 Duo:
370,405 probes was used to make datasets as comparable as possible

CNV quality control
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We calculated Quality Control (QC) measures on our HumanHap660 GWAS data based
on statistical distributions to exclude poor quality DNA samples and false positive CNVs.
The first threshold is the percentage of attempted SNPs which were successfully
genotyped. Only samples with call rate > 98% were included. The genome wide intensity
signal must have as little noise as possible. Only samples with the standard deviation
(SD) of normalized intensity (LRR) < 0.30 were included. All samples must have clear
European ethnicity based on Eigenstrat smartPCA scoring and all other samples were
excluded. Wave artifacts roughly correlating with GC content resulting from
hybridization bias of low full length DNA quantity are known to interfere with accurate
inference of copy number variations. Only samples where the GC wave factor of LRR
|GCWF|<0.05 were accepted. If the count of CNV calls made by PennCNV exceeds 100,
the DNA quality is usually poor. Thus, only samples with CNV call count < 100 were
included. Any duplicate samples (such as monozygotic twins) had one sample excluded.

Statistical analysis of CNVs
CNV frequency between cases and controls was evaluated at each SNP using Fisher’s
exact test. We only considered loci that were significant between cases and controls
(p<0.05) where cases in the discovery cohort had the same variation, replicated in an
independent cohort or were not observed in any of the control subjects, and validated
with an independent method. We report statistical (p-value) local minimums to narrow
the association in reference to a region of nominal significance including SNPs residing
within 1 Mb of each other. Resulting significant CNVRs were excluded if they met any
of the following criteria: i) residing on telomere or centromere proximal cytobands; ii)
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arising in a “peninsula” of common CNV arising from variation in boundary truncation
of CNV calling; iii) genomic regions with extremes in GC content which produces
hybridization bias; or iv) samples contributing to multiple CNVRs. A peninsula is
defined as a false positive association arising from a region of common CNV extending
variably due to variability in probe performance and variability in samples. In other
words, the specific significant subregion is confounded by contributing calls also
extending to a non-significant subregion.
To fully correct for population stratification, we performed (PCA) on the genotypes and
used the resulting first three components as covariates of the logistic test for CNV
association using Plink.
Combined p-values were calculated using Fisher’s method.
k

X  2 log( pi )
2

i 1

Where pi is the p-value for the ith study. Under the null hypothesis, X2 follows a chisquared distribution with 2k degrees of freedom, where k is the number of studies. In this
case, there were two studies yielding a chi-squared distribution with four degrees of
freedom.

To inform multiple testing correction, CNV filtering steps have been performed as part of
the analysis. Firstly, it is important to note that of the intersection set of 302,108 SNPs on
the Illumina array, 3,911 (1.295%) showed deletion and 8,830 (2.923%) showed
duplication in at least eleven or more unrelated cases in the discovery cohort (frequency ≥
0.150%). 41,392 (13.701%) deletion and 45,050 (14.912%) duplication SNPs were
observed in at least two individuals. The threshold of three cases harboring a given CNV
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is selected because it is the minimal case frequency to provide minimal expectation of
frequency differences between cases and controls to yield nominal statistical significance
and reproducibility for the calls in a given region. We find this upfront exclusion to be
very similar to the inclusion threshold of 1% minor allele frequency in GWA SNP
genotype studies. These SNPs were collapsed into 101 deletion and 76 duplication
CNVRs based on necessary multiple neighboring SNP signals to call a CNV and
resulting redundancy of individual SNP statistics. This results in a total of 171 tests being
performed corresponding to a multiple testing correction bar of p=2.92E-4 close to the
p=5E-4 bar we have seen previously.

Gene Category Enrichment
Given the diverse etiology of diseases and more generally, lack of fitness in an
evolutionary context, the genes underlying the broad consideration of ageing are similarly
diverse. Single significant loci are certainly of interest to the common genomic CNVs
resulting in specific genes to study. However, strong confidence in the result set
generated can be achieved by observing the same biological system being perturbed by
multiple independently significant loci. Motivated by this, genes directly overlapped by
associated CNVs were prepared as a single list and non-RefSeq hypothetical gene IDs
were removed. This list was entered into DAVID functional annotation enrichment tool
in contrast with a background representing genome-wide regions covered by the array.
Taking into account the size of different genes and the gene family size of different
annotations, the enrichment of our CNV impacted list was assigned a p-value with
Benjamini and Hochberg correction for multiple testing. Functional annotations from

99

multiple databases were used including KEGG and GO (gene ontology). Functional
categories were reviewed for genes contributing from distinct genomic regions to reject
enrichment of closely clustered gene families.

A major contributor to lifespan abbreviation is congenital heart disease resulting in the
narrowing of major blood vessels or other structural anomalies. Congenital heart disease
also involves holes in the heart leading to mixing of oxygenated and deoxygenated blood
chambers. In the next chapter, we advance from an assay resolution of 550 thousand SNP
array data to a resolution of 2.5 million SNP array data and whole exome sequencing to
achieve high resolution on protein coding genes.

100

Chapter 5
5.0 Increased Frequency of De novo Copy Number Variations in
Congenital Heart Disease by Integrative Analysis of SNP Array and
Exome Sequence Data

Summary
The rationale of this study is congenital heart disease (CHD) is among the most common
birth defects. Most cases are of unknown etiology. The objective is to determine the
contribution of de novo copy number variants (CNVs) in the etiology of sporadic CHD.
Methods include 538 CHD trios using genome-wide dense single nucleotide
polymorphism (SNP) arrays and/or whole exome sequencing (WES). Results were
experimentally validated using digital droplet PCR. We compared validated CNVs in
CHD cases to CNVs in 1,301 healthy control trios. The two complementary highresolution technologies identified 65 validated de novo CNVs in 53 CHD cases. A
significant increase in CNV burden was observed when comparing CHD trios with
healthy trios, using either SNP array (p=7x10-5, Odds Ratio (OR)=4.6) or WES data
(p=6x10-4, OR=3.5) and remained after removing 16% of de novo CNV loci previously
reported as pathogenic(p=0.02, OR=2.7). We observed recurrent de novo CNVs on
15q11.2 encompassing CYFIP1, NIPA1, and NIPA2 and single de novo CNVs
encompassing DUSP1, JUN, JUP, MED15, MED9, PTPRE SREBF1, TOP2A, and ZEB2,
genes that interact with established CHD proteins NKX2-5and GATA4. Integrating de
novo variants in WES and CNV data suggests thatETS1 is the pathogenic gene altered by
11q24.2-q25 deletions in Jacobsen syndrome and that CTBP2 is the pathogenic gene in
10q sub-telomeric deletions. In conclusion, we demonstrate a significantly increased
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frequency of rare de novo CNVs in CHD patients compared with healthy controls and
suggest several novel genetic loci for CHD.

5.1 Introduction and Significance
Congenital heart disease (CHD) is the most frequent birth defect, affecting approximately
7 in 1000 live births,(90) and is a significant cause of childhood morbidity and
mortality.(199)Rare Mendelian disorders, specific chromosomal abnormalities, and copy
number variants (CNVs) are known to explain a subset of CHD cases,(52, 187, 199)but
the cause of over 80% of CHD remains unexplained.(31, 51, 73, 78, 132, 165, 186, 203)

The application of evolving technologies that detect structural variation throughout the
genome has demonstrated a considerable contribution of CNVs to CHD. Early
cytogenetic studies recognized an increased prevalence of de novo chromosomal
abnormalities in syndromic CHD patients, observations that were replicated and extended
to non-syndromic CHD with successive generations of CNV detection technologies
including array CGH and low density SNP arrays.(17, 25, 50, 52, 78, 89, 154, 173, 186,
187, 201, 214) Using these techniques, researchers have demonstrated significant burden
of large de novo CNV in some specific CHD lesions. Such CNVs are reported to occur in
13.9% of infants with single ventricles compared to 4.4% in controls,(25)in 10% of nonsyndromic tetralogy of Fallot (TOF) compared to 4% of controls,(78) and in 12.7%
children with hypoplastic left heart syndrome compared to 2% of controls.(214)Among
different CHD lesions, the frequency of large de novo CNVs is similar.(214)While many
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large CNVs are unique to a single CHD patient, several are recurrent in CHD cohorts. A
3-Mb 22q11.2 deletion is the most common recurrent de novo CNV associated with
syndromic conotruncal defects (CTDs) and is found overall in at least 10% of TOF,(72,
170) 35% of truncus and 50% of interrupted aortic arch (IAA) type B cases.(29)Recurrent
de novo CNVs in CHD patients reported in multiple studies also occur at chromosomes
1q21.1,3p25.1, 7q11.13, 8p23.1, 11q24-25, and 16p13.11.(78, 214)

The identification of CHD loci that are altered by CNVs provides opportunities to
elucidate disease pathogenesis. However, discerning the causal gene(s) and inferring
critical networks and pathways that cause or contribute to CHD has been difficult
because low-resolution technologies used in many studies (array CGH and low-density
SNP arrays) typically define large CNVs(>100kb)involving many genes. To address
these issues, we capitalized on two independent strategies, high-density SNP genotyping
arrays (Illumina Omni-1.0 and 2.5M) and whole exome sequencing (WES), to detect
smaller de novo CNVs in a family-based trio study of sporadic CHD cases with
conotruncal, heterotaxy, and left ventricular outflow tract defects.(155) We compared
CNVs found in CHD trios to those identified in healthy control trios. Through these
analyses we sought to compare the robustness of genome-wide CNV detection using
array-based and sequence-based technologies to determine if there was an increased
burden of smaller de novo CNVs in CHD patients as was demonstrated with larger
CNVs, and to determine if fewer genes altered by these CNVs enabled more precise
detection of gene networks and pathways contributing to the pathogenesis of CHD.
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5.2 Results
5.2.1 Identification of De Novo CNVs
We studied 415 CHD trios genotyped by SNP arrays and 356 trios by WES analysis,
including 233 trios studied by both methods. No trios had an affected first-degree relative
and the genetic cause of CHD in all studied children was unknown (Supplementary
Tables 5.1 and 5.2).

Sixty-five de novo CNVs identified in CHD cases were independently confirmed by
ddPCR (Table 5.1). De novo CNVs were identified in 53 unique probands (9.8%). These
CNVs ranged in size from 0.1 kb to 12.8 Mb. Fifty of these (74%) were <500kb and half
were smaller than 110 kb. The number of genes in the CNV intervals ranged from 1 to
175 with 44 (68%) having ≤ 5 genes. Four de novo intervals contained no genes. Six
probands had two de novo CNVs, two had three CNVs and one had four CNVs.

The parental origin of deletion CNVs was determined when the haplotype of the
remaining copy could be uniquely assigned to one parent. Seven de novo CNVs arose on
maternal chromosomes and10 on paternal chromosomes. The remainder could not be
assigned due to uninformative or insufficient numbers of informative parent-of-origin
SNPs.

104

Table 5.1. Confirmed de novo CNVs in Discovery Cohort.
Genomic coordinates refer to hg19.
ID

Chr

Start

End

Band

CNV1

Syndrome/ gene

1-01401

1

59247993

59251097

p32.1

1

JUN

1-03171

1

145586403

145799634

q21.1

3

1q21.1 dup/ GJA54
4

Analysis
Observed2
A

Cardiac Lesion:
(diagnosis)3
LVOT(HLHS)

Parent
Origin
-

Extracardiac
-

N
genes
1

AE

CTD(TOF/APVS)

-

-

7

213.2

E

CTD(TOF)

M

-

15

785.1

Size (kb)
3.1

1-01036

1

146631133

147416212

q21.1

3

1q21.1 dup/ GJA5

1-01486

1

194201171

194304070

q24.2- q25

3

CDC73

A

LVOT(HLHS)

-

Yes

0

102.9

1-01518

1

248750565

248795110

q44

3

OR2T10,OR2T11

A

LVOT(HLHS)

-

-

2

44.5

1-01536

2

70168995

70359345

p13.3

1

PCBP1

A

CTD(TOF/PA)

-

-

5

190.4

1-01401

2

102493466

103001458

q11.2- q12.1

1

MAP4K4

E

LVOT(HLHS)

-

-

6

508.0

4

1-01401

2

145155868

145274931

q22.3

1

Mowat-Wilson/ ZEB2

E

LVOT(HLHS)

-

-

1

119.1

1-00762

3

60661

11712230

p26.1

3

A

ASD/PS (ASD)

-

Yes
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11651.6

1-01049

3

15637812

15643461

p25.1

3

ARL8B,ARPC4,CAMK1,CAV3,
CRBN,EMC3,ITPR1,SEC13,
SETD5,VGLL4
BTD,HACL1

E

CTD(TOF)

-

-

2

5.6

1-01045

3

47780965

48309270

p21.31

3

A

LVOT(HLHS)

-

-

14

528.3

1-02093

3

197143652

197186111

q29

3

CDC25A,DHX30,
MAP4,SMARCC1
BDH1

A

CTD(TOF/PA)

-

Yes

0

42.5

1-00771

4

185603346

185638397

q34.1

1

CENPU,PRIMPOL

E

CTD(DTGA/VSD)

P

Yes

2

35.1

1-00789

5

136464

232969

p15.33

3

A

CTD(TOF)

-

-

4

96.5

1-00113

5

133706994

133730455

q31.1

1

CCDC127,LRRC14B,
PLEKHG4B,SDHA
UBE2B

-

Yes

1

23.5

A

CTD(TOF)

M

Yes

53

6686.9

1

NKX2.5

36651971

p21.2

1

CDKN1A

A

HTX(HTX)

-

-

1

5.2

43484783

43485159

p21.1

3

POLR1C

E

CTD(TOF)

-

-

1

0.4

50179707
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-
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M

-

15
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Copy number: 1- deletion; 3- duplication,
Analysis: A- identified with SNP Array; E- identified with WES
Parental Origin: M- maternal chromosome; P- paternal chromosome
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De novo CNV loci that were previously reported as pathogenic
Abbreviations: CTD-conotruncal defect; LVOT-Left Ventricular Outflow Tract Obstruction;TA-truncus arteriosus;TOF-tetralogy of Fallot;HLHS-hypoplastic left heart syndrome;APVSAbsent pulmonary valve syndrome ; ASD- Atrial septal defect; CoA-Coarctation of the Aorta ; DTGA-dextro-Transposition of the great arteries; HTX-Heterotaxy; PA- PulmonaryAtresia;
PS-Pulmonary Stenosis; TriAtresia-Tricuspid atresia ; VSD-Ventricular Septal Defect ;
2
3
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5.2.2 Comparison of SNP Array and WES CNV calling
To consider the accuracy of identifying de novo CNVs from SNP array data, we first
considered a set of 40 high-confidence PennCNV de novo CNV calls that contained ≥10
adjacent SNPs, were >10 kb in length, and passed visual inspection. Among these 40
high-confidence putative CNVs, 32 (80%) were experimentally confirmed. For smaller
de novo CNVs identified using the high-density array data, we considered a set of 97
high-confidence PennCNV putative de novo CNV calls based on 7-9 SNPs. While 88%
were experimentally validated by ddPCR in the proband, only four of the 97 (5%) were
confirmed to be de novo.

From the WES data, we selected an initial set of 29 putative CNVs with a size range
spanning six orders of magnitude from 530 bases in length (two exons) to more than 8Mb
in length covering hundreds of exons. Twenty-six of the 29 CNVs (90%) confirmed
experimentally. The three false positive CNVs included one 530-bp region that contained
only two exon targets and two different inherited CNVs that were miscalled as de novo
because both parents harbored CNVs at the locus. Based on these considerations, we
restricted subsequent WES de novo CNV calls to those containing ≥3 exons and for
which each parental dataset contained no CNVs within the locus.

To evaluate false negative rates of the two platforms and analyses, we tested our ability to
detect four CNVs (two 22q11 deletions, one 17p11 duplication, and one 10q terminal
deletion; Supplemental Table 5.5) in clinical cases previously diagnosed with these
CNVs. These four CNVs served as positive controls and were distinct from the PCGC
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cohort. Both the SNP array and WES platforms detected each of these four large,
Figure 5.1. Comparison of CNVs detected by SNP array
and WES platforms in the subset of 233 probands
studied by both technologies.

clinically significant CNVs.

We also compared the results of de novo
CNVs analysis from the 233 trios
studied by both SNP array and WES.
Among 42 confirmed de novo CNVs in
these trios, 24% (10/42) were identified
by both platforms while 40% (17/42)
Based on confirmation data, CNVs that span ≥10 SNPs
on arrays and ≥3 exons on WES had high confirmation
rates and were deemed detectable by both technologies.
We assessed how many CNVs identified by one
platform could not be identified by the other technology
because they were below the detection limits. Both SNP
Array and WES platforms have a false negative rate of
~30-35% based on detectable regions.

were identified only with the SNP
arrays and 35% (15/42) only by WES
(Figure 5.1). The recognized technical
limitations of each platform prevented

detection of some CNVs. For example, CNVs that occur exclusively in noncoding
sequences are not captured by WES whilst CNVs in coding or non-coding genomic
regions where the SNP density is sparse can escape detection by SNP arrays.
From our studies we deduced that de novo CNVs were accurately detected by arrays
when ≥10 adjacent SNPs were impacted or by WES when greater than three adjacent
exons were impacted. In our dataset, 29 of 42 CNVs fulfilled both of these criteria and
should have been identified by both technologies (Figure 5.1). However, only
34% (10/29) of these CNVs were identified by both platforms. SNP arrays uniquely
identified 34% (10/29) and WES analyses uniquely identified 31% (9/29). Taken
together, the false negative rate of each methodology is approximately 30-35%. Overall,
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the genome-wide analyses of de novo CNVs identified by SNP arrays was reasonably
concordant with WES data, but each also identified complementary CNVs. The minimum
CNV size that we reliably detected by SNP arrays was 10 kb and by WES was 1 kb,
although some smaller CNVs identified by these techniques were validated.

5.2.3 CNV Burden Analysis
The burden of de novo CNVs in CHD cases and control trios was initially compared
using analyses from SNP arrays. De novo CNVs were assessed in 841 control trios,
studied using the Illumina Omni1M array to match the case trio array resolution and
called using the PennCNV algorithm using computational parameters described
previously(176) that required >20 SNP probes. Nine de novo CNVs were identified
among 841 control trios. Twenty-two de novo CNVs were identified among 462 CHD
patients. These data define a significant burden of CNVs in CHD cases compared to
controls (OR: 4.6, Fisher p-value: 7 x 10-5; Table 5.2). After excluding nine previously
identified CHD-associated CNVs, the calculated burden of novel CNVs identified in
CHD cases remained modestly significant (OR:2.7, Fisher p=0.02).
Table 5.2. Case Control de novo CNV Burden

N Probands N (%) CNVs
SNP Array

P-value

SSC1

841

9 (1%)

-

-

PCGC: all CNVs

462

22 (4.7%)

4.6

7 x 10-5

13 (2.8%)

2.7

0.02

PCGC: novel loci
WES

OR

SSC2

872

14 (1.6%)

-

-

PCGC: all CNVs

356

19 (5.6%)

3.5

6 x 10-4

13 (3.9%)

2.3

0.03

PCGC: novel loci
1

Controls derived from State, 2011.(176)
Controls derived from three studies: Iossifov, 2012;(97) Sanders, 2012;(177) and an additional set of
unpublished controls provided by Matthew State selected by the same criteria and sequenced as described
in.(177)
2
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To provide further support for this finding, we analyzed the burden of de novo CNVs that
were identified by WES. WES in CHD cases and control trios were technically
comparable, including the same Nimblegen V2 exome capture chemistry and similar
sequence read depths obtained on identical Illumina platforms. Sixty percent of control
trios were sequenced at the same site (Yale Center for Genome Analysis) that sequenced
the cases. Raw sequence reads were processed through the identical short read aligner
(Novoalign) for CNV burden analysis. SNP genotyping of CHD and control datasets and
principal component analysis did not identify any systematic biases (Supplemental
Figure5.5). Cases and controls were matched for gender as best as possible with slight
excess of male cases. Using an identical XHMM pipeline (CNVs involving≥3 exons and
no parental CNVs within 1 MB), we identified 19 de novo CNVs in 358 CHD trios,
and14 de novo CNVs in 8732 control trios (OR: 3.5, Fisher p=6 x 10-4; Table 5.2).
Excluding the six de novo CNVs previously identified as CHD-associated, we identified
a similar OR and p-value as in the SNP array data (OR:2.3, Fisher p=0.03).
Our data identify an increased burden of CNVs, detected by SNP arrays or WES, in CHD
patients compared to controls. We observed a larger mean size of de novo CNVs with
increased burden in CHD patients (3.6 Mb) than controls (495 kb; t-test p=0.035) with
the distribution of CHD CNVs skewed towards the largest CNVs identified in CHD
cases. The median size of de novo CNVs from CHD cases (522 kb) was also significantly
larger than controls (118 kb; Mann-Whitney p=0.028). Of the CNVs identified by SNP
array which were capable of detecting CNVs outside of coding regions, there was a trend
towards an increased number of de novo CNVs in controls that contained no coding exon
(4/9) compared to PCGC cases (3/22; Fisher p= 0.15).
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5.2.4 Putative CHD Loci at 15q11.2 and 2p13.3
Overlapping de novo CNVs found in multiple cases and not in controls likely contain
disease genes. Sixteen of 65 (25%) de novo CNVs in CHD probands have been
Figure 5.2. Genomic Boundaries of 4 recurrent de novo
CNVs

previously implicated in CHD(78),
including four 22q11.2 deletions,
three 8p23 deletions (involving
GATA4), two 1q21.1 duplications
(involving PRKAB2, PDIA3P,
FMO5, CHD1L, BCL9, ACP6 and
GJA5), one 22q11.2 distal

Red rectangles represent de novo deletion calls.

microdeletion, one 2q22.3 deletion
(that causes Mowat-Wilson syndrome), one 11q24.2-q25 deletion (that causes Jacobsen
syndrome) and four with CNVs in 15q11.2.

CNVs in four CHD probands (two deletions, two duplications) at the 15q11.2 locus that
spans approximately 225 kb (chr15:22,836,000-23,062,000) were observed as recurrent
de novo events (Figure 5.2 and 5.3). Both patients with duplications (1-00192, 1-00315)
and one with a deletion (1-00243) had LVO due to aortic coarctation. The remaining
proband (1-01396) had TOF with pulmonary atresia. As there was no de novo CNV
identified in this region among 814 and 872 control trios studied respectively by SNP
arrays or WES, this locus has a significant burden of de novo CNVs in CHD cases (4/538
CHD vs. 0/1301 controls; Fisher p=0.007). CNVs at the 15q11.2 locus were observed at
low frequency (AF<1%) in the Database for Genomic Variants (DGV). Among the three
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genes altered by this CNV (CYFIP1, NIPA1, and NIPA2), only CYFIP1 is highly
expressed in the developing mouse heart. (224) (223) (222) (221) (215) (216) (214) (213)
(212) (210) CYFIP1encodes the cytoplasmic FMR1-interacting protein 1, which has dual
roles in inhibiting local protein synthesis and in promoting actin remodeling.(42) An
earlier study observed an increased burden of inherited deletions in CHD cases at
15q11.21 and a recent paper identified a single proband with a 6-Mb de novo duplication
at 15q11.2-q13.1(214) and two additional cases with inherited 300-400-kb duplications at
15q11.2. Our data provide additional evidence that de novo CNVs at 15q11.2 may
contribute to disease risk in CHD.

In addition, a recurrent CNV was observed to alter a novel locus at chromosome 2p13.3.
A de novo 190-kb deletion was

Figure 5.3. A novel recurrent de novo deletion on
15q11.2.

identified in a TOF proband (1-01536)
and was maternally inherited in a
proband with truncus arteriosus (101805). No 2p13.3 CNV was found in
control samples or in DGV. Among
three genes included in the CNV
interval (ASPRV1, PCBP1 and PCBP1AS1), only PCBP1 is highly expressed
in the developing mouse
SNP Array PennCNV Plot for diploid mother, diploid
father, and deleted child with CNV region in red with
flanking diploid in blue.
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heart.(224)PCBP1 encodes a major
cellular poly(rC)-binding protein,

which controls translation from mRNAs containing the DICE (differentiation control
element).(143)In Database of Chromosomal Imbalance and Phenotype in Humans using
Ensembl Resources (DECIPHER), patient 257771 with an atrioventricular canal defect
had a 7-Mb overlapping deletion of 2p13.3, suggesting this locus may also contribute to
disease risk in CHD.

5.2.5 Integration of CNV and Sequence Data to Identify CHD Genes
To improve the identification of specific genes altered by CNVs that might cause or
contribute to CHD, we searched the WES data for de novo, rare loss-of-function (LOF)
variants in genes encoded in CNV intervals. We identified a terminal deletion of
chromosome 11q24.2-q25, which causes Jacobsen syndrome in one CHD patient (101486) with clinical manifestations typical of this dominant disorder (hypoplastic left
heart, coarctation of the aorta, mitral and aortic valve atresia, strabismus, and short
stature). ETS1 has been proposed as the critical CHD gene in the Jacobsen syndrome
locus based on impaired ventricular development in an Ets1-null mouse.(223) WES
analyses identified a de novo ETS1 frameshift mutation (chr11:128350159GTCCT>G,
c.1046_1049delAGGA, [p.K349fs]) in another CHD patient without the chromosome
11q24.2-q25 deletion with cardiac abnormalities observed in Jacobsen syndrome
(hypoplastic left heart and mitral valve atresia). Our data provide the first human genetic
evidence to suggest that ETS1 mutations contribute to the cause of cardiac malformations
in Jacobsen syndrome.
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We also assessed whether de novo CNVs in combination with a rare or novel deleterious
variant on the other allele might produce recessive forms of CHD. One CHD patient (101179) with a de novo 10q25-26 deletion also had a novel CTBP2 variant (p.R134W) on
the remaining allele. The hemizygous variant was absent from public genome
databases,(1, 62) is predicted to be damaging (Polyphen2 score of 0.998), and altered a
phylogenetically conserved residue (PhyloP score = 2.54). Cardiac abnormalities are
present in approximately one third of patients with subterminal chromosome 10q
deletions and recently CTBP2 was proposed as a candidate CHD gene.(37)The clinical
manifestations of our patient, truncus arteriosus and right aortic arch, resemble the
phenotypes identified in a Ctbp2-null mouse (failure of vascular remodeling and cardiac
looping).(87)We suggest that CTBP2 sequence analyses in individuals with chromosome
10q deletions may identify additional variants in a subset of patients that modify
phenotype.

5.2.6 Correlation of CHD Phenotypes and CNVs
The frequency of de novo CNVs was 10% among conotruncal anomalies, 6% among leftsided obstructive lesions and 21% in heterotaxy. We observed a modest trend towards
increased extra-cardiac manifestations such as developmental delay in patients with de
novo CNVs (Supplemental Table 5.6). Approximately 31% of all CHD patients studied
with SNP arrays or WES had extra-cardiac manifestations, whilst 40% (21/52; OR:1.5,
Fisher p=0.2) of patients with de novo CNVs had extra-cardiac features. This association
has been found in some,(18) but not all,(214) previous studies, perhaps due to differences
in the ages of the CHD patients studied, methods of clinical data collection, and the
definition of an extra-cardiac anomaly.
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5.2.7 Gene Networks Impacted by CNVs in CHD
We employed pathway and network analysis with DAVID,(91) DAPPLE,(174)and
WebGestalt,(210) using as input four different lists of genes encoded within all de novo
CNV loci (Methods and Supplemental Table 5.4). Initial gene lists contained:(1) all genes
encoded in a de novo CNV interval; (2) genes previously defined as causative within
CNVs intervals plus all genes in novel de novo CNV intervals; (3) only genes contained
within novel de novo CNV intervals; (4) all genes contained within de novo CNV
intervals that are highly expressed (top 25%) in the developing heart.(224)

DAVID identified enrichment of gene pathways implicated in acetylation (p<2.3x10-4),
phosphoprotein (p<3.9x10-4), and G protein-activated inward rectifier potassium channel
(p<2.5x10-2) (Benjamini-Hochberg corrected). WebGestalt implicated an enrichment of
previously identified CHD genes including ELN, NKX2.5, GATA4, and ZEB2
contributing to Gene Ontology processes: anatomical structure formation involved in
morphogenesis (p<0.03), cardioblast differentiation (p<0.03), and septum secundum
development (p<0.02) (Benjamini-Hochberg corrected).

Using DAPPLE, we identified two additional sub-networks of direct protein/protein
interactions that were consistently observed across four gene lists. Among genes encoded
within CNVs that are highly expressed in the developing heart, a sub-network consisting
of NKX2.5 and GATA4 (p<0.1, Figure 5.4a) and a sub-network consisting of ETS1, JUN,
TOP2A, and MKI67 (p<0.01, Figure 5.4b) were identified. By further expanding the
CNV gene lists to include genes with de novo LOF mutations, the ETS1/JUN/TOP2A
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sub-network was significantly elaborated upon and enriched (p<0.005). Each of these
three genes was directly linked

Figure 5.4. Network analysis of CNV loci genes.

through protein-protein interactions
to sub-networks containing ≥ 10
additional genes identified in either
CNV or WES datasets.(224) This
entire network incorporated over 60
genes implicated in CHD (Figure
Two networks of direct protein-protein interactions, (A)
NKX2.5/Gata4 and (B) ETS1/JUN/TOP2A, were
consistently identified in the DAPPLE de novo CNV
loci analysis. P-values from the genes highly expressed
in the developing heart, the most restrictive gene set list,
are presented here. (C) The ETS1/JUN/TOP2A network
was significantly elaborated upon by incorporating
genes with deleterious de novo point mutations and
indels in the WES exome sequencing analysis in
addition to the CNV loci. Of note, two probands had de
novo ETS1 variants (one CNV and one frameshift), two
probands had de novo SMAD2 variants (a splice site
mutation and a highly conserved missense variant) and
two probands had de novo ELN variants (both Williams
syndrome CNVs).

5.4c). As the ETS1/JUN/TOP2A subnetwork was robust to the specific de
novo CNV gene list (criteria 2 above)
and expanded with the addition of
genes containing rare de novo LOF
mutations, the data suggest that this
sub-network contains genes and

pathways involved in CHD.

5.3 Discussion
We report whole-genome CNV analyses using complementary detection technologies in
a large cohort of CHD patients. CNV detection in WES has been investigated in
schizophrenia(60)and autism,(162) but array-based and sequence-based strategies have
not previously been directly compared, and our data highlight the differences between
array-based and sequence-based strategies to detect de novo CNVs. By defining small
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CNVs with high resolution and integrating these findings with WES data that identified
rare deleterious mutations, we identified novel de novo CNVs and genes involved in the
pathogenesis of CHD. We show that 9.8% (53/538) of CHD patients without a previously
identified genetic etiology have rare de novo CNVs (Figure 5.5). We previously
demonstrated that 10% of CHD patients in our cohort have de novo single nucleotide or
small insertion/deletion mutations in genes highly expressed in the developing heart that
are likely to be damaging.(224) None of the CHD patients with rare de novo CNVs
reported here carry these variants. Even if all the de novo CNVs and de novo predicted
pathogenic sequence variants we have identified were causative, we do not yet know the
etiology for the majority of CHD subjects in our study.
Our detection rate of approximately
Figure 5.5. Distribution of de novo rare, damaging
genetic variants in the case cohort with unknown CHD
etiology.

10% de novo CNVs in CHD patients
is equivalent to previous studies,(18,
78, 214) despite identifying small
CNVs. Had we not excluded patients
with known pathogenic CNVs
identified through clinical care, we
expect that de novo CNVs would

Of the CHD probands without identified genetic
etiologies based upon clinical evaluations including
karyotype and chromosome microarray, approximately
2.5% of CHD probands had de novo CNVs that have
been previously described as pathogenic and had not
been clinically recognized upon study enrollment. 7.3%
of CHD probands had novel de novo CNVs. 10% of
CHD probands studied by WES had de novo rare,
damaging variants in genes that are highly expressed in
the developing mouse heart.(224)
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have been identified in approximately
15% of CHD patients, based on the
prevalence of common de novo CNVs
in CHD (e.g., 7% of TOF with

chromosome 22q11 deletions, and 1% of TOF to 1q21 CNVs). In our study, these CNV
loci accounted for <1% of CHD probands

Despite these exclusion criteria, we identified a four-fold increased frequency of de novo
CNVs relative to the background frequencies of 1.2% (detected by SNP arrays) and 1.8%
(detected by WES) of de novo CNVs in controls (p=7 x 10-5, p=4 x10-4 respectively).
Even after excluding previously defined CNVs, we still observed an approximate twofold increase in novel de novo CNVs (p=0.02).
Since the odds ratio of de novo CNVs in cases vs controls was 3.5-4.6, we estimate that
between 50-70% of de novo CNVs observed in cases may be disease causing. The
possibility exists that a higher percentage of de novo CNVs increase the risk of CHD but
may not be sufficient to cause CHD without other contributing genetic or environmental
factors. Additionally, subtle anatomic defects in the heart may not have been diagnosed
in the control group since controls were not systematically examined by echocardiogram.
Overall, our evidence suggests a model in which de novo CNVs contribute to CHD.
The comparison of dense array-based platforms and WES analyses to detect
independently validated CNVs indicate that each strategy identifies only ~70% of the
CNVs that should be within the detection limitations of each technology. As such, these
two CNV methodologies provide substantial complementary information. An important
corollary to this conclusion is that previously published CNV analyses in human disease
may have significantly underestimated the burden conveyed by these structural variants.
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Amongst all confirmed de novo CNVs, 61% (41) were deletions and 39% (26) were
duplications. The proportion of these classes of CNVs are not significantly different;
whether or not the trend toward more CNV deletions in CHD is biologically meaningful
or reflects greater sensitivity to detect deletions by these methods will require further
analyses. De novo CNVs ranged in size from less than 1 kb to 12.8 Mb, with a median
size of 110 kb. Thus, half of the independently confirmed CNVs were smaller than the
reported detection limit of most prior studies. While the pathogenicity of the identified
CNVs remains to be determined, we propose that the smaller CNVs involving fewer
genes are particularly valuable in defining specific candidate CHD genes in comparison
to larger CNVs that typically include many more candidates. The ability to reliably detect
small CNVs is helpful, particularly if they fall within large CNVs previously identified
and define a critical interval of overlap. For example, we identified one de novo CNV
that only affected JUN and another that only altered TOP2A, two genes that were
implicated by network analyses as interacting with transcription factors SMAD2, SMAD4
and ETS1, molecules that play important roles in cardiovascular development.

Although there is considerable complexity in CHD phenotypes, we observed no
significant difference in the frequencies of de novo CNVs among distinct CHD subclassifications. While CHD patients with CNVs in our cohort were more likely to have
extra-cardiac phenotypes (OR: 1.5), this trend fell short of significance. Whether this
finding reflects shared developmental biologic pathways among different organ systems or
the possibility that CNVs perturb multiple genes that individually contribute to organ
system development is unknown.
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We identified several de novo CNVs that impacted established CHD genes including
GATA4 and GJA5. We also identified a CHD patient with a deletion of chromosome
5q34-q35.2, encompassing NKX2-5. LOF NKX2-5 mutations are an established cause of
CHD,(31, 78, 180, 186, 187, 203)and CNVs encompassing NKX2-5 have been previously
recognized in CHD.(8, 22, 201)

We identified recurrent de novo CNVs involving deletions or duplications at
chromosome 15q11.2. As the proximal region of chromosome 15 is meiotically unstable
due to the segmental duplications that serve as breakpoint hotspots, recurrent de novo
events at this locus might reflect locus genomic instability. However, the excess burden
of de novo CNVs at this locus in CHD patients compared to controls (Fisher p=0.007)
suggests significant enrichment. The report of an excess burden of inherited deletions in
CHD patients at this locus(187) lends further evidence for pathogenicity although this
study lacked information on inheritance.

The 200-kb CNV that we identified at 15q11.2 is from BP1-BP2 and is encompassed
within the BP1-BP3 Prader-Willi syndrome interval at 15q11-q13.(21),(20)
Approximately 20% of Prader-Willi patients have congenital heart defects,(204) and a
patient with a large 6-Mb duplication in the Prader-Willi locus has been described in
another CHD cohort.(214)
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Chromosome 15q11.2 deletions and duplications are implicated in neurodevelopmental
disorders including schizophrenia, intellectual disability and autism.(106, 190, 192)That
chromosome 15q11.2 CNVs are also associated with CHD adds to a growing list of loci
(22q11,(109) 1q21,(78, 142)7q11.23,(75)16p11.2,(63, 74) and 16p13.11(74, 214) that
link cardiac malformations and neurocognitive disorders. These (and other) genetic loci
may explain in part the significant co-expression of heart and brain developmental
phenotypes in many children.

By integrating CNV and sequencing data from WES, we also identified candidate genes
within CNV regions that may cause dominant or recessive forms of CHD. We present the
first humanETS1 LOF mutation that likely contributes to Jacobsen syndrome. We also
identified a rare inherited and predicted deleterious CTBP2 missense variant that is
hemizygous due to a de novo CNV deletion, associated with a CHD phenotype
comparable to that observed in Ctbp2-null mice. Continued integration of CNV and
sequence data should enable more comprehensive assessments of genetic causes of
disease. The current study provides suggestive data, and sequencing large cohorts of
CHD patients for mutations in these two genes will be necessary to unambiguously prove
the role of these genes in CHD.

Network analyses by DAPPLE was more successful in elucidating novel network biology
than DAVID and WebGestalt, which rely heavily on previously annotated gene sets and
are challenged by the addition of unrelated genes encoded with CNV intervals along with
pathogenic genes. If pathogenic CNVs on average contain one main causal gene and
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approximately five unrelated genes, then we might expect DAVID and WebGestalt to be
less informative for CNV network analyses.(93) Conversely, DAPPLE, based on
proteome-wide protein-protein interaction data rather than previously curated gene lists,
calculates p-values through within-degree node-label permutation, which is more
permissive to background noise.(174)

DAPPLE network analysis reinforced the central role of transcriptional regulation in
congenital heart disease. The identification of one network, including NKX2.5/GATA4,
provided a robust positive control as protein-protein interactions and substantial
contributions by these molecules to CHD are previously described.(179, 194) Direct
protein-protein interactions between ETS1/JUN/TOP2A have also been reported,(113,
130, 147) but this network has not been previously implicated in CHD. In an expanded
network analysis of these molecules that included rare LOF mutations identified from
exome sequencing, JUN was linked to SMAD2 and SMAD4, molecules that participate
in cardiac development through TGF-beta.(23, 26, 134, 209)
We focused our current analysis solely on de novo CNVs. As the etiology of CHDs is
known to be polygenic, and incomplete penetrance of genes for CHD has been previously
described, future analyses of rare inherited CNVs may expand these findings.
Replication of the overall effect and the magnitude of the risk of these identified variants
is needed. While it is not yet possible to draw a conclusion about whether any particular
de novo CNV is causal, the identification of additional CNVs and mutations in specific
genes within the CNV intervals will be required to validate the new loci identified here.
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In summary, integration of high resolution complementary platforms for CNV and
sequence data on large numbers of patients with CHD has proven valuable to define the
underlying genomic architecture of CHD and expand the genes and networks involved in
cardiac development and is likely applicable to the study of other diseases.

5.4 Methods
5.4.1 Ethics Statement
The protocol was approved by the Institutional Review Boards of Boston Children’s
Hospital, Brigham and Women’s Hospital, Great Ormond St. Hospital, Children’s
Hospital of Los Angeles, Children’s Hospital of Philadelphia, Columbia University
Medical Center, Icahn School of Medicine and Mt. Sinai, Rochester School of Medicine
and Dentistry, Steven and Alexandra Cohen Children’s Medical Center of New York, and
Yale School of Medicine. Written informed consent was obtained from each participating
subject or their parent/guardian.
5.4.2 Patient cohorts
CHD probands and parents were recruited into the CHD Genes Study of the Pediatric
Cardiac Genomics Consortium (CHD genes: ClinicalTrials.gov identifier NCT01196182)
as previously described,(155) using protocols approved by Institutional Review Boards of
each institution. Trios selected for this study had no history of CHD in first-degree
relatives. CHD diagnoses were obtained from echocardiograms, catheterization and
operative reports; extra-cardiac findings were extracted from medical records and
included dysmorphic features, major anomalies, non-cardiac medical problems, and
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deficiencies in growth or developmental delay. The etiologies for CHD were unknown;
patients with previously identified cytogenetic anomalies or pathogenic CNVs identified
through routine clinical evaluation were excluded. Whole blood samples were collected
and genomic DNA extracted.

CHD trios were studied by SNP arrays (n=414) or by WES (n=358), including a subset
(n=233) that were analyzed by both methods. The distribution by CHD lesions in patients
genotyped by arrays was: 403 (61%) left ventricular obstruction (LVO); 197 (30%)
conotruncal defects (CTD); 49 (7%) heterotaxy (HTX); and 12 (2%) other cardiac
diagnoses (Supplementary Table 5.1). The distribution by CHD lesions in patients
studied by WES was 284 (46.1%) left ventricular obstruction (LVO); 235 (38.1%)
conotruncal defects (CTD); 78 (12.7%) heterotaxy (HTX); and 19 (3.1%) with other
cardiac diagnoses (Supplemental Table 5.2).

Control trios were the unaffected sibling and parents of a child with autism who were
consented and recruited through the Simons Simplex Collection (SSC). CNVs were
identified in the same way in the control trios as in the cases using SNP arrays (n=814) or
WES (n=872), including a subset (n=385) analyzed by both methods.(56, 176, 177)

Additional data on the distribution and prevalence of previously reported CNVs in the
general population was derived from the Database of Genomic Variants
(http://dgv.tcag.ca) and from 649 de-identified control subjects who had participated in
an unrelated psychiatric case-control study, genotyped on the same high density SNP
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array platforms at the same genotyping center as the CHD probands (438 on the Illumina
Omni-1M and 211 on the Illumina Omni-2.5M). These controls were used only to
prioritize the de novo CNVs identified by SNP array methods that were selected for
confirmation analyses.
5.4.3 Array Genotyping and CNV identification
A total of 360 CHD parental samples genotyped on the Omni1M and 654 on Omni2.5M
arrays were applied for cluster definition using Illumina Genome Studio clustering
algorithm. Raw data is publicly available through the database of genotypes and
phenotypes (dbGaP) National Heart, Lung, and Blood Institute (NHLBI) Bench to
Bassinet Program: The Pediatric Cardiac Genetics Consortium (PCGC) under dbGaP
Study Accession: phs000571.v1.p1.We removed clusters with outlier values of SNP call
rate, Hardy-Weinberg equilibrium, AA/AB/BB cluster means, and minor allele frequency
to improve the intensity noise (Log R ratio standard deviation) from a mean of 0.2 (using
the default cluster file from Illumina) to 0.1 for CHD samples. Briefly, individual
samples were filtered through a standard quality control pipeline.(176)B-allele frequency
(BAF) and LogR ratio (LRR) values were exported from Illumina Genome Studio. Only
samples with SNP call rate > 98%, standard deviation (SD) of normalized intensity
(LRR) < 0.3, absolute value of GC-corrected LRR <0.005, as well as CNV call count
<800 for Omni1-Quadv1 or <300 for Omni2.5-8v1 were included.(71)Samples with high
inbreeding coefficients, that were duplicated, or had gender mismatches, and trios with
Mendelian errors > 1% were removed from analyses. We started with 1,536 genotyped
samples (512 trios), including 561 on the Illumina Omni-1M and 969 on the Illumina
Omni-2.5M. Four hundred and sixty-one trios had the same array version for all family
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members. Upon completion of these QC procedures 1,245 samples, including 447
genotyped on the Illumina Omni-1M and 798 on the Illumina Omni-2.5M high-density
SNP array platforms, were taken forward for analysis, constituting 415 complete trios
(Supplemental Table 5.3).

Three groups (CHOP, Harvard, Yale) independently analyzed genotyping data using
slightly different algorithms to detect putative de novo CNVs. For each of the three
independent analyses, CNVs were called for each subject using PennCNV(211) with the
hidden Markov model algorithm and custom-made population frequency of B-allele
(PFB) and GC model files. CNVs were called when 10 or more consecutive probes
demonstrated consistent copy number change. The PennCNV detect_cnv --trio option
was used to boost transmission probability of CNV calling for initially de novo scored
CNVs. Fragmented CNV calls were merged using clean_cnv. All candidate CNVs were
visually inspected to ensure the appropriate pattern of LRR and B-allele frequency was
consistent with the CNV call. Additionally, Gnosis,(176) QuantiSNP,(34) and Nexus
(biodiscovery.com) were used to increase specificity. De novo CNVs were prioritized for
quality by genomic length, number of probes, confidence score based on signal strength,
50% overlap of two or more algorithms, low parental origin p-value using
infer_snp_allele, and visual BAF/LRR review. All putative de novo CNVs were
experimentally evaluated by digital droplet PCR (ddPCR, Supplemental Figure 5.1), and
only validated CNVs are reported.
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De novo CNV loci that were previously reported as pathogenic were defined by reported
recurrence in at least two publications using independent data. Although some of the
CNVs reported here overlap with previously reported CNVs in CHD patients based on
review of the literature,(207), they do not meet our frequency constraint for previously
reported pathogenic de novo CNV loci.
5.4.4 CNV identification and variant calling from WES Data
WES data from 356 CHD trios were analyzed for de novo CNVs (Supplemental Table
5.2). WES samples were captured with the Nimblegen SeqCap Exome V2 chemistry and
sequenced on the Illumina HiSeq 2000 platform as previously described.(224) Sequence
reads were aligned to the human reference genome hg19 using Novoalign
(http://novocraft.com), BWA,(123) and ELAND.(38)Duplicates were marked with Picard
(http://picard.sourceforge.net). Indel realignment and Base Quality Score Recalibration
was done with GATK. XHMM is an algorithm to detect exon-level copy number
variation and assign CNV quality metrics(60)and was used at four of the PCGC analysis
sites (CHOP, Harvard, Columbia and Mount Sinai) to identify de novo CNVs
(Supplemental Figure 5.2). Candidate de novo CNVs were inspected visually. Putative de
novo CNVs were prioritized for confirmation based on genomic length, low sequence
depth variability and low prevalence in the XHMM call set data (AF<1%). All putative
de novo CNVs were independently confirmed by ddPCR.

SNP and short insertions/deletions (indels) were called from the Novoalign alignment of
WES trios using a pipeline derived from GATK version 2.7 best practices.(47) Briefly,
aligned reads were first compressed using the GATK ReducedReads module and variants
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were called on all CHD WES trios using the UnifiedGenotyper joint variant calling
module. Identified variants were filtered using GATK variant quality score recalibration.
Variants were annotated using SnpEff.(33) De novo SNPs and indels were independently
confirmed using Sanger sequencing.

5.4.5 CNV confirmation with digital droplet PCR
Putative CNVs were experimentally confirmed with ddPCR as previously reported(157)
using an 18-27 base pair FAM probe designed within each candidate CNV region,
avoiding homopolymer runs or probes that began with G. A VIC probe targeting the
RPP30 gene was used as reference. Reaction mixtures of 20 μL volume comprising
ddPCR Master Mix (Bio-Rad), relevant forward and reverse primers and probe(s) and
100 ng of digested DNA were prepared, ensuring that approximately 25-75% of the
10,000 droplets ultimately produced were positive for FAM or VIC signal. For de novo
CNV confirmations, DNA from the CHD patient and parents was used. After thermal
cycling, plates were transferred to a droplet reader (Bio-Rad) that flows droplets singlefile past a two-color fluorescence detector. Differentiation between droplets that contain
target and those that did not was achieved by applying a global fluorescence amplitude
threshold in QuantaSoft (Bio-Rad). The threshold was set manually based on visual
inspection at approximately the midpoint between the average fluorescence amplitude of
positives and negative droplet clusters on each of the FAM and VIC channels. Confirmed
CNV duplications had approximately 50% increase in the ratio of positive to negative
droplets as did the reference channel. Conversely confirmed CNV deletions had
approximately half the ratio of positive to negative droplets as did the reference channel.
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5.4.6 Network analysis
Three bioinformatic algorithms were utilized: DAVID,(91) DAPPLE,(174)and
WebGestalt.(210) Four different gene lists derived from the de novo CNV loci were used
(Supplemental Table 5.4). The lists were constructed as follows:(1) All genes contained
within de novo CNV intervals; (2) Published “causative” genes from previously reported
CHD CNVs intervals in addition to all genes in novel CHD CNV intervals. “Causal”
genes in previously reported CNV intervals included ELN(Williams syndrome),
RAI1(Smith-Magenis syndrome),TBX1(22q11 deletion), GATA4
(8p23.1 deletion), GJA5(1q21.1 duplication),and NKX2.5(5q35.1 deletion); (3) Genes
contained solely within novel CHD CNV intervals (e.g., exclude genes from previously
published CNVs); (4) Genes contained within de novo CNV intervals that are highly
expressed in the developing mouse heart (top quartile of all genes expressed E14.5 mouse
heart).(224) We anticipated that genes in list 2 and list 4 would have increased specificity
for CHD in comparison to genes in list 1 and that genes in list 3 would be biased towards
new disease networks.

We expanded network analysis input gene lists by including both de novo CNV genes
and de novo single nucleotide variants (SNV) that were previously identified in CHD
probands by WES.(224) Only de novo SNVs predicted to be deleterious (e.g., loss of
function (LOF): nonsense, frame-shift, and splice site mutations and missense variants
that alter highly conserved amino acid residues or predicted to be deleterious by SIFT or
PolyPhen2) were included in the expanded gene list. The additional gene lists included:
(5) All genes within a de novo CNV interval (e.g., list 1) and protein-altering SNVs and
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(6) Published “causative” genes from previously reported CHD CNVs intervals in
addition to all genes in novel CHD CNV intervals (e.g., list 2) and protein altering SNVs.

5.4.7 Statistical analysis
Burden calculations were done with a Fisher exact test computed in the R statistical
computing environment. For analyses using DAVID, networks with an enrichment of
genes impacted by CNVs were assigned a p-value with Benjamini and Hochberg
correction for multiple testing with a false discovery rate of 0.05. In DAPPLE, type I
error was controlled through permutation. p-values of less than 0.05 were considered
significant.

5.5 Heart Histone Modification Single Nucleotide
Variants
Congenital heart disease (CHD) is the most frequent birth defect, affecting 0.8%
of live births. Many cases occur sporadically and impair reproductive fitness, suggesting
a role for de novo mutations. Here we compare the incidence of de novo mutations in 362
severe CHD cases and 264 controls by analyzing exome sequencing of parent–offspring
trios. CHD cases show a significant excess of protein-altering de novo mutations in genes
expressed in the developing heart, with an odds ratio of 7.5 for damaging (premature
termination, frameshift, splice site) mutations. Similar odds ratios are seen across the
main classes of severe CHD. We find a marked excess of de novo mutations in genes
involved in the production, removal or reading of histone 3 lysine 4 (H3K4) methylation,
or ubiquitination of H2BK120, which is required for H3K4 methylation. There are also

131

two de novo mutations in SMAD2, which regulates H3K27 methylation in the embryonic
left–right organizer. The combination of both activating (H3K4 methylation) and
inactivating (H3K27 methylation) chromatin marks characterizes ‘poised’ promoters and
enhancers, which regulate expression of key developmental genes. These findings
implicate de novo point mutations in several hundreds of genes that collectively
contribute to approximately 10% of severe CHD.

In addition to de novo variants, transmitted variants were assessed for over-transmission
above expected 0.5 chance for WES (Table 5.3) and array (Table 5.4).

Table 5.3. Exome Transmission Enriched CNVs by TDT in CHD.

CNVR(hg19)

Transmit
TDT P Untrans
mit

Gene

Average
Average
Conf CNV
Numsnps
Length Case(bp) Type
Case

DQ601342,MIR4650chr7:720237580.011412 t=9;u=1 1,POM121,SBDSP1,S 22.66667
72414061
PDYE7P,TYW1B
chr1:2478354200.0455 t=4;u=0 OR11L1,TRIM58
22.75
248652837
chr5:373581690.0455 t=4;u=0 NUP155,WDR70
55.625
37725152
chr11:955684540.05778 t=8;u=2
MTMR2
13.05263
95621425
chr20:443510070.059347 t=13;u=5
SPINT4
3.03125
44354321
chr2:978150160.071861 t=17;u=8
ANKRD36
26.95
97849405
chr1:65858114DNAJC6,LEPR,LEPR
0.083265 t=3;u=0
15
65897602
OT
chr3:11896710.083265 t=3;u=0
CNTN6
10.33333
1427481
chr6:1177307260.083265 t=3;u=0
GOPC,ROS1
3.5
117739697
chr7:59205010.083265 t=3;u=0
OCM
11.83333
5923630
chrY:253757310.083265 t=3;u=0 DAZ2,DAZ3,DAZ4
1
25375830

132

333137.7

94

Dup

599049.4

99

Dup

373516.1

96

Dup

42981.53 93.73684 Dup
3831.656 97.84375 Del
113748.7

93.85

Del

43594

99

Dup

179273.7 97.83333 Dup
12226.5

94

Dup

100091.7

94

Dup

100

31

Dup

Table 5.4A. Array Transmission Enriched CNVs by TDT for Common CNVs.
CNVR(hg19)

Transmit :
P TDT CNV Untransmit
CNV

Distance Copy
from
Gene (bp) Number

Gene

chr19:208016071.52E-13 t=184;u=67
20802000

ZNF626

745

1

chr3:1317118961.87E-11 t=249;u=120
131712898

CPNE4

0

1

chr20:422721989.24E-11 t=155;u=60
42273045

IFT52

0

1

chr16:230482339.84E-10 t=131;u=49
23049446

USP31

23282

1

chr18:549467663.36E-09 t=126;u=48
54948517

ST8SIA3

71204

1

chr16:253413729.26E-09 t=137;u=57
25343049

ZKSCAN2

72517

1

chr11:299675963.52E-07 t=108;u=45
29968238

KCNA4

63050

1

chr15:397444255.13E-06 t=120;u=59
39744669

THBS1

128611

1

chr15:860574376.94E-06
86059128

t=81;u=33

AKAP13

0

1

chr17:415177055.93E-05
41518185

t=92;u=45

MIR2117

3989

1

chr15:658175276.33E-05
65819037

t=0;u=16

PTPLAD1

3790

3

chr11:656421276.68E-05 t=100;u=51
65642343

EFEMP2

1722

1

chr14:547112420.000451 t=85;u=45
54713593

CDKN3

150080

1

Table 5.4B. Array Transmission Enriched CNVs by TDT for Rare CNVs.
CNVR(hg19)
chr12:7398843974105393
chr2:8151911481557442
chr10:1305658713060410
chr10:62427293-

Transmit :
P TDT CNV Untransmit
CNV

Gene

Distance
from
Copy
Gene Number
(bp)

0.008151

t=7:u=0

LOC100507377

421563

1

0.014306

t=6:u=0

5S_rRNA

165896

1

0.018422

t=14:u=4

AK311458,CCDC3

0

1

0.025347

t=5:u=0

ANK3

0

1
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62428017
chr22:4456497544565393
chr12:9999431599995706
chr12:9840524898405248
chr1:1761619417619279
chr19:5418040054180706
chr20:4420486144378173
chr10:5508655355086886
chr5:7418258674186901
chr8:122325332122341946

0.032509

t=11:u=3

PARVB

0

1

0.033895

t=7:u=1

ANKS1B

0

1

0.033895

t=7:u=1

MIR4303

16022

1

0.033895

t=7:u=1

PADI3

5467

3

0.034808

t=9:u=2

MIR520E

1349

1

0.034808

t=9:u=2

SPINT4,WFDC10A,WFDC10B,
WFDC11,WFDC13,WFDC8,WFDC9

0

1

0.0455

t=4:u=0

PCDH15

475647

1

0.0455

t=4:u=0

FAM169A

0

1

0.0455

t=4:u=0

HAS2

283325

3

To assess the control frequency directly in a test statistic compared to controls, we use
Fisher’s exact test for both WES (Table 5.5) and array (Table 5.6) data.

Table 5.5. WES Case-Control CNV Association in CHD

CNVR(hg19)

P
(perm adj)

Cases Controls
CNV
CNV

Gene

Avg
Num
Exons

25

265,755

80

Dup

Avg Avg CNV
Length Conf Type

chr1:145273185145282043 1q21.1

0.004

20

2

NOTCH2NL
SEC22B,
NBPF14,
NBPF9

chr19:5419762354216713
19q13.42

0.03

11

0

MIR517A,

24

48,456

89

Del

chr7:2624598826251828 7p15.2

0.04

14

1

CBX3

4

17,394

70

Del
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Table 5.6. Array Case-Control CNV Association in CHD
CNVR(hg19)

P CNV
Logistic

chr15:600904574.01E-10
60103464

Cases Controls
CNV
CNV

Gene(s)

Average Copy
Exon
Numsnps Number Distance

P CNV
Fisher

14

5

BNIP2

13.0

1

108815

0.017882

8.31E-09

15

1

SLC45A1/ RERE

5.4

1

21636

0.000125

1.11E-08

8

1

MIR4307

14.3

1

101867

0.014167

1.33E-08

36

14

PDZD2

46.7

3

364

0.000242

6.93E-08

12

2

SORCS2

8.1

1

8117

0.004893

3.57E-07

14

1

EYS

13.0

1

10911

0.000249

2.52E-06

9

1

EPHA3

11.2

1

441577

0.007493

9.12E-06

9

1

ALG10

152.4

3

256999

0.008521

9.54E-06

14

3

SLK

9.8

1

7366

0.002511

9.66E-06

64

20

LOC646813

28.2

3

163692

7.7E-09

2.22E-05

13

4

KANSL1

25.6

1

240

0.005428

2.79E-05

15

1

AK310876

6.7

1

61147

0.000124

0.000103

21

3

DCDC2

28.3

1

23355

3.61E-05

0.000214

7

1

TENM3

17.5

3

3080

0.028486

0.000383

104

107

TPTE

44.7

3

48092

0.000768

chr16:1620334516261251

0.00045

7

1

ABCC1,ABCC6

285.7

3

0

0.028093

chr1:232460612232461177

0.00048

10

2

SIPA1L2

16.4

3

72535

0.016979

chr1:83591108362754
chr14:2747979827481036
chr5:3210662832107084
chr4:71839847186257
chr6:6607442166080908
chr3:8870681988715097
chr12:3443823534478239
chr10:105718227105720104
chr11:5054349450585298
chr17:4424983844263765
chr9:6684988666861820
chr6:2432562724325627
chr4:183570100183571844
chr21:1085854010858651

Now that we have better understood congenital heart disease we move into
neurodevelopmental disorders and comparing a variety of disorders and different arrays
in a meta-analysis.
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Chapter 6
6.0 CNV Meta-Analysis of 5 Major Neurodevelopmental Disorders

Summary
Psychiatric disease in children and young adults poses a major health burden and is
growing rapidly in prevalence. However, diagnostic phenotypes are not necessarily
distinct from each other suggesting a shared genetic etiology. There is also a potential to
target a shared associated variant using a shared therapeutic. Here, we investigate copy
number variants in cohorts of schizophrenia, bipolar, autism, ADHD, and depression. We
can consider the effected domains of cognition, psychosis, and mood. A total of 11,418
cases were compared to 14,789 controls. The well-known 22q11 deletion was found to be
enriched in cases vs. controls (p=5.33x10-7). Duplication of DOCK8/KANK1 was found
to be significant p=7.5x10-7. Several known and novel loci were significant by casecontrol association with CNVs enriched in cases across the neurodevelopmental
disorders.

6.1 Introduction
Studies of the base variants of DNA in psychiatric disease in very large cohort sizes have
begun to bear intriguing results (3, 117, 118, 168, 193). However, these single nucleotide
polymorphisms (SNPs) imprecisely tag nearby genes and have modest odds ratios. Copy
number variants (CNVs) have more direct gene dosage impacts and have been implicated
in psychiatric disease by a number of smaller cohort sizes with high odds ratios (49, 65,
67, 68). Although family studies have been very popular for avoiding population
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stratification issues, de novo and transmission disequilibrium (TDT) tests lack power to
find recurrent and significant results respectively. Case-control studies allow an
abundance of independent controls, population based allele frequency comparisons,
correction for population stratification of rare CNV variants by linear mixed model, with
enhanced power for recurrent significant confident results. Ambiguity in CNV calling in
different cohorts with different array resolutions can be challenging and impinge on
independent replication efforts. Here we process 5 large psychiatric disease cohorts in a
systematic manner to promote comparability of results.

6.2 Results
Five large psychiatric diseases with matched SNP array version controls were genotyped
and quality metric filtered (Table 6.1).
Table 6.1. Psychiatric Disease Cohorts Analyzed

Disease Cohort
Schizophrenia
Bipolar cohort
Schizophrenia
Autism
ADHD
Depression

Cases

Controls

Array

Statistic

3,377

1,301

Illumina 1MDv3

GEMMA

2,790
3,360
1,244
647

4,500
3,288
4,110
1,590

Affymetrix 6.0
Illumina 550v3
Illumina 550v1
Perlegen 660k

GEMMA
GEMMA
Fisher
Fisher

GEMMA and Fisher exact test p-values and Betas/odds ratios were calculated for each
disease case-control study. The closest gene was used as the marker name instead of the
rs ID SNP name to allow for more dynamic matching between CNVs derived from
different arrays (Table 6.2).
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Table 6.2. SNP ID Matches between SNP arrays (top panel) and Gene ID Array Matches for Deletions
(middle panel) and Duplicaitons (bottom panel)

Matches SNPs
Between Cohorts
1,758,390
385,436
225,641
88,750
9,976
Matches Genes Del
Between Cohorts
2,921
2,671
1,900
14,547
7,900
Matches Genes Dup
Between Cohorts
2,865
2,776
1,844
15,297
7,262

Count
1
2
3
4
5

Count
1
2
3
4
5

Count
1
2
3
4
5

Significant
CNVRs
127
30
25
7
0
Significant
CNVRs
12
20
18
40
175
Significant
CNVRs
37
22
7
16
43

The lowest p-value was used for meta-analysis. Using Genome-wide Efficient Mixed
Model Association (GEMMA) for the initial discovery cohorts of patients with
schizophrenia, schizoaffective, and bipolar disease, we performed principal components
analysis (PCA) and subsequently matched Caucasians cases with Caucasians controls, to
, correct for residual population stratification while maintaining power for rare CNV
variants. Correction for population stratification for rare population frequency variants
which may be geographically concentrated or dispersed while maintaining power,
remains an important fundamental open challenge of ongoing investigation(127, 137).
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The known and well characterized 22q11 deletion was found across psychiatric diseases
and we were able to resolve smaller
Figure 6.1. DOCK8/KANK1 Duplications

CNVs in a couple patients on COMT
and PRAME, implicating these genes
as key drivers in the deletion
phenotype for these psychiatric
disorders (Figure 6.3).
A novel duplication of DOCK8 and
KANK1 on 9p24 was the most
significant result with duplication
CNVs enriched in each of the 5 caseGreen rectangles represent duplication calls.

control cohorts meta-analyzed with

significant contributions from each cohort (Table 6.3) (Figure 6.1). These were
subsequently validated visually (Figure 6.4) and experimentally (Table 6.10).
Table 6.3. DOCK8 Contributing Signals from each Psychiatric Disease Cohort
P

Beta/OR

Cases
Dup

Cases Controls Controls
Diploid
Dup
Diploid

ChrPosHg18

SNPID

Schizo
Bipolar

chr9:435364

rs4741936

0.00693 3.15E-01

6

2911

0

1113

DOCK8 1006

CHOP
Schizo

chr9:383339

SNP_A2057057

0.00800 10.7119

7

957

1

1465

DOCK8 2773

CHOP
Autism

chr9:432030

rs1887958

0.00384

infinity

7

2071

0

2518

DOCK8

CHOP
ADHD

chr9:344334

rs943625

0.08985 3.31932

4

1235

4

4105

DOCK8 11257

CHOP
chr9:283360
Depression

rs943628

0.00731 4.96401

8

639

4

1586

DOCK8 3779
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Gene

Exon
Distance

Cohort

21

Analysis, using GEMMA for the various disease cohorts in Table 6.1 (Schizophrenia
Bipolar, Schizophrenia, Autism, ADHD, and Depression) demonstrated significant P
values across multiple loci (Table 6.4).
Table 6.4. Meta-analysis across five major neuropsychiatric cohorts. Deletions (top table) and Duplications
(bottom table)

MarkerName
Deletion
KIAA1693
NBPF20
POTEA
CYP2A6
COMT
GRIN3B
CTNNA3
AK058147
C21orf56
DUSP22
DKFZp434L187
ZNF804A
MAMDC1
PSG11
ASB3
HCN1

Weight

Zscore

4
4
3
4
3
3
4
4
3
3
4
4
4
4
4
4

7.185
7.036
5.756
4.637
4.494
-4.482
-4.439
4.394
4.112
4.007
3.916
3.88
3.8
3.743
3.666
3.597

Meta pvalue
6.73E-13
1.97E-12
8.59E-09
3.54E-06
6.99E-06
7.41E-06
9.05E-06
1.11E-05
3.93E-05
6.15E-05
9.02E-05
0.000104
0.000145
0.000182
0.000247
0.000322

*Direction
-+++?
++++?
+?++?
++++?
+?++?
-?--?
----?
++++?
+?++?
++?+?
+++-?
++++?
++++?
++++?
++++?
+++-?

MarkerName
Meta pWeight Zscore
Direction
Duplication
value
DOCK8
5
4.948 7.50E-07 +++++
AK075337
3
4.629 3.68E-06
+?++?
AF161442
3
4.574 4.78E-06
?-++?
KANK1
5
4.141 3.45E-05 +++++
AK123120
4
4.128 3.67E-05
+-++?
FAM60A
5
4.111 3.94E-05
++++UNKL
3
3.816 0.000136
+?++?
ALG10B
4
3.748 0.000179 ++++?
*Some arrays had poor coverage or no CNVs observed on certain genes, resulting in missing direction of
association (“?”); “+” indicates more cases than controls while; “-“ indicates more controls than cases.
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Analysis of Protein-Protein Interaction Network was performed using brain expression
Figure 6.2. Protein-Protein Interaction Network Brain Expressed.

filters
capturing 20
genes of 55
(Figure 6.2).
Topological
features:
1. the main
network is
around gene

20 genes (of 55). Topological features: 1. the network is around gene UBC 2. small
cluster involving ZWINT neighborhood (also RAB11FIP3 and ERBB4).

UBC
2. smaller

cluster involving ZWINT neighborhood (also RAB11FIP3 and ERBB4).

Calcium channels have been associated in GWAS meta-analysis of the psychiatric
diseases(3). These CACNA genes, specifically CACNA1H (p=7.33x10-5) demonstrated
the strongest signal in autism, and more modest signals in schizophrenia, bipolar, and
depression. Interestingly, ADHD had a significant lack of CNVs in this region.

6.3 Discussion
There is mounting evidence for the shared genetic and epidemiological etiology
of psychiatric disorders. We are the first to perform CNV meta-analysis between all five
major neurodevelopmental disorders: autism, ADHD, schizophrenia, bipolar, and
depression. These genetic discoveries pave the way for new drugs and diagnostics which
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can be applied across clinical indications. Using gene based association statistics, we
were able to robustly meta-analyze different psychiatric conditions across different
microarrays and generate and uncover novel loci with neurodevelopmental/psychiatric
disease associations.
22q11 deletion is a well know locus for schizophrenia and syndromic conditions with
heart and brain involvement. Here, we are able to partially gain greater resolution of
pathogenic CNVs in this genomic locus, highlighting COMT.9p24 duplications of
DOCK8 and KANK1 are intriguing given that these genes have been shown to be
involved in severe mental dysfunctions of mental retardation and cerebral palsy,
respectively. DOCK8 is the dedicator of cytokinesis 8, a member of the DOCK180
family of guanine nucleotide exchange factors (GEF), of which there are 11 DOCK
genes. Guanine nucleotide exchange factors interact with Rho GTPases and are
components of intracellular signaling networks. GEF proteins activate some small
GTPases by exchanging bound GDP for free GTP. Mutations in DOCK8 have been
shown to cause mental retardation. KANK1 is KN motif and ankyrin repeat domains 1
(KANK1). There are 4 KANK genes. KANK1 functions in cytoskeleton formation by
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regulating actin polymerization. Mutations in this gene cause cerebral palsy spastic
quadriplegic type 2, a central nervous system development disorder. KANK1 inhibits
neurite outgrowth. KANK1 inhibits actin fiber formation and cell migration. KANK1 also
inhibits RhoA activity; the function involves phosphorylation through PI3K/Akt
signaling and may depend on the competitive interaction with 14-3-3 adapter proteins to
sequester them from active complexes. Inhibits the formation of lamellipodia (projection)
but not of filopodia (far projection); the function may depend on the competitive
interaction with BAIAP2 to block its association with activated RAC1. KANK1 inhibits
fibronectin-mediated cell spreading; the function is partially mediated by BAIAP2.
KANK1 is involved in the establishment and persistence of cell polarity during directed
cell movement in wound healing. In the nucleus, KANK1 is involved in beta-catenindependent activation of
Figure 6.3. 22q11 Deletion in Individual Sample Profiles

transcription.
CACNA was first implicated in our
previous schizophrenia CNV
association study(REF). A GWAS
meta-analysis of psychiatric disease
base genotypes also implicated this
locus as highly significant. Here we
show CACNA1H as highly
significant further underscoring the

Red rectangles represent deletion calls.

importance of this gene family in

psychiatric conditions.
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These CNVs add to the catalog of neurodevelopmental variants(77) to be further
investigated and replicated(83) by ongoing studies in this important domain.

6.4 Conclusion
With mounting awareness of childhood psychiatric conditions comes mounting need for
large-scale genetic studies and unified picture of the catalog of rare variants underlying
these conditions. We take the unprecedented step to meta-analyze CNVs across
psychiatric diseases and reveal multiple significant genes which could serve as viable
drug targets with cross-indication clinical utility.

6.5 Methods
Sample
The dbGaP non-GAIN schizophrenia samples were downloaded from the dbGaP website.
We did have total of 5825 non-GAIN Affymetrix 6.0 raw CEL files. The CEL files were
converted to raw intensity data using PennCNV Affy workflow
[http://www.openbioinformatics.org/penncnv/penncnv_tutorial_affy_gw6.html]. We
only included samples with call rate>=98% for generating CNVs.
PennCNV and QC
CNV were generated using PennCNV(211) a Hidden Markov Model(HMM) based
algorithm which combines multiple source of information including LRR, BAF ,SNP
spacing and population frequency of B allele to generate the CNV. The following QC
criteria were used to select the CNV’s for further analysis: 1) For all Illumina chip
platform call rate >98%, SD LRR <0.3, |GCWF| <0.05 and count CNV <100; 2) For
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Affymetrix 6.0 data call rate >96%, SD LRR <0.35, |GCWF| <0.02 and count CNV <80
(70) .
For Affymetrix 6.0 Schizophrenia dbgap non-gain samples, we did LD based SNP
pruning using Plink(167).We only included the SNP with genotype rates < 5%, minor
allele frequency > 0.01, as well as HWE P value > 0.0001. We generated the pairwise
IBD values for samples using genome command and excluded one sample from any pair
with a PI_HAT value exceeding 0.3.
We ran PCA on Affymetrix 6.0 data using Eigenstrat(163) package. The first 10 Eigen
vectors were plotted and samples were excluded if the values were greater than 0.05 for
the first 2 principal components to select eastern European individuals.
CNV Association
ParseCNV(70) was used to conduct the CNV association analysis. Case control CNV
association was done on Schizophrenia (case=2790, control=4500), Autism (case=3360,
control=3288) cohorts separately which generates a deletion, duplication CNVRs based
on probe statistics of CNV’s. The –includeped option was used in the ParseCNV(70)
which generates a ped file for SNP analysis.
GEMMA
The bed file was imported into GEMMA version 0.94(227).The relatedness matrix for
genotype was calculated using the -gk 1 option .The matrix file was then imported for
univariate linear mixed model association which accounts for population stratification
estimate the proportion of variance of phenotype and -lmm 4 option was used which
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includes Wald test, likelihood ratio test and score test statistics, we also removed SNPs
whose MAF<0.000005.
InsertPlinkPvalues
We used InsertPlinkPvalue program from ParseCNV(70) package to insert the SNP pvalue generated by GEMMA association result to define ParseCNV CNVRs .
METAL
For meta-analysis, METAL was used on SNP-based population CNV association
statistics sorted by p-value to include the most significant SNP in each gene. The
logarithm of the odds ratio was taken to ensure consistency with Beta for the direction of
association considerations.
Statistical Analysis
Two-tailed fisher’s exact test and Gemma linear mixed model. P-values of less than 0.05
after correction for 100 independent and informative tests (5x10-4 uncorrected) were
considered significant.
Table 6.5. GEMMA analysis in Schizophrenia/Bipolar discovery samples together with CHOP samples
from Schizophrenia, Autism, ADHD and Depression cases.

A)
Marker Name
Del
LOC729862
HLA-B
MED18
C11orf74
NBPF4
HINT1
BC035867
SLITRK6
CPNE4
POTEA

Weight

Zscore

P-value

Direction

Region(hg19)

3
3
3
3
3
3
3
3
3
3

7.042
4.882
4.773
4.745
4.709
4.698
4.677
4.671
4.669
4.559

1.90E-12
1.05E-06
1.81E-06
2.09E-06
2.49E-06
2.62E-06
2.91E-06
3.00E-06
3.03E-06
5.13E-06

+?++?
++?+?
+++??
-?++?
+++??
+?++?
+?++?
+?++?
+++??
+?++?

chr5:28926976-28927420
chr6:2618277-2704782
chr1:28655512-28662478
chr11:36616066-36696390
chr1:108918459-108953434
chr5:130494874-130501034
chr22:20970516-21011201
chr13:86366921-86373483
chr3:131253576-132004254
chr8:43147584-43218328
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RNF168
PHACTR4
WDR53
HCN1
C3orf43
BC070396
RGS18
KHDRBS2
CCDC91
AK093205
LOC10014460
2
KCND2
GUCY1A3
SESN2
FBXO45
BC051808
PER4
JARID2
PRR16
SEMA5A
OR12D3
AK098570
KCNJ3
ARHGEF16
BC034799
SPRY2
EYS
DPP10

3
4
3
3
3
4
4
4
3
4

4.525
4.455
4.449
4.371
4.296
4.252
4.207
4.077
4.07
4.046

6.03E-06
8.38E-06
8.64E-06
1.24E-05
1.74E-05
2.12E-05
2.59E-05
4.57E-05
4.69E-05
5.20E-05

+++??
++++?
+++??
+?+-?
+++??
++++?
++++?
++++?
+?++?
++++?

chr3:196195656-196230639
chr1:28696092-28826881
chr3:196281058-196295413
chr5:45255051-45696220
chr3:196233749-196242237
chr3:103646038-103730578
chr1:192127591-192154945
chr6:62389864-62996100
chr12:28332209-28703099
chr4:33893553-33908510

4

4.039

5.38E-05

++++?

chr4:66535678-66559104

3
3
3
3
4
3
3
3
3
3
3
3
4
4
3
4
4

3.889
3.804
3.79
3.766
3.711
3.646
3.626
3.604
3.602
3.6
3.587
3.579
3.563
3.561
3.523
3.493
3.482

0.000101
0.000143
0.000151
0.000166
0.000206
0.000267
0.000288
0.000313
0.000315
0.000319
0.000335
0.000345
0.000367
0.00037
0.000427
0.000477
0.000499

+?++?
++?+?
+++??
+++??
++++?
+?++?
+++??
+?++?
+?++?
++?+?
+?++?
?+++?
++++?
++++?
+?++?
-+++?
++++?

chr7:119913721-120390387
chr4:156587861-156658214
chr1:28585962-28609002
chr3:196295724-196315930
chr1:108963310-108975804
chr7:9673899-9675447
chr6:15246526-15522253
chr5:119800018-120022964
chr5:9035137-9546233
chr6:29341199-29343068
chr5:29143667-29153802
chr2:155555092-155713014
chr1:3371146-3397677
chr4:58292037-58332152
chr13:80910111-80915086
chr6:64429875-66417118
chr2:115199898-116602326

Zscore

P-value

Direction

Region(hg19)

6.232
4.87
4.725
4.358
4.217
4.15
4.026
3.99
3.77
3.756

4.60E-10
1.12E-06
2.30E-06
1.31E-05
2.48E-05
3.33E-05
5.68E-05
6.62E-05
0.000163
0.000172

??++?
+?++?
++++?
+?+??
+?++?
?++??
?++??
+?++?
-??+?
?++??

chr9:139543061-139554873
chr21:44834397-44847002
chr4:33897960-34041515
chr19:21106058-21133503
chr19:28129390-28137384
chr1:55423541-55423614
chr5:151988595-151988771
chr13:92050934-93519487
chr21:11057795-11098937
chr20:17855141-17855219

B)
Marker Name
Weight
Dup
AF161442
2
SIK1
3
BC036345
4
ZNF85
2
AK075337
3
TRNA_Lys
2
TRNA_Pseudo
2
GPC5
3
C19orf36
2
TRNA_Gln
2
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AK056166
AF088005
HLA-A
HCN1
ITGB2
BX648270
ALG10B
ICOSLG
AX747706
TRNA_His
LOC728989

2
2
3
3
2
2
3
2
2
2
2

3.732
3.726
3.669
3.656
3.639
3.637
3.622
3.619
3.616
3.512
3.512

0.00019
0.000195
0.000243
0.000256
0.000273
0.000276
0.000293
0.000296
0.000299
0.000444
0.000444

+??+?
+??+?
++?+?
+?++?
??++?
++???
+?++?
??++?
??-+?
?++??
?++??

chr20:17855141-17855219
chr19:13209841-13213974
chr6:1150035-1295564
chr5:45255051-45696220
chr21:46305867-46348753
chr2:132442469-132457442
chr12:38710556-38723528
chr21:45646721-45660834
chr9:139442078-139444195
chr1:145396880-145396952
chr1:146490894-146514599

Description of schizophrenia/bioplar discovery cohort samples
The unrelated schizophrenia (SCZ), schizoaffective (SA), or bipolar I (BP) patients were
from 28 clinical trials (Table 6.6) conducted by Janssen Research & Development, LLC
to assess the efficacy and safety of risperidone, paliperidone and an investigative
compound (R209130). The diagnoses of SCZ, SA, and BP were based on expert clinician
interviews conducted using DSM-IV-TR criteria. In two studies (NCT00397033 and
NCT00412373), the diagnosis of schizoaffective disorder was confirmed using an
interview based SCID (Structured Clinical Interview for DSM-IV-TR). Detailed
descriptions of these clinical trials can be found at ClinicalTrials.gov, as well as in
published works1-30, and thus, are not repeated here.

A total of 5,544 DNA samples from 5,431 patients and 49 quality control (QC) samples
were genotyped on the Illumina Human1M-DuoV3. DNA samples from all patients who
participated in these clinical trials and consented to the genetic study were genotyped for
21 out of the 28 clinical trials. A small number of DNA samples from the remaining 7
clinical trials were also genotyped (Table 6.6). The DNA samples were genotyped in 2
batches, with 3,102 samples in the first batch and 2,491 samples in the second batch.
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Genotype data were successfully generated on 5,508 samples. A few sample QC steps
were performed to remove the duplicated and/or problematic samples. First, gender
discrepancies were examined using both the heterozygosity rate of the X-chromosome
SNPs and the call rate of the Y-chromosome SNPs. Samples with discrepant and
ambiguous gender information were excluded. Second, the relatedness of the genotyped
samples was examined using pairwise Identity-by-State. Planned but not confirmed
duplicates, as well as unplanned duplicates, with discrepant phenotype data were
excluded from subsequent analyses. For each pair of samples that were planned and
confirmed duplicates, unplanned duplicates with consistent phenotype data, or samples of
related individuals, the sample with a smaller standard deviation of the LogR-ratio (LRR)
was retained. After the sample QC, there were 4,962 samples (3,251 SCZ, 377 SA, and
1,334 BP) remaining.

Table 6.6: Summary of the clinical trial samples
Number of
ClinicalTrials.gov
Disease
Patients
Identifier
Genotyped
NCT00791232
SCZ
1

Genotyping
Batch

Publication

1

Cleton et al 2007

PMID

NCT00086320

SCZ

187

1

Kramer M et al 2007

17224706

NCT00085748

SCZ

93

1

Tzimos A et al 2008

18165460

NCT00078039

SCZ

473

1

Kane J et al 2007,

17092691,
18466043

NCT00077714

SCZ

296

1

NCT00083668

SCZ

333

1

NCT00334126

SCZ

220

1

Canuso CM et al 2009

NCT00397033

SA

173

2

Canuso CM et al 2010

NCT00412373

SA

187

2

Canuso et al 2010

NCT00299715

BP

310

2
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Meltzer HY et al 2008
Marder SR et al 2007,
Meltzer HY et al 2008
Davidson M et al 2007,
Meltzer HY et al 2008

Berwaerts J et al 2012

17601495,
18466043
17466492,
18466043
19411369
20492853,
20957127
20814330,
20957127
20624657

NCT00309699

BP

350

2

Vieta E et al 2010

20565430

NCT00309686

BP

214

2

Berwaerts J et al 2011

20947174

NCT00074477

SCZ

168

1

Kramer M et al 2010

19941696

NCT00111189

SCZ

14

1

Hough D et al 2010,

NCT00210717

SCZ

493

1

NCT00210548

SCZ

249

1

Kozma CM et al 2011
Fleischhacker WW et al
2011
Gopal S et al 2010

19959339,
21696265

NCT00101634

SCZ

404

1

Nasrallah HA et al 2010

20555312

NCT00119756

SCZ

17

1

Hough D et al 2009

19481579

NCT00590577

SCZ

468

2

Pandina GJ et al 2010,
Bossie CA et al 2011

20473057,
21569242

148

2

Simpson GM et al 2006

16965196

62

1

120

2

Gharabawi GM et al
2006
Hass M et al 2009

SCZ

8

1

Turner M et al 2004

15201572

NCT00253162

BP

233

2

Smulevich AB et al 2005

15572276

NCT00257075

BP

186

2

15169694

NCT00034775

SCZ

16

1

Hirschfeld RM et al 2004
Lindenmayer JP et al
2004

SCZ

7

1

SCZ

1

1

NCT00297388
NCT00061802
NCT00076115

NCT00063297

SCZ or
SA
SCZ or
SA
BP

21777507
20389255

17054789
19839994

15323593

Data presented in table 6.7 below summarize the basic demographic information of these
patients.
Table 6.7: Basic demographic information of the JNJ SZ, SA, and BP patients

Sex, n (%)
F
M
Age, years
Mean (SD)
Median (Range)
Race, n (%)
Asian
Black or African American
White
Other

Schizophrenia
(N=3251)

Schizoaffective
(N=377)

Bipolar
(N=1344)

1240 (38.1)
2011 (61.9)

152 (40.3)
225 (59.7)

629 (47.2)
705 (52.8)

40.2 (12)
40 (17, 81)

38.7 (9.5)
39 (19, 61)

37.8 (13.5)
39 (10, 77)

117 (3.6)
703 (21.6)
2360 (72.6)
71 (2.2)

52 (13.8)
86 (22.8)
228 (60.5)
11 (2.9)

37 (2.8)
247 (18.5)
1021 (76.5)
29 (2.2)
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Schizophrenia GAIN and non-GAIN: Inclusion criteria for samples included in the
analysis were as follows: The subject must give signed, informed consent. The proband
must have a consensus best-estimate DSM-IV diagnosis of SZ (schizophrenia) or of
schizoaffective disorder with at least 6 months’ duration of the “A” criteria for
schizophrenia. The subject must be over 18 years of age at interview (male or female).
The informant should have known the subject for at least 2 years, be familiar with the
psychiatric history, and have at least 1 hour of contact per week with the proband (close
family members preferred).
Exclusion criteria were as follows: The subject is unable to give informed consent to all
aspects of the study. The subject is unable to speak and be interviewed in English (to
ensure validity of the interviews).
Psychosis is deemed secondary to substance use by the consensus diagnostic procedure
because psychotic symptoms are limited to periods of likely intoxication or withdrawal,
or there are persistent symptoms likely related to substance use (e.g. increasing paranoia
after years of amphetamine use, symptoms limited to visual hallucinations after extensive
hallucinogen use). The psychotic disorder is deemed secondary to a neurological
disorder, such as epilepsy, based on the nature and timing of symptoms. For example,
nonspecific, nonfocal EEG abnormalities are common in SZ, but subjects with psychosis
that emerged in the context of temporal lobe epilepsy would be excluded.
The subject has severe mental retardation (MR). A subject with mild MR (IQ ≥ 55 or
based on clinical and educational history) can be included if SZ symptoms and history
can be clearly established.
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Control Population Typed on Affymetrix 6.0 at CHOP
The control population included de-identified subjects collected at CHOP and UPenn was
Only Caucasian samples from subjects without psychiatric disease were included and
validated by Eigenstrat principal components analysis before use.

Autism
The ASD subjects within the ACC cohort were collected from multiple collaborative
projects across the US. We assembled an ASD Autism Case-Control (ACC) cohort by
collecting, from multiple sites within the United States, 859 subjects of European
ancestry affected with ASD (Table 6.8). Among these subjects, 703 were male and 156
were female, all of whom met diagnostic criteria for autism based on ADI, and 124 met
criteria for other ASDs based on ADOS. The best estimate procedure was used with
autism experts evaluating all available information (including ADI/ADI-R and ADOS
which was attained for all subjects) to provide the final diagnosis of Autism or ASD.
Subjects ranged from 2-21 years of age when diagnosis was made. ADI-Autism
Diagnostic Interview, ADOS-Autism Diagnostic Observation Schedule, IQ-Intelligence
quotient, NVIQ-nonverbal IQ, VIQ-verbal IQ, FSIQ-full scale IQ.
Table 6.8. ACC Cohort Description

blood
cell line

98%
2%

Female
Male

156
703

ADI_dx Autism
ADI_dx not Autism
ADOS_dx ASD
ADOS_dx Autism
ADOS_dx not Autism
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859
0
124
708
27

IQ age (months)
Median
Mean
SD

n=496
117
141.4
95.5

NVIQ
Median
Mean

n=382
92
89

SD

25.5

VIQ
Median

n=378
86

Mean
SD

81.1
29.5

FSIQ
Median
Mean
SD

n=453
87
85.7
25.5

Control subjects from the Children’s Hospital of Philadelphia
The control group included 2519 children of self-reported Caucasian ancestry (mean age
was 8.7 years, median=9, SD=5.46 and 52.5% males). All controls had no history of
ASD. The CHOP controls were recruited by CHOP nursing and medical assistant staff
under the direction of CHOP clinicians within the CHOP Health Care Network, including
four primary care clinics and several group practices and outpatient practices that
included well child visits. The controls are recruited though our primary care and well
child clinics - they range in age from 1-19 years; both questionnaire data (obtained during
recruitment) and electronic health care records (average coverage 3-4 years) indicated
that they have no chronic disease and are developmentally on target; age, sex and ethnic
background are also reported. The questionnaire data asked specifically if the patient has
been evaluated for autism; any underlying medical condition and any medication they
may be taking (so all the controls are negative for autism or any other CNS disorder,
chromosomal disorder, syndrome or genetic disorder).
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Autism Genetic Resource Exchange (AGRE)
The Autism Genetic Resource Exchange (AGRE; http://www.agre.org) has a collection
of DNA samples and clinical information from families with autism spectrum disorder
(ASD). We have collected DNA samples from 943 families (4,444 individuals) from the
entire AGRE collection (as of August 2007). These AGRE families include 917
multiplex families, 24 simplex families and 2 families without ASD diagnosis (not used
in analysis).
The AGRE annotation database classifies autism, broad spectrum (patterns of
impairment along the spectrum of pervasive developmental disorders, including PDDNOS and Asperger’s syndrome) or Not Quite Autism (individuals who are no more than
one point away from meeting autism criteria on any or all of the social, communication,
and/or behavior domains and meet criteria for “age of onset”; or, individuals who meet
criteria on all domains, but do not meet criteria for the "age of onset"). In our analysis,
AGRE patients with “Autism” (n=1202) and “Broad Spectrum” (n= 134) phenotype
annotation were treated as a single ASD group. Among them, 11 subjects had autism
diagnoses assigned by ADOS (Autism Diagnostic Observation Schedule) without ADI-R
(Autism Diagnostic Interview-Revised). SRS-Social Responsiveness Scale (Table 6.9).
Table 6.9. AGRE Cohort Clinical Description

Multiplex
Simplex

95%
5%

Cell Line

1336

Female
Male

284
1052

Sibs

Count

ADOS_Diagnosis
Autism
not ASD or Autism
Spectrum

Count
775
76
171

SRS
Median
Mean
SD

n=821
106
104.2
33.7

Assessed age yrs
Median
Mean
SD

8
9.2
5.3

SRS Age yrs
Median
Mean
SD

9.49
10.0
4.6
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0
1
2
3

282
438
54
4
AGRE Status Count
Autism 1202

BroadSpectrum 134

ADIR
Autism
Asperger's
PDD

Count
93
18
16

Raven IQ
Median
Mean
SD

n=645
103
100.7
18.9

7.08
8.0
4.4

Raven IQ Age
yrs
Median
Mean
SD

8
8.9
3.9

Assessed age yrs
Median
Mean
SD

ADHD
Our discovery cohort included a total of 1,013 ADHD cases of European descent
recruited and genotyped at The Children’s Hospital of Philadelphia (CHOP) consisting of
664 cases without parents and 349 cases from complete trios. We established a minimum
inclusion IQ threshold of 70 to exclude cases with intellectual disability. The control
group included 4,105 healthy children of European ancestry 32% female and 68% male
aged 6-18 years old. Medical records and parental/self-reported questionnaires were
screened for developmental delays and special educational needs. Additional 128 cases
from NIMH and 90 cases from The University of Utah were used for replication. The
DNA samples were genotyped on different platforms; to manage differences in CNV
detection between arrays we used controls genotyped on platforms matching case
platforms.

Additional controls on the Illumina platform were genotyped on the InfiniumII
HumanHap550 BeadChip technology (Illumina San Diego CA), at the Center for Applied
Genomics at CHOP. Subjects were primarily recruited from the Philadelphia region
through the Hospital's Health Care Network, including four primary care clinics and
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several group practices and outpatient practices that performed well child visits.
Eligibility criteria for this study included all of the following: (1) disease-free children
and parents of these children in the age range of 0–18 yr of age who had high quality,
genome-wide genotyping data from blood samples (defined in Supplemental Methods);
(2) self-reported ethnic background; and (3) no serious underlying medical disorder,
including but not limited to neurodevelopmental disorders, cancer, chromosomal
abnormalities, and known metabolic or genetic disorders. For more details see33.
Depression
Case:Control Data
Raw genotyping data from three Genetic Association Information Network (GAIN)
projects typed on the Perlegen 600K (Perlegen Sciences Mountain View, CA, USA) array
were accessed through dbGaP. MDD cases and controls who were at low liability for
MDD were utilized from the case:control project “Major Depression: Stage 1
Genomewide Association in Population-Based Samples (phs000020.v2.p1)”. Psoriasis
Cases and Controls were used to supplement our Perlegen 600K control cohort for MDD
“Collaborative Association Study of Psoriasis (phs000019.v1.p1)”. Lastly, parents from
parent-offspring trios were used to further supplement the control from “International
Multi-Center ADHD Genetics Project (phs000016.v2.p2)”. Parents from the ADHD
study were used to maximize the number of unrelated individuals that could be leveraged
for optimal study power.

Case selection
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MDD cases were recruited through mental health care organizations, general practices
and in the community setting. The inclusion criteria for the 1,780 (1,693 of which were
used in this study) participants are: 1) a DSM-IV diagnosis of major depressive disorder
as confirmed by the CIDI psychiatric interview, 2) an age between 18 through 65 years,
3) sufficient knowledge of the Dutch language, and 4) North-European ancestry. As the
samples should be representative of patients seen in different settings, there are few a
priori exclusion criteria. Excluded patients are: 1) those with a primary diagnosis of
psychosis, bipolar disorder, obsessive compulsive disorder, severe addiction disorder and
2) those with insufficient knowledge of the Dutch language.

Control selection
Age and gender matched control subjects are mainly derived from the Netherlands Twin
Register, for which data collection in twin, their parents, spouses and siblings occurred in
1991, 1993, 1995, 1997, 2000, 2002/3 and 2004/5. A total of 1860 (1,697 of which were
used in this study) controls were selected (only one member from each family) with the
following inclusion criteria: 1) age 18 through 65 years, 2) never scoring high (> 0.65) on
a general factor score for anxious depression (a combined measure of neuroticism,
anxiety and depressive symptoms via questionnaires), 3) never reported a history of
MDD in any survey, and 4) North-European ancestry. Controls and their parents were
born in the Netherlands or northwestern Europe.

Additional control subjects were obtained from two other studies both of which were
unrelated to MDD. The first one included a case control study on psoriasis who were
genotyped on the Perlegen platform and included as controls (n=1,600). The psoriasis
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cases were diagnosed by dermatologists and their matched controls had no history of
psoriasis, no family history of psoriasis or other auto-immune disorders. All subjects
were 18 years of age or older. The second control cohort included parents from the
ADHD parent-offspring trios study who were also genotyped on the Perlegen platform
and included as controls (n=1,209). For more details see34.
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Figure 6.4. KANK1 Duplications Raw BAF LRR Plots

Red points show the elevated Log R Ratio (hybridization intensity) and triallelic B allele
frequency (genotype) in the duplicated region with flanking blue points showing normal
diploid state. Schizophrenia and bipolar cases are represented.
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Subject ID

Table 6.10. KANK1 Duplications Independent Validation with Roche Universal Probe Library
Assay #:
132
134
135
137
141
145
Duplication call
Chromosomal
chr9:279,035 chr9:326,544 chr9:416,891 chr9:460,349 chr9:537,138 chr9:559,914 Chromosomal
Location
-279,138
-326,608
-417,000
-460,443
-537,211
-560,007 Location (hg18):
(hg18):
chr9:4742994303995005
2
2
3
3
3
1
702599
chr9:5497155026401799
2
2
2
2
2
1
626251
chr9:3238206626851238
2
3
3
3
3
1
733353
chr9:5167736921106789
2
2
2
2
3
1
801972
chr9:3961187015457340
2
2
3
3
3
1
689065
chr9:3238207565556942
2
3
3
3
4
1
801972
chr9:4908117720672852
2
2
2
3
3
1
534956
chr9:2873959392414481
2
3
3
3
3
1
723374
chr9:3081549527354896
2
2
3
3
3
1
474850
chr9:4681542885798241
2
2
3
3
3
1
697859
chr9:2631618697617291
2
3
3
3
3
1
520703

Six assays were run on each subject, with the assays covering much of the region covered
by the duplications. The copy number calls for each subject for each of the six assays is
shown. The table has been colored gray for assays that were within the predicted deletion
call for that subject, and the CNVs detected are highlighted with the red numbers. In 10
out of 11 samples with duplications of KANK1 by array analysis, duplications were
observed by independent validation. There are a few regions flanking the called CNVs
where duplications were observed, refining the CNV boundaries. Four assays were
designed that fell between chr9:559,000 and chr9:601,000, and only one ran properly in
the control dilutions that were run. When that assay (Assay #145) was applied to these
subjects, it repeatedly (3 independent runs) resulted in CN:1 calls in all subjects. It is
suspected that those results are incorrect, but an experimental reason to discard them was
not uncovered. They are provided here for completeness and because they were
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reproducible. Unfortunately, the trouble with the assays in that region means that one of
the subjects (5026401799) had no predicted duplication region covered by a good assay.

Taken together, we have explored CNVs or the brain in neurodevelopmental disorders,
the capstone project of this dissertation. We have traveled a long distance through
different genomic assays, diseases, and study designs and uncovered multiple loci that are
shared among multiple neuropsychiatric/neurodevelopmental disorders. Future work will
tell if effective therapies can be developed in relation with the targeted loci observed.
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Chapter 7
7.0 Conclusions and Future Directions

7.1 Significance and Impact of My Thesis Work
My dissertation research, comprised of three broad components, aims to elucidate the
genetic etiology of complex disease that is mediated through CNVs. I have used large
disease projects, including CHD and brain developmental disorders as representative of
human complex disease in relation to copy number variant analysis. My approach is as
follows: First, to examine de novo (variant not present in unaffected parents, but present
in affected child) CNV frequency in both congenital heart disease and healthy families.
Second, to find and define genes significantly associated to CHD, true recurrent de novo
CNVs through a genome-wide analysis. Third, to assess biological gene function of
single de novo CNVs as well as CNV networks impacting selective biological pathways.

In Chapter 2 I present a computational method that I developed to perform a genomewide association study of CNVs in complex disease with quality tracking. ParseCNV
takes CNV calls as input and creates probe based statistics for CNV occurrence in (1)
cases and controls, (2) families, or (3) populations with quantitative traits, then calls
CNVRs based on neighboring probes of similar significance. CNV calls may be from
aCGH, SNP array, exome sequencing, or whole genome sequencing. I compare other
methods, such as Plink results from Autism case-controls datasets to ensure consistency
and compare features.
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In Chapter 3 I present a large population-based CNV study to robustly define rare CNV
frequency. The large sample, genotyped at the same lab with the same array content,
considerably adds to detection power in case-control studies for rare variants. Here, we
evaluate 68,000 individuals typed with 520,000 probes in common, and report 4,969
deletion, 2,633 duplication, and 263 homozygous deletion CNVRs observed in multiple
unrelated individuals. The CNVs uncovered are shown to co-localize with ncRNA,
GWAS, and OMIM annotated regions above random expectation. We performed CNV
association clustering across the broad disease categories of cancer, autoimmune,
cardio/metabolic disease, and neurological disease populations in comparison to healthy
controls. Subsequently, we assessed their contributions in different ethnic groups.
In Chapter 4 I focused on the potential lifespan longevity impact of CNVs by comparing
rates of CNVs genome-wide in pediatric populations and geriatric populations. CNVs at a
significantly higher frequency in a pediatric cohort in comparison with a geriatric cohort
were considered risk variants impacting lifespan, while those enriched in the geriatric
cohort were considered longevity protective variants. We performed a whole-genome
CNV analysis on 7,313 children and 2,701 adults of European ancestry genotyped using
302,108 SNP probes. Positive findings were evaluated in an independent cohort of 2,079
pediatric and 4,692 geriatric subjects. We detected eight deletions and 10 duplications
that were enriched in the pediatric group (P=3.33x10-8 - 1.6x10-2 unadjusted), while only
one duplication was enriched in the geriatric cohort (P=6.3x10-4). Population
stratification correction resulted in five deletions and three duplications remaining
significant (P=5.16x10-5-4.26x10-2) in the replication cohort. Three deletions and four
duplications were significantly combined (combined P=3.7x10-4-3.9x10-2). All associated
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loci were experimentally validated using qPCR. Evaluation of these genes for pathway
enrichment demonstrated that ~50% are involved in alternative splicing (P=0.0077
Benjamini and Hochberg corrected).

In Chapter 5 I present the results from analysis of congenital heart disease (CHD)
families for CNV association, the first large cohort study using WES and dense state of
the art SNP arrays. CHD is among the most common birth defects. Most cases are of
unknown etiology. To determine the contribution of de novo CNVs in the etiology of
sporadic CHD, we studied 538 CHD trios using genome-wide dense SNP arrays and/or
whole exome sequencing (WES). Results were experimentally validated using digital
droplet PCR. We compared validated CNVs in CHD cases to CNVs in 1,301 healthy
control trios. The two complementary high-resolution technologies identified 65
validated de novo CNVs in 53 CHD cases. A significant increase in CNV burden was
observed when comparing CHD trios with healthy trios, using either SNP array (p=7x105, Odds Ratio (OR)=4.6) or WES data (p=6x10-4, OR=3.5), and remained after removing
16% of de novo CNV loci previously reported as pathogenic (p=0.02, OR=2.7). We
observed recurrent de novo CNVs on 15q11.2 encompassing CYFIP1, NIPA1, and
NIPA2; and single de novo CNVs encompassing DUSP1, JUN, JUP, MED15, MED9,
PTPRE SREBF1, TOP2A, and ZEB2 genes that interact with established CHD proteins
NKX2-5 and GATA4. Integrating de novo variants in WES and CNV data suggest that
ETS1 is the pathogenic gene altered by 11q24.2-q25 deletions in Jacobsen syndrome, and
that CTBP2 is the pathogenic gene in 10q sub-telomeric deletions. We demonstrate a
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significantly increased frequency of rare de novo CNVs in CHD patients compared to
healthy controls and suggest several novel genetic loci for CHD.

In Chapter 6 I present genome-wide CNV meta-analysis across five major
neuropsychiatric/developmental disorders. Psychiatric diseases in children and young
adults pose a major health burden, and are just beginning to be widely diagnosed.
However, diagnostic phenotypes are not necessarily distinct from each other, suggesting
a shared genetic etiology. There is also a potential to target this shared variant using a
shared therapeutic. Here, we investigate CNVs in cohorts of schizophrenia, bipolar,
autism, ADHD, and depression. We can consider the affected domains of cognition,
psychosis, and mood. A total of 11,418 cases were compared to 14,789 controls. The
well-known 22q11 deletion was found to be significant (p=5.33x10-7). Duplication of
DOCK8/KANK1 was found to be significant (p=7.5x10-7). Several known and novel loci
were significant by case-control association with CNVs enriched in cases across the
neurodevelopmental disorders.
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7.2 Discussion and Future Directions
7.2.1 Summary of the Thesis Project
DNA variants abound in the human genome and give rise to complex traits. These
variants may be base or copy number variants. However, many variants are neutral in
selection and disease etiology, making detection of true common and rare frequency
variants impacting disease traits difficult. Comparing allele frequencies in cases and
controls, and in families, can reveal disease associations. SNP arrays and exome
sequencing are popular assays of variants genome-wide. Uniform version and processing
is crucial between samples being compared to limit bias. Bases occupy single points,
while copy variants occupy segments. Bases are bi-alleleic, whereas copies are multiallelic. One genome also encodes many different cell types, such as heart and brain. I
chose to examine CHD as it is the most common birth defect and cause of infant
mortality. I have also chosen to examine neuropsychiatric/developmental diseases as they
affect the quality of life and cognitive potential of a large number of children.

In the thesis, I describe ParseCNV, which I developed to perform disease association
studies using SNP arrays or exome sequencing generated CNV calls with quality tracking
of variants, contributing to each significant overlap signal. Red flags of variant quality,
genomic region, and overlap profile are assessed in a continuous score shown to correlate
with independent verification over 90%. Comparing congenital heart disease families,
cases, and controls genotyped both on SNP arrays and exome sequencing, we uncovered
significant and confident loci with intriguing biological insights. We compared this with
a large cohort CNV map that gave a robust rare variant frequency in unaffected
166

populations. By evaluating thoroughly the variant frequencies in pediatric individuals, we
can compare these frequencies in geriatric individuals to gain insight on lifespan.
Through these investigations, we have uncovered a number of CNVs that are
significantly enriched in ncRNA, OMIM, and GWAS regions. Congenital heart disease is
associated with de novo variants in histone modification genes. Longevity associated
CNVs enriched in pediatric patients aggregate in alternative splicing genes. In the
neuropsychiatric/developmental domain, CACNA, GRM, CNTN, and SLIT gene families
show multiple significant CNV signals impacting a large number of developmental and
psychiatric disease traits, with the potential of informing therapeutic decision-making.
Through a new tool development and analysis of large disease cohorts genotyped on a
variety of assays or whole exome sequenced, I have uncovered important biological role
and disease impact of CNV in complex disease.

7.2.2 Copy Number Analysis in Whole Genome Sequencing Data
WGS can be used to detect CNVs, although there are still many challenges. Indeed, Mills
and colleagues recently reported that only 53% of CNVs could be mapped to nucleotide
resolution from 185 human WGS data sets using the previously developed CNV
detection tools for sequencing (146). The methods that have thus far been developed are
unreliable as they only make partial use of the information available, such as paired-end
read distance or region-specific sequence coverage to make calls. The PennCNV(211)
program, which was used widely to infer CNVs from GWAS data, advanced a new
adapted hidden Markov model (HMM) based algorithm (PennCNV-SEQ), for reliable
and efficient detection and localization of CNVs from WES and WGS datasets. The
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PennCNV-SEQ program is novel, incorporating sequence depth coverage, allelic dosage,
population allele frequency, and paired-end reads distance to infer CNVs, as well as an
alignment algorithm for post-calling breakpoints refinement.
WGS read mapping can be done with BWA or mrsFAST-Ultra(81) for CNV and
SNP-aware read mapping. Genome STRucture in Populations (STRiP) is the most
sensitive and specific method available taking into account read depth (RD), aberrant
distance or orientation read pairs (RP), and split reads (SR) having segments mapping to
non-contiguous genome regions (84). The continuous nature of whole genome
sequencing data allows CNV calling with higher confidence than tag SNP microarrays or
WES. WGS also allows for inversion and translocation detection, which cannot be
performed using microarrays. By optimizing sequencing properties – coherence (multiple
read pairs supporting the same deletion), heterogeneity (null expected read depth based
on a population with low standard deviation vs. an observed aberration in an individual),
and substitution (CNV alleles often alternative) – confident CNV calls can be made using
sequencing. Genome STRiP considers discordant RPs as a starting point and RD as a
downstream filter. Similarly, DELLY (171) analyzes discordant RPs first, and then
attempts to strengthen the results with supporting SRs. cnvHiTSeq (13)uses an integrative
approach to sequencing-based CNV detection and genotyping that jointly models all
available NGS features at the population level. By organically combining evidence from
RD, RPs and SRs, cnvHiTSeq provides sensitive and precise discovery of all CNV
classes even from low-coverage sequence data. Furthermore, the probabilistic model
employed allows extensive pooling of information across individual samples and
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reconcile copy number differences among data sources, thus achieving a high CNV
genotyping accuracy.
Singular value decomposition is a powerful method to remove high variance
features contributing to noise and to mitigate sample-to-sample biases in sequencing data.
High-count chimeric clones found in libraries and loci flanked by homologous sequences
causing incorrect alignment can be filtered out to limit the false positive rate of CNV
detection. Visualization of reads at CNV-called loci, using Integrative Genomics Viewer,
further establishes confidence. We will also attempt to negate the CNV-calling
limitations of WGS by using de novo assembly of unaligned reads, and the use of a
number of existing tools, including BreakDancer, CREST and Pindel, which have been
developed for this purpose. We will also utilize SNP array platforms in union with WGS
to delineate CNVs in individuals when CNV results are unclear from the WGS data,
which should greatly assist the de novo assembly process. We anticipate that progress in
this area will be rapid, and we will adopt new technologies and algorithms as they
emerge.
A major challenge we have addressed is to generate B-allele frequency (BAF) values
from sequencing. Certainly, for each base we can get count reference (A) and count
variant (B) reads, respectively. These BAF values calculated directly are distributed
uniformly (0-1) in a test data, due to quality and variability in regions. Thus, some quality
heuristics as proposed by the VarScan2 paper and expected value of B (variant) allele
frequency (i.e. clustering) are needed to normalize to 0.5. Specific heuristics VarScan2
proposed were read position 10-90, strandedness 1-99%, variant reads ≥4, variant
frequency ≥5%, distance to 3’ ≥20, Homopolymer <5, map quality difference <30, read
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length difference <25, and mismatch quality sum difference <100. Another challenge is
binning the per-base BAF into each exon, since the depth is calculated per exon. Three
ways to obtain the allele counts per sample are: samtools mpileup and VarScan v2 (108)
yields (1) VarFreq (Allele frequency of variant by read count), (2) GATK VCF contains
AD (depth per allele by sample) and DP(depth of coverage), and (3) SNVer provides
both Filtered and unfiltered total depth and allele depth while GATK only provides
filtered total depth and unfiltered allele depth, which may not always be comparable. We
calculate a continuous value for genotype (0,1) rather than the static 3 state calls AA 0/0,
AB 0/1, BB 1/1, NC
Figure 7.1. Mosaicism Profiles by WGS derived BAF and LRR

./.. The BAF is a
continuous value for an
individual’s genotype
with expected values: 0A/AA/AAA, 0.25AAAB, 0.33-AAB, 0.5AB, 0.66-ABB, 0.75ABBB, 1-B/BB/BBB.
The straightforward
approach would simply

Blue dots show representative modes of mosaicism.

take the frequency of

reads with the B allele, divided by the total reads. The RPKM (SVD-ZRPKM or
zPCARD i.e. LRR or intensity) is a value across a targeted exon, whereas BAF would be
one value per base. Therefore, the BAF values would need to be summarized across the
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exon by a majority-voting scheme. If there are more than 10% of values 0.4-0.6, the
diploid evidence is quite strong and 0.5 would be a reasonable exonic BAF. Else, select
majority 0-0.1, 0.1-0.4, 0.6-0.9, 0.9-1. This is conditional on the population frequency of
the B allele.
Mosaicism is a mixing of cell-populations with different copy number states.
Liver specific somatic copy number variation could mix with blood cell diploid copy
number to result in
Figure 7.2. CNV Model for Sequencing with Intensity, Genotype, Pairs
and Split HMM Emissions

mosaicisim. Therefore,
fractional copy numbers
must be considered. RGADA(160) and
BAFsegmentation (188)
can detect mosaicism
CNV calls using
normalized intensity and
allele depth / total depth
WGS BAF profiles
(Figure 7.1). Mosaic
Alteration Detector

Sequencing features informing CNV detection shown.

(MAD) (99) is a module

of R-GADA specifically for mosaic detection. Characteristic genotype (BAF) banding is
observed in mosaic deletion and duplication in tandem with intensity (LRR) banding.
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Depth, genotype, pairs split and assembly can be used in an integrative model to
optimize CNV break point resolution (Figure 7.2). Split reads can allow for base-pair
resolution CNV breakpoint detection. Lengths of confidently mapped reads flanking the
CNV are also important variables for establishing the precise diploid to CNV transition
Figure 7.3. XHMM Test Data Deletion Detected by Intensity
(Depth/ZPCARD) Verified by BAF

point. Pairs and split
features can be used to
enhance calling for
sequencing, which relies
primarily on normalized
depth and genotype
frequency. SR performs
on deletion and small

Sequencing features informing CNV detection shown.

insertions. However, SR

has low sensitivity in regions with low-complexity, as they rely on unique mapping
information to the genome. The copy number of each base can be calculated based on its
number of overlapping high-quality mapped reads to predict breakpoints in base pair
resolution, at the trade-off of more noisy local signals rather than a smoothed window
size of 100 base pairs. De novo assembly (AS) first reconstructs DNA fragments
(contigs) from short reads by assembling overlapping reads. By comparing the assembled
contigs to the reference genome, the genomic regions with discordant copy numbers are
then identified. AS is very computationally intensive and requires minimum read depth
but can resolve to the base pair CNV boundaries.
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ParseCNV (70) was developed at CAG and can be used to perform disease
association studies using WGS generated CNV calls with quality tracking of variants
contributing to each significant overlap signal. Red flags of variant quality, genomic
region, and overlap profile are assessed in a continuous score shown to correlate with
independent verification over 90%.
The exome as defined by Nimblegen V2 capture contains 628,118 dbSNP
reported common SNPs which could inform CNV detection, similar to the utility
demonstrated by supplementing intensity with genotype in SNP array studies.

My contribution in this dissertation is to explore the genetic etiology of complex disease
where I have focused on the study of copy number variation in congenital heart disease
and neuropsychiatric/developmental disorders.
Others have advanced on similar frontiers of research, I contribute to the scientific
discussion and provide novel insights and methods for evaluating CNV overlap quality
for statistically significant associations in ParseCNV.
These findings seek to serve the greater good of improving patient care through more
targeted genetic diagnostics and therapeutic interventions.
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